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Complete transection of peripheral nerves can result from trauma, tumor removal, infection, or as 
adverse consequences of various surgeries. Current commercially available nerve guides cannot 
repair large nerve defects because these guides are engineered to provide mechanical support for 
the developing axon and do not actively promote axonal growth.  For large nerve gaps, targeting 
axonal growth is particularly important because the length of the nerve that must be regrown is 
the distance from the lesion to the innervated muscle.  Therefore, there is enormous clinical 
potential for a nerve guide capable of improving axonal outgrowth across large nerve defects. 
Our underlying hypothesis is that delivery of Glial Cell Line-Derived Neurotrophic Factor 
(GDNF) from a nerve guide will improve peripheral nerve regeneration across large defects. 
To test this hypothesis, biodegradable poly(caprolactone) (PCL) nerve guides were 
prepared with manufacturing parameters optimized for protein delivery and retention at the 
injury site.  Quantitative changes in the diffusion of small molecular weight proteins and glucose 
through PCL conduit walls were measured to determine the independent and combinatorial 
effects of three fabrication variables: wall thickness, pore size and porosity percentage.  Double-
walled microspheres were then fabricated as a method of sustained protein delivery, and were 
incorporated within the luminal wall of PCL nerve guides using a novel solvent specific 
embedding technique.  
 The overall efficacy of our nerve guide design was confirmed by encapsulating and 
delivering GDNF in the rat sciatic nerve injury model.  Evaluation of sensory reinnervation 
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following a long gap, 1.5cm nerve injury at 16 weeks showed a significant increase in animal 
response time to stimuli from animals treated with GDNF as opposed to negative control PCL 
guides.  Furthermore, the measured gastrocnemius contraction force in animals treated with 
GDNF was significantly higher than negative controls and was not significantly different from 
the isograft positive control group.  Histological assessment of explanted conduits after 16 weeks 
showed improved tissue integration within GDNF releasing nerve guides compared to negative 
controls.  Nerve fibers were present across the entire length of GDNF releasing guides, while 
nerve fibers were not detectable beyond the middle region of negative control guides.  Therefore, 
the results reported within this dissertation support our original hypothesis that; the long-term 
delivery of a neurotrophic factor from nerve guides results in improved functional recovery 
above negative controls following large axonal defects in the peripheral nervous system.   
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1.0  INTRODUCTION 
1.1 INCIDENCE AND IMPACT OF PERIPHERAL NERVE INJURIES 
Because of the intimate nature of nerve development within tissue structures, including 
superficial or subcutaneous tissues, nerves are often considerably vulnerable to injury during 
trauma or surgical procedures.  For example, nerves which are in direct contact with bone may 
be severed as a consequence of bone fracture or damage.  Additionally, nerves traverse joints 
with little or no intervening soft tissue which renders them exposed during joint dislocation, 
stretch or compression.  For example, the peroneal nerve is frequently and seriously injured in 
association with knee injuries with or without fracture.  Nerves are also damaged as a side effect 
of various surgical procedures.  The ilioinguinal and iliohypogastric nerves are typically injured 
as a result of surgical procedures in the lower abdominal wall and cause disabling pain in the 
groin.  The ilioinguinal nerve can be entrapped by scar, sutures or staples or stretched or 
contused as a result of herniorrhaphy, appendectamy or other gynecological procedures such as 
child birth [1].  Additionally, the cavernosal nerve within the neurovascular bundle on the 
rectolateral aspect of the prostate is often severed during prostatectomy, leading to end organ 
morbidity with significant impairments in the quality of life for a large group of patients [2].  
Nerve injuries which result in partial or total loss of motor or sensory functions can cause 
personal tragedy and great suffering for patients as well as substantial socioeconomic burden. 
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Nerve-related upper extremity outpatient visits and procedures in the United States have been 
estimated at ~ 2.7 million per year, which accounts for 13% of total outpatient visits.  Of these 
2.7 million, upper extremity nerve lesions resulting in possible paralysis and sensory defects in 
the affected extremity corresponded to 8% of the patient procedures [3].  For example, the usual 
arm level injury would likely involve (among others) the radial nerve.  Types of trauma affecting 
this nerve include humeral fracture, glass, knife and gunshot wound and contrusive soft tissue 
injuries.  Because the human hand is such a delicate sensory organ and working tool, studies 
point out that transection injuries of nerve trunks in hand injuries are highly costly as the patient 
loses work production (sick leave), may have to change work or even retire [4, 5].  In a 2005 
Swedish study, it was estimated that the median cost for society of an employed person with a 
median nerve injury is ~51K euros [6]. 
 When nerve damage occurs, direct anastamosis of the severed nerve ends is the most 
surgically preferred method of repair.  However, when nerves cannot be aligned due to tension at 
the site of coaptation, a non-essential sensory nerve is often harvested during a second surgical 
procedure and grafted autologously [7].  There are several negative aspects to the use of nerve 
autografts including; semi-permanent sensory loss from the target organ of the harvested nerve, 
potential development of neuromas at the donor site, and the necessity of harvesting a large 
length of nerve which may not always be available, such as in combat casualty care.  Because of 
these drawbacks with nerve autografts, nerve guides have emerged as a potential mode of 
bridging small nerve gaps for repairing peripheral nerve defects.  
There are currently five nerve guide implants approved by the U.S Food and Drug 
Administration for human application that provide an alternative to using precious autologous 
nerve tissue.  A 2006 evaluation of the efficacy of nerve guides reported that regeneration 
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success obtained with resorbable synthetic nerve guides is within the range of 0 to 69% which is 
equivalent to repair achieved with autologous nerve grafts [8]. Therefore, there is strong 
evidence that nerve guides can be used in treating nerve lesions instead of autologous nerve.  
However, currently nerve guides cannot repair large (greater than 3 cm of lost nerve tissue) 
defects because guides are only engineered to provide an initial mechanical support for the 
developing axon. Therefore, nerve guides meet a basic function for gross guidance for nerve 
fascicles between the proximal and distal stumps. The guides rely on self-regulatory biological 
mechanisms by containing growth factors secreted by the surviving nerve stumps and existing 
Schwann cells to the injured area.  However, by exploiting the natural regenerative capacity of 
the peripheral nerves by developing conduits which promote and direct axonal outgrowth, it may 
be possible to overcome the current length barriers for synthetic nerve grafts. 
1.2 PERIPHERAL NERVE ANATOMY 
The peripheral nervous system (PNS) resides outside the central nervous system and functions to 
receive input from the environment and innervate muscle tissue for motor control.  To 
accomplish this task, the PNS consists of cranial nerves arising from the brain, spinal nerves 
originating from the spinal cord, and the sensory nerve cell bodies (Figure 1a) [9].  Sensory 
information is transmitted to the central nervous system through afferent fibers in the dorsal 
spinal roots while outgoing efferent motor fibers originating within the ventral horns of the 
spinal cord serves the limbs and organs in terms coordinating body movement (Figure 1b) [10]. 
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Figure 1. The Organization of the Peripheral Nervous System (Modified from [11, 12]).   
   
 
1.2.1 Nerve architecture 
The functional element of the peripheral nervous system is the neuron, which consists of a cell 
body and axonal and dendritic extensions.  The cell bodies of neurons originate in the spinal 
cord, dorsal root ganglion and autonomic ganglion.  The axons of peripheral nerves extend from 
the centrally located cell bodies and terminate in neuromuscular endings (motor neurons), end-
organs, or receptors (sensory or sympathetic fibers).  Histologically, peripheral nerves can be 
divided amongst two classifications, those nerve fibers which are myelinated or those that are 
unmyelinated.  This distinction in nerve type describes the presence or absence of an 
accompanying layer of Schwann cells which concentrically encircle an axon with a lipoprotein 
covering, termed myelin (discussed in Section 1.2.2).  Nerve fibers are further organized by 
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distinct layers of connective tissue which provides a framework for nerve fibers and the 
accompanying blood vessels [13]. 
  Beginning with the most basic layer of nerve trunk organization, individual nerve fibers 
composed of an axon surrounded by Schwann cells are supported by an organized layer of 
connective tissue termed the endoneurium.  The endoneurium is mostly collagen and divides 
nerve fibers into small undulating groupings which allows nerves to resist elongation under 
tension [14].  Additionally, fibroblasts, mast cells and macrophages reside within the 
endoneurium [10].   Groups of nerve fibers are further surrounded by an additional layer of 
connective tissue termed the perineurium, which condenses many layers of flattened fibroblasts 
and organized elastin and collagen fibrils into bundles of nerve fibers called fascicles.  The 
function of the perineurium is to provide further protection for nerve fibers and to maintain an 
intra-fascicle pressure necessary for promoting a proximal-distal flow within the cytoplasm of 
axons.  Additionally, the perineurium is the primary source of tensile strength of the peripheral 
nerve [10].   
 Finally, fascicles are further protected by the epineurium, a sheath of loose fibro-
collagenous tissue that provides motility for the nerve trunk from surrounding structures.  The 
epineurium is composed of longitudinally aligned collagen and elastin fibers and a small volume 
of adipose tissue which cushions the nerve against deforming forces.  Cellular populations within 
this connective tissue layer include fibroblasts and mast cells.  Additionally, the epineurium is 
highly vascularized and contains lymphatics which provide drainage for the arterial and venous 
supply [10].  Together, the nerve fibers, endoneurium, perineurium, and epineurium constitute 
motor, sensory or sympathetic peripheral nerve trunks (Figure 2). 
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Figure 2.  Organization of Peripheral Nerve Trunks. (Image from [15]) 
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Depending on axon diameter and nerve conduction velocity, peripheral nerve fibers can 
be classified amongst three groups described in Table 1 [10]. 
 
 
Table 1.  Classification of Peripheral Nerve Fibers 
 
Group Diameter (μm) Conduction 
Velocity (M/sec) 
Function 
A 2.5 – 22 15 -100 Myelinated somatic afferent and efferent 
B 3 3 – 15 Myelinated preganglionic autonomic (visceral) 
C 0.2 – 1.5 0.3 – 1.6 Unmyelinated somatic afferent and autonomic postganglionic efferent (pain, pilomotor, 
sudomotor and vasomotor) 
 
 
1.2.2 Schwann cells 
In the PNS, Schwann cells are located around the axons (myelinated axons) or are related to 
several axons (nonmyelinated axons) and aid in axon function.  Sensory and motor nerves 
contain both unmyelinated and myelinated axons in a ratio of 4 to 1 [16].  In myelinated axons, 
Schwann cells align longitudinally along the length of an axon and concentrically envelope the 
axons with tightly compressed lipid membranes.  As the nerve fiber matures, the number of 
wrappings of Schwann cells around axons increases and as such, an increase in myelination 
around an axon indicates increased nerve fiber development [14]. 
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 During embryonic development, Schwann cells and neurons of the peripheral nervous 
system are generated together in the neural crest and migrate ventrally into the peripheral body 
tissues.  As the number of nerve fibers increase, neuronal signaling correspondingly promotes an 
increase in Schwann cell populations [17].  Studies performed in vitro suggest that direct cell 
contact between axons and Schwann cells promotes Schwann cell proliferation [18].  In addition, 
direct neuronal contact promotes a large increase in the amount of secreted levels of major basal 
lamina components such as types I, III, IV and V collagen and laminin by Schwann cells [17, 
19].  Furthermore, Schwann cells also maintain neuronal development through paracrine 
signaling by secreting factors such as Glial Cell Line-Derived Neurotrophic Factor (GDNF), 
Neuturin, Ciliary Neurotrophic Factor (CNTF), and Leukemia Inhibiting Factor (LIF).      
 In addition to neuronal maintenance, another vital function of Schwann cells is to insulate 
the axon and improve the efficiency of action potential propagation within the transmitting axon.  
Gaps in the connectivity of myelin are called Nodes of Ranvier and are important for the 
propagation of action potentials along the length of nerve fibers.  While unmyelinated axons 
propagate electrical impulses at 2 to 2.5 m/s, myelinated fibers can conduct electrical impulses at 
3 to 150 m/s [16]. 
1.2.3 Supporting vasculature 
Peripheral nerves are abundantly vascularized by an intraneural plexus of successively dividing 
vessels which provides a rich supply of oxygen and nutrients to all elements of the nerve trunks 
[14].  From either the main vessel of a limb or their named branches, arteriae nervorum enter a 
nerve and travel predominantly in the epineurium and interfascicular epineurium, though the 
perineurium is also traversed by blood vessels [13].  These large outer blood vessels divide and 
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supply the perineurium and intrafascicular space as a fine mesh of obliquely running capillaries.  
The importance of nerve vasculature is evident from literature reporting impaired nerve 
regeneration when the blood supply is restricted from entering an area of injured nerve by 
nonporous tubes [20, 21].   
1.3 NATIVE REPONSE TO NERVE INJURY 
Severe nerve injuries are most commonly caused by trauma, which may include glass, knife and 
gunshot wounds [1].  In addition, motorcycle and car accidents often result in traction injuries 
that are particularly damaging to the brachial plexus and result in limited upper limb range of 
motion [22].  Furthermore, peripheral nerves may be injured during bone fractures or joint 
dislocations.  Depending on the severity of nerve damage, the potential for nerve regeneration 
ranges between high for mild injuries that do not disrupt the connective tissue macrostructure to 
extremely poor when large segments of nerve trunks are lost.   
1.3.1 Classification of nerve injuries 
The degree of damage to a nerve fiber depends on the nature, site and severity of the injury [14].  
By distinguishing injuries according to the harm placed upon the endoneurial tube, nerve injuries 
may be classified into three fundamental categories: neurapraxia, axonotmesis, and neurotmesis 
[13, 14]. 
Neurapraxia describes the mildest form of nerve injury and involves a temporary 
interruption of nerve fiber conduction without a loss of axonal continuity between the neuron and 
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end organ.  This type of injury can result from compression of the nerve fiber or from relatively 
mild, blunt blows that occur close to the nerve [23].  Following direct compression and ischemia, 
paralysis and sensory impairment occur within 15 to 45 minutes of injury [14].  However, 
because the overall organization of the connective tissue is maintained along with the 
microscopic anatomy of the axon, recovery occurs easily and requires a recovery period that 
ranges between several minutes to up to 5-6 weeks [13].  Because the axon is contained within 
the endoneurial tube and the regenerative process is ensured, this type of injury is not addressed 
further within the context of the described work within this dissertation. 
 Axonotmesis is a more severe injury than neurapraxia and involves the loss of continuity 
of both the axon and the corresponding sheath of associated myelin, however with this injury the 
general framework of connective tissue is maintained.  This type of injury commonly results 
from cuts and lacerations, bone fractures, traction, and prolonged compression [23].   Because 
the axonal innervations of target organs are interrupted, end-target regions of both motor and 
sensory functions are lost and recovery can require a significant amount of time.  The final 
classification of nerve injury, neurotmesis, reflects severe forms of injury such as cuts, stretch or 
laceration of tissue which results in an interruption of not only the nerve fiber, but also the 
perineurial and endoneurial connective tissue structure.  
 A similar classification system developed by Sunderland scales nerve injuries according 
to damage done to fascicular structure.  A simple grade-I or first-degree injury describes 
neurapraxia.  Grade-II injuries are used to describe a loss of axon continuity with a preservation 
of endoneurial organization (axonotmesis).  Grade-III injuries require that the axon and 
endoneurial continuity are lost with the preservation of perineurium, also described as a mixed 
axonotmesis-neurotmesis injury.  With grade IV injuries, there is a loss of fascicle structure 
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which includes the axons, endoneurium and perineurium.  This is the predominant type of nerve 
injury [13].  The final level of nerve injuries according to the Sunderland scale is grade V or 
complete neurotmesis.  Figure 3 illustrates the relationship between the two common descriptive 
scales for peripheral nerve injury. 
 
 
 
Figure 3.  Classification of Peripheral Nerve Injuries (Image modified from [24]). 
 
 
Each degree of nerve injury results in a unique mechanism for nerve regeneration.  
Assuming the offending agent ceases to operate, injuries resulting with neurapraxia are 
temporary and do not result in a discontinuity of nerve fibers, and therefore the regenerative 
process is straight forward and will not be discussed further.  However, axonotmesis and 
neurotmesis related injuries result in a disorganization of the remaining nerve fiber or trunk 
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which requires a more complex regenerative process that proceeds in two stages.  The first stage 
involves the disintegration of the axon and myelin sheath along the entire length of the nerve, 
known as Wallerian degeneration.  Following degeneration, the entire axon pathway has perished 
and regeneration of the axon proceeds as described below.  
1.3.2 Wallerian degeneration and nerve regeneration 
The degenerative response to injury within the mammalian PNS is a highly conserved process 
[25]. Upon axotomy, nerve fibers are severed and the connective tissue of the endoneurial tube 
becomes so disorganized that the normal architecture is completely destroyed.  Within the first 
hours after injury, neurotubules and neurofilaments fragment, resulting with the axoplasms 
filling with granular material [26].  Protease activity and separation from metabolic resources of 
the nerve cell body cause the distal axon cytoskeleton to break down and the cell membrane 
collapses. The dissolution of cell components within the endoneurial tubes in the distal end 
results in debris which is further compacted by Schwann cells shedding their myelin lipids. From 
2 to 3 days after injury, Schwann cells inside the basal lamina proliferate and cooperate with 
infiltrating macrophages and monocytes to remove and recycle both axonal and myelin-derived 
materials. These cells also prepare the environment into which regenerating axons grow by 
releasing neurotrophins which lead axons toward their synaptic targets, resulting in restored 
neuronal function.     
 Proximal to axonal disruption, the nerve stump immediately swells after injury as the gap  
in nerve continuity is filled with a blood clot [23].  Following the typical tissue response to 
damage (e.g. edema and non-specific cellular responses) the neuron undergoes central 
chromatolysis as the function of the neuron shifts from maintenance of nerve conduction to 
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regenerating structural proteins [10].  In addition to the dissolution of Nissl bodies, the neuron 
also experiences nuclear eccentricity, nuclear and nucleolar enlargement, cell swelling and a 
retraction of the dendrites [27].  Synthesis of glycolytic and respiratory enzymes and neuronal 
lipoproteins necessary for axonal membrane synthesis all increase [10].  After Wallerian 
degeneration has occurred, the distal injury site has been cleared and the regenerating nerve 
fibers grow from the proximal stump across the gap and toward the distal endoneurial tubes to 
reinnervate the target organs.  Schwann cells differentiate from a replicating satellite cell 
population and accompany the proximal sprouts across the area of injury. 
1.3.3 Surgical strategies for nerve repair 
The surgical management of peripheral nerve injuries depends upon meticulous microsurgical 
techniques and aims to enable the maximum number of axons to regenerate [28, 29].  Depending 
on the severity of tissue damage, common surgical techniques for nerve repair include nerve 
stump realignment through primary nerve repair or when a gap exists, auto- or allografts may be 
employed. 
1.3.3.1 Anastamosis of proximal and distal nerve stumps 
Primary nerve repair is defined as the placement of a nerve suture immediately after or within the 
first several days following injury such that the injured nerve is still in the inflammatory phase 
and has not yet begun to scar [3].  Primary nerve repair, also known as end-to-end anastamosis, 
can be performed when a nerve can be realigned such that the elongation required to 
reapproximate the nerves is no more than 10% of the nerve length [30].  Beyond 10% in nerve 
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strain, the microcirculation is reduced and the potential for tearing of the nerve and a break-down 
of the repair is high.     
The three most commonly used techniques for primary nerve repair include: utilizing a 
few well placed sutures in the epineurium to maintain alignment of the major fascicles within the 
nerve, group fascicular suturing, and the epineurial splint technique in which the external 
epineurium is peeled back and rejoined on the deep surface relieving tension from fascicles 
which are later coapted internally [3].  Regardless of the technique selected, primary nerve repair 
must be performed without excessive tension and requires that sutures are not placed in the 
endoneurium or perineurium.  When tension is excessive, the nerve gap must be bridged with 
either a nerve graft or nerve conduit.     
1.3.3.2 Nerve grafting  
The standard approach for repairing segmental defects in nerve continuity involves grafting 
autologous donor nerve, typically the sural nerve, as a bridge across the nerve gap.  Common 
surgical techniques for nerve grafting include free nerve grafting (“cable grafting”), and 
interfascicular nerve grafting.  Cable nerve grafting was developed by Seddon to allow for a 
defect in a single, thick nerve to be repaired using small cutaneous nerves that can be harvested 
without a loss of function.  In this technique, several thin skin nerves are assembled using 
stitches or glue and fashioned between the interstump gap with two sites of anastamosis.  With 
this technique, some segments of the graft often survive better than others causing partial fibrosis 
of the graft.  Additionally, failure of the sprouting axons to cross the distal anastamosis has been 
shown to occur in 14% of grafts longer than 3 cm [3]. 
 The disadvantages experienced by surgeons when performing cable grafting led to the 
development of the interfascicular grafting technique in which cutaneous segments of the graft 
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are not sutured or glued together but instead, minor units of the graft are dissected and connected 
individually across a nerve defect.  Inherent challenges with this technique include the potential 
of neuroma formation at donor nerve harvesting sites.  To avoid this, surgeons often remove the 
entire length of nerves at higher levels such that the proximal stump disappears into the depth of 
the subfascial space and thus causing large longitudinal skin incisions which result in visible scar 
formation.  Additionally, donor nerves have changing fascicular patterns along the longitudinal 
axis which the requires surgical skill and time for dissection into usable segments for grafting 
[3].   
 Though autologous graft placed into a defect results in a better outcome than primary 
nerve sutures performed under tension, there is a very large disadvantage in this type of therapy, 
mainly the requirement of a second surgery to harvest the nerve. Sensory deficits and painful 
neuroma formation can occur at the donor site. Unfortunately, motor and sensory recovery 
following nerve grafting (as measured by the Medical Research Council Grading System for 
Nerve Recovery) is often below standards as indicated by a 2000 study in which only 50% of 
patients demonstrated useful recovery following ulnar nerve repair [31]. For these reasons, the 
development of synthetic nerve guidance channels is of enormous utility for surgeons attempting 
to manage neurotmesis related problems. The disappointing functional outcome of peripheral 
nerve trauma urges researchers to optimize therapeutic interventions. 
1.4 CONDUITS FOR BRIDGING NERVE GAPS 
Although nerve grafts serve as the standard of care for bridging nerve defects, the major 
disadvantages associated with their use has led to the development of engineered conduits 
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through which nerves with a defect distance of 3 cm or less can regenerate through [32].  Nerve 
guides (also referenced as guidance channels) are cylindrical conduits of either biologic-based or 
synthetic materials that have been used beginning in the late 1970’s to bridge nerve defects [5].  
The use of such nerve guides has many advantages, including providing an enclosure for the 
accumulation of secreted neurotrophic factors from endogenous cells within the site of injury, 
supporting fibrin clot formation between the injured nerve stumps, preventing neuroma and 
fibrous tissue formation and decreasing tension across a nerve gap [5, 33, 34].   
 Within the enormous breadth of nerve guide literature, many of the mechanical 
requirements of implantable nerve guides have been defined.  For example, the guide must be of 
the proper dimensions: the length must be long enough to bridge the gap without tension and the 
width must house the nerve stumps without compression.  Furthermore, the material must be 
mechanically sound to resist tearing from sutures yet soft enough to avoid tissue inflammation 
from mechanical irritation [1].  Finally, it must be possible to produce a porous guide wall yet 
the nerve guide must be slowly degrading so as to provide support for the entire regeneration 
period and have a low degree of swelling to avoid compression of the nerve injury.  With these 
parameters in mind, nerve guides have been constructed from a variety of both biologic and 
synthetic based materials [35] and with a variety of design additives such as luminal fillers [36] 
or delivered growth factors [37].     
1.4.1 Biomaterials for nerve guide synthesis 
Both natural and synthetic materials have been used to fabricate nerve guides.  The essential 
parameters of a nerve guide material is that the selected material must be easily formed into a 
conduit that accommodates the nerve being repaired, it should require little effort from surgeons 
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to implant, it must be sterilizable and biocompatible [38].  The term biocompatible indicates that 
the implanted material not cause inflammation, irritation, or scarring [1].  Ideally, an implanted 
nerve guide should also be biodegradable so as to avoid a secondary procedure for device 
removal [8].   
1.4.1.1 Natural materials 
 Collagen types I and III constitute 49% of the total protein in nerves [39].  Because of 
this, collagen has been widely assessed as a biomaterial for nerve guide fabrication [40-42].  
When compared to silicone conduits, work by Kemp et al.,  suggest that collagen guides enhance 
axonal regeneration, myelination and vascularization in a 10 mm rat sciatic nerve defect [43].  
The increase in nerve area and dramatic increase in myelinated nerve fiber numbers were 
attributed to previous work demonstrating that collagen rapidly revascularizes and integrates into 
the host tissue following implantation [44].  Though collagen guides have demonstrated useful 
functional sensory and motor recovery in animal models of peripheral nerve injury, the rapid 
degradation rate of the material requires that the collagen be cross-linked so as to provide 
mechanical stability for the regenerative period required for critical size defects [45, 46]. 
 In addition to collagen, purified natural extracellular matrix (ECM) components such as 
laminin and fibronectin have shown a significant role in axonal development [9].  Laminin is the 
first ECM protein expressed during embryogenesis and has been shown to both promote axonal 
outgrowth and guide developing neurites [35].  Other naturally derived molecules that have 
demonstrated utility in nerve guide fabrication as either the main component for nerve guide 
fabrication or as a copolymer or nerve guide coating include hyaluronic acid [47, 48], fibrinogen 
[49], alginate [50],  chitin [51, 52], and chitosan [53].      
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 Disadvantages of manufacturing these materials include high cost and potential xenograft 
problems that exist because the materials are typically extracted from animal sources. In 
addition, natural polymers tend to collapse following implantation or have early resorption 
periods that prevent mechanical support of regenerating nerves across long gaps [21].  Despite 
this, two nerve guide implants that are currently commercially available are composed of type I 
collagen, the NeuroMatrix/NeuroFlex by Stryker, and the NeuraGen by Integra Neurosciences. 
Both of these guides are limited to two centimeters in length and are therefore designed for 
relatively short gaps.   
1.4.1.2 Synthetic materials 
 Biodegradable, well characterized, FDA established polymers such as poly(lactic acid) 
(PLA), poly(glycolic acid) (PGA), poly(caprolactone) (PCL), and copolymers thereof,  have also 
been used to manufacture nerve guides [20, 54-56]. Two guides composed of biodegradable 
polymers are sold commercially. The Neurotube by Synovis Micro Companies is comprised of 
PGA, degrades within three months of implantation and is therefore optimal for very small 
defects (shorter than 1 cm).  The Neurolac by Polyganics which is composed of poly-DL-lactide-
co-caprolactone, degrades within 16 months. Both of these implants are packaged in lengths no 
greater than 4 centimeters [57].  
 Non-degradable polymers such as silicone [58, 59], polyethylene [60], polyurethanes 
[61], Teflon [62] and polysulfone [63] have also been examined in human implant studies. While 
one commercially available guide is made of a non-degradable poly(vinyl alcohol) hydrogel, the 
Salubridge by SaluMedica LLC, most surgeons prefer fully resorbable scaffolds. This is because 
permanent materials pose a higher risk for infection, are more likely to result in chronic 
inflammation and may cause late adverse effects due to nerve compression [64]. In general, 
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synthetic materials are often attractive candidates for nerve tissue engineering because their 
chemical and physical properties (for example stiffness, degradation rate and porosity) can in 
theory be optimized to the specific needs of the application. 
1.4.2 Fabrication techniques 
Successful synthetic nerve guides are optimized for not only the essential mechanics and 
geometry of the nerve that is being replaced as discussed in Section 1.4, but nerve guides should 
also allow for the attachment and migration of the endogenous Schwann cell population and 
provide adequate mass transfer of nutrients and metabolites.  To accomplish this, nerve guides 
have been fabricated using a variety of conventional techniques which include particulate 
leaching, electrospinning and super-critical fluid technology.  While each processing 
methodology has inherent attributes and drawbacks, the following sections describe effective 
methods of processing biodegradable materials into cylindrical conduits with high porosity and 
surface area. 
1.4.2.1 Particulate leaching 
 Particulate leaching requires the dispersal of a porogen within a polymeric or biologically 
monomeric solution, followed by particle leaching.  Because the particulate employed 
temporarily holds volume within the scaffold wall, pores remain following particle removal.  
Typically porogens include sodium chloride, sucrose or lipid microparticles such as those made 
of Softisan 154 and Witepsol H42 [65].  Benefits of using this fabrication technique include the 
capability of producing scaffolds with locally porous internal structures, the low cost of the 
fabrication process and the production of highly interconnected porous microstructures [66].   
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Synthesis of porous nerve guides using the method of particulate leaching has been 
performed with poly(caprolactone) [67], poly-D,L-lactide [68-71], poly(lactic-co-glycolic acid) 
[71-73], and copolymers such as trimethyl carbonate and ε- caprolactone [74], poly(L-lactide-co-
ε-caprolactone) [75, 76], and poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) [77].  Important 
conclusions drawn from this body of work include: solvent casting with porogens is an easily 
adaptable method for producing highly porous nerve guides with interconnected pores, the pore 
morphology of resulting nerve guides is defined by the size of the salt crystals and the salt 
weight fraction of the polymer solution [71] and it is possible to create both uniform 
(homogenously) porous guides as well as asymmetric conduits with directed solute permeability 
[73].  However, it has also been reported that dip-coating often results in guides that range in 
wall thickness along the length, with as much as 45% variability in nerve guide wall thickness 
within a single guide [77].  Histological evaluation of regenerated nerve using solvent cast nerve 
guides showed that nerve guides with small pore diameters of 10 μm or less result in smaller and 
less myelinated nerve fibers than those produced of 30 – 50 μm [77].     
 
1.4.2.2 Electrospinning 
 Electrospinning is performed using either a polymeric or natural solutions that is pumped 
into a highly charged spinneret adjacent to a collector.  When a significantly large voltage is 
applied to a solution of choice, surface tension is created in the spinneret (typically a small 
orifice or flat-tipped needle) and droplets of solution stretch and elongate until a continuous jet is 
ejected onto a dynamic collecting surface [66].  Solvent evaporation or cooling of the polymer 
melt solution once the jet stream reaches the collector results in electrospun fibers with diameters 
ranging between 200 nm and 5 mm.  Electrospinning can be used with relatively small expense 
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and can be used to create scaffolds of high porosity and surface area.  Furthermore, though it can 
be challenging to accurately control deposition of electrospun fibers, literature suggests that pore 
sizes can be controlled through defined fiber diameter and spacing.  
Several studies have been conducted to measure neurite outgrowth within electrospun 
nerve guides of varying biomaterial, fiber size, and fiber orientation [78-81].  In vitro studies 
using dorsal root ganglion explants have demonstrated that neurites follow highly aligned 
poly(L-lactide) fibers upon contact and are longer in length than those cultured on randomly 
aligned substrates [82].  Furthermore, Patel et al., demonstrated that aligned nanofiber matrices 
reduced neurite branching and encouraged neurite outgrowth, a highly desirable feature of nerve 
guides [83].   
In addition to processing and aligning polymer fibers, electrospinning techniques can also 
be utilized for incorporating cells and growth factors within the nerve guide wall [66].  In a 2007 
study by Chew et al., highly aligned fibers of caprolactone copolymerized with ethyl ethylene 
phosphate were electrospun with glial cell line-derived neurotrophic factor (GDNF) such that ~5 
ng/mg GDNF was cumulatively released over 80 days (measured in vitro) [84].  The authors 
demonstrated that fiber alignment in the longitudinal direction resulted in improved nerve 
regeneration as measured with electrophysiology when compared to circumferentially aligned 
fibers.  Furthermore, longitudinally aligned fibers used in combination with GDNF delivery 
resulted in increased number of myelinated axons, nerve cross sectional area and myelin 
thickness [84].  The percentage of rats with functional recovery as measured with 
electrophysiology was also improved with GDNF treatment when compared to aligned conduits 
that did not deliver GDNF.  While the addition of growth factor delivery from electrospun nerve 
guides presented an improvement in nerve guide fabrication, the technique used to incorporate 
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GDNF was suboptimal and resulted with a burst release of GDNF within the first day, a 
drawback common with single walled microsphere delivery systems that is likely a result of the 
protein aggregates near the surface of the polymer matrix.                  
1.4.2.3 Gas foaming and supercritical fluid technology 
 Gas foaming of biodegradable polymers allows for a solvent-free formation of porous 
materials by saturating molded polymer solutions with pressurized gas, typically carbon dioxide 
(CO2).  By slowly releasing the pressure within the system, air bubbles within the material 
nucleate, potentially reaching 100 μm in size.  Disadvantages of this fabrication technique 
include the possibility of pores resulting which are not interconnected and are variable in size.  
Through addition of effervescent salts, the effectiveness of creating highly porous structures can 
be improved [66].      
Alternatively, porous nerve guides have been generated using both biological and 
synthetic materials by lyophilizing the solvent at supercritical temperatures.  Using this 
technique, nerve guides have been constructed of collagen-glycosaminoglycans [85], chitosan 
[86], chitin/chitosan [87], poly(D, L-Lactide) [54], and poly(lactic-co-glycolic acid) [88].  To 
create nerve guides, polymers were first dissolved in an appropriate solvent, typically acetic acid, 
water, or acetone.  The polymer solution was then injected into a cylindrical mold that was 
cooled by liquid nitrogen to temperatures of at least -40°C.  Frozen conduits were then 
lyophilized to sublimate and remove the solid solvent, creating pores from the displaced liquid 
volume.  Through this process, highly porous ( < 90%) polymer guides can be generated [54]. 
Advantages of this fabrication technique include the batch-to-batch consistency in nerve 
guide geometry because of the employment of molds.  Depending on the complexity of the mold 
design, guides have been fabricated with longitudinally aligned channels [88] or microtubules 
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[86], or with radially aligned pores [85].  Drawbacks of using this fabrication technique include 
the requirement of a more sophisticated apparatus for guide fabrication, the potential for the 
resulting pore morphology to be oriented instead of interconnected, and the small diameter of 
generated pores (often less than 10 μm) [54]. 
1.4.3 Chemotrophic factors 
Neurotropism is a concept describing events in nerve regeneration in which axonal growth is 
directed by a chemotactic diffusible substance along a concentration gradient towards the source 
[89].  The growth cone of the regenerating axon actively samples the environment for both 
permissive and inhibitory soluble factors through different tyrosine kinase cell surface receptors 
[90].  This concept was first demonstrated in the 1980’s when it was shown that a distal nerve 
stump can attract axons from a neighboring proximal stump over distances of about 0.5 cm even 
when the stumps were placed out of alignment [91].  In a study by Politis et al., proximal stumps 
of transected rat sciatic nerve were inserted into the single inlet end of a hollow, Y-shaped 
Silastic tube.  Regenerating axons were provided with a vacant arm as an alternative target to the 
distal sciatic nerve graft arm.  In addition, 0.2 micron pore size filters were placed between the 
distal nerve segment and the proximal segment.  These results strongly supported the hypothesis 
that rat sciatic nerve fibers migrate exclusively toward the distal nerve stump because of a 
chemical gradient of soluble tropic molecules secreted by cells within the distal nerve stump 
[25].  Furthermore, these chemical attractants are not exclusively neurotropic as both the 
migration of Schwann cells and endoneurial fibroblasts are also promoted [89]. 
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1.4.3.1 Nerve Growth Factor and other Neurotrophic Factors 
 Neurotrophic factors investigated to promote peripheral nerve regeneration include nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
neurotrophin-4/5 (NT-4/5), ciliary neurotrophic factor (CNTF), and glial cell line-derived growth 
factor (GDNF) (Table 2) [9].   
 
 
Table 2. Neurotrophic Factors Investigated to Promote Nerve Regeneration 
 
Substance Abb. Function 
Nerve Growth Factor NGF Survival and maintenance of sympathetic and sensory neurons 
Brain-Derived 
Neurotrophic Factor BDNF 
Supports motor neuron survival and promotes axonal growth 
of motor and sensory neurons 
Neurotrophin-3 NT-3 Promotes motor neuron survival and motor and sensory growth 
Neurotrophin-4 NT-4 Supports axonal outgrowth of motor neurons 
Glial Cell Line-
Derived Neurotrophic 
Factor 
GDNF 
Upregulated by Schwann cells after injury.  Promotes survival 
of motor, sensory and autonomic neurons 
Ciliary Neurotrophic 
Factor CNTF 
Produced by Schwann cells. Promotes motor neuron survival, 
outgrowth and sprouting 
 
 
 Because NGF is a known promoter of sensory neuron survival, outgrowth and branching, 
extensive research has been invested in the delivery of NGF into nerve lesions [92, 93].  NGF is 
continuously expressed at low levels in uninjured peripheral nerve and is upregulated in the 
distal nerve stump upon nerve injury or transection [94].  In addition, NGF has been shown to 
promote sensory neuron survival, outgrowth and branching [95].  When used in solution inside a 
nonporous silicone tube, NGF treatment has been shown to yield significantly more myelinated 
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fibers, thicker myelin sheaths, and higher recordings of nerve conduction velocity than those 
values seen in the negative controls [96].  Because of the short half-life of NGF, delivery 
methods have been investigated for the sustained delivery of the neurotrophic factor over the 
duration of nerve regeneration.  NGF has been encapsulated within biodegradable microspheres 
[97, 98] or lipid microtubules [99], adsorbed onto the polymer surface of the nerve guide or 
coated on the inside of the nerve guides with centrifugal casting [100].  When used in a critical 
size defect in the rat animal model (13 mm), high doses of NGF (20 to 50 ng/mL) have resulted 
in a total fiber number and fiber width that was comparable to autograft controls within 
transverse sections from the midpoint of the implanted guide [101].  However, NGF treatment 
groups were inferior to autografts in the distal regions of the conduits, suggesting that NGF was 
not supplied to the injured nerve for enough time or at sufficient concentration.  In addition, 
when compared directly, alternative neurotrophic factors such as BDNF, NT-3, and GDNF have 
proven more successful than NGF for promoting nerve regeneration in terms of myelinated axon 
diameter [102] and total number of myelinated axons [103].  Finally, work by Doubleday and 
Robinson suggest that tropic molecules secreted from the distal nerve stump that direct axonal 
outgrowth are unlikely to include NGF as rats immunized to NGF produced the same directed 
growth [89]. 
 BDNF has been reported in the literature to support motor neuron survival [104], as well 
as promote both motor neuron [105] and sensory neuron axonal outgrowth [106].  The effects of 
BDNF on peripheral nerve regeneration have been assessed following delivery by osmotic mini-
pumps [107, 108], calcium alginate spheres [109] or through direct cross-linking to a collagen 
nerve guide matrix [110].  In studies performed comparing BDNF treatment to lactated Ringer 
solution for repair of a primary cut and repair injury in the rat sciatic nerve, BDNF did not result 
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in an improvement in either fiber count or mean axon diameter above the negative control [108].  
Additionally, 6 mm sciatic nerve defects repaired with BDNF covalently linked to collagen nerve 
guides did not result in an improved nerve conduction velocity but did show improvement in the 
mean axon count [111].  In addition to BDNF, CNTF has also been shown to promote motor 
neuron survival, outgrowth and sprouting [112-114].  When used in combination with BDNF, 
CNTF has been shown to promote axonal sprouting into the distal segment of a 6 mm defect in 
the sciatic nerve as well as increasing the average axonal diameter [111].  However, CNTF has 
also been demonstrated to participate in glial scarring resulting in nonpermissive growth as an 
inducer of reactive gliosis [115, 116].  
 Following peripheral nerve lesion, GDNF has also been correlated with improved 
regeneration in several in vivo models [103, 117-125].  GDNF has been reported to promote not 
only axonal outgrowth and maturation [119, 123, 126], but also Schwann cell proliferation and 
myelination of normally unmyelinated small axons [127].  Therefore, this trophic factor holds 
great potential as a therapeutic for the treatment of neurodegenerative diseases [128].  Further 
documentation of GDNF use in in vivo studies can be found in Section 5.1.  
1.4.4 Additional factors for enhanced nerve regeneration 
Acidic and basic Fibroblast Growth Factors, (aFGF and bFGF) are strong promoters of 
angiogenesis, are mitogenic for endothelial cells, fibroblasts, and Schwann cells and have 
therefore been hypothesized to enhance peripheral nerve regeneration following injury [129-
132].  When bFGF was adsorbed onto nitrocellulose paper that was implanted within the lumen 
of a silicone nerve conduit in a rat sciatic nerve, histological transverse sections of the proximal 
half of the excised conduits revealed that bFGF improved tissue integration of perineurial-like 
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cells, vasculature, and Schwann cells when compared to silicone controls which resulted in fibrin 
matrix and erythrocytes [131].  Furthermore, aFGF used in combination with a collagen matrix 
to repair a 1 cm rat sciatic nerve defect demonstrated regeneration comparable to autografts and 
were superior to collagen used with NT-3 or BDNF [133].     
Similar to aFGF and bFGF, Vascular Endothelial Growth Factor (VEGF) has been shown 
as an angiogenic factor through high specificity of endothelial cell migration and has been 
hypothesized to aid in nerve regeneration.  Silicone conduits filled with matrigel and VEGF were 
fabricated to quantify the morphological effect on Schwann cell and axonal regeneration.  
Results indicated that very high doses of VEGF (500 ng/mL) were required to produce 
significantly improved increase in total fiber counts and axon diameter as compared to matrigel 
controls without VEGF.  However, the fascicular area and myelin thickness of the regenerated 
nerve was not improved, nor was the resulting gastrocnemius muscle mass higher than negative 
controls [134].      
Other trophic factors such as Endothelial Growth Factor (EGF) and Insulin-like Growth 
Factor (IGF) have also been employed in in vivo models of nerve repair with limited results.  The 
effects of EGF on axonal regeneration were evaluated within collagen tubes across a 7 mm gap 
in the sciatic nerve in the rat animal model.  Although EGF was used at a very high dose of 3 
mg/mL, no significant improvements were observed in electrophysiological recordings or axonal 
regeneration [135].  The IGFs (IGF-I and IGF-II) have neurotrophic effects in vivo [136, 137] 
and are upregulated in distal regains of peripheral nerve following crush injuries and then 
decrease with the progression of nerve regeneration [138].  Results from a study comparing IGF 
therapy within nerve guides made from acellular muscle grafts with cultured Schwann cells 
across a 2 cm rat sciatic nerve defect showed a decrease in nerve regeneration when compared to 
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grafts used without IGF.  However, autografts used in combination with IGF delivered via 
osmotic pump had a significantly increased axon count and an improved g-ratio compared to 
autografts without IGF-I [139].  These contrasting results may indicate a negative response of the 
IGF dosage used in combination with Schwann cell populations seeded within the muscle grafts.  
These studies underline the need for further development of controlled release systems to 
progress the current understanding of the dose dependent effects of nerve regeneration following 
growth factor administration.  
1.4.5 Tissue engineered nerve guides 
Tissue engineered nerve guides have been fabricated to investigate the regenerative capacity of 
complex scaffolds that integrate multiple cell adherence and axonal guidance cues for nerve 
repair.  In addition to soluble factors, nerve regeneration can also be improved by supplementing 
nerve guides with supportive extracellular matrix components such as small intestinal submucosa 
(SIS) or with cell adhesion molecules.  Furthermore, genetically engineered cells that are capable 
of overexpressing active growth factors in a controllable, sustained manner for the entire 
duration of nerve regeneration have been incorporated into nerve guides.   
1.4.5.1 Nonautologous / acellular grafts 
 Because the internal structure and extracellular matrix of grafted nerve segments have 
proven highly effective for promoting nerve repair in terms of guiding cell migration and 
promoting axon elongation, several types of acellular tissue grafts have been investigated as  
potential nerve guides [140].  Studies using decellularized sciatic nerve allograft show that the 
manner in which the grafts are decellularized significantly affects the capacity to support nerve 
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regeneration.  While freeze-thaw cycles and chemical treatments with Triton-X produce acellular 
grafts with greatly reduced axonal regeneration when compared to fresh isograft controls, the use 
of sophisticated and lengthy processing protocols of harvested allografts have achieved nerve 
regeneration comparable to the gold standard of nerve repair, the autograft in a 1 cm rat sciatic 
nerve defect [140].   
 Acellular nerve grafts have also been prepared from venous and muscle grafts [141].  The 
first uses of acellular muscle grafts involved digital nerve repair; a lack of viable Schwann cell 
populations were seen in grafts of increased length [141].  Therefore, nerve regeneration in 
venous and muscle grafts seeded with cultivated Schwann cell populations were compared to 
isograft controls.  In terms of both regenerated axon counts and nerve conduction velocity, both 
muscle and vein grafts failed to equal the regenerative capacity of positive control treatments 
[141, 142].  
 As an alternative to grafting whole tissue, small intestinal submucosa (SIS) has also been 
processed into conduits for nerve repair.  SIS is a minimally immunological xenograft transplant 
processed from the extracellular matrix of porcine small intestine.  The material has been 
reported to contain a large number of inherent tissue growth stimulating factors.  In addition, 
depending on the processing technique used, SIS is readily reorganized and absorbed by the host, 
providing great potential to replace the lesioned nerve segment with native tissue [143].  
However, when SIS nerve guides were implanted across a 1 cm defect and allowed to regenerate 
for 90 days, a period adequate for measureable nerve regeneration across this established defect 
length, no functional recovery could be measured and sciatic nerve growth into the guide was 
restricted to the proximal portions of the conduit.  These results may have occurred as a result of 
the rapid resorption rate of SIS, which is between 4 and 16 weeks [144].  It is therefore possible 
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that implanted guides comprised of SIS were not mechanically adequate to support axonal 
outgrowth over the entire regeneration period.     
1.4.5.2 Schwann cell seeded nerve guides 
 The importance of Schwann cells for peripheral nerve regeneration has been well 
documented [145, 146].  Schwann cells produce extracellular matrix, cell adhesion molecules, 
integrins and neurotrophins, and have therefore been intensely studied as additives in nerve guide 
implants.  Therefore, it has been hypothesized that the use of artificial conduits containing viable 
Schwann cell populations would be a promising strategy to repair peripheral nerve injuries [147-
149].  Nerve guides investigated with seeded Schwann cell populations and matrigel have shown 
that functional recovery following nerve regeneration was similar between autograft controls and 
only those conduits seeded with autologous Schwann cells populations [150].  Implantation of 
conduits with Schwann cells isolated from mice of the same strain or mice of the same litter 
resulted in inferior functional recovery following repair of a 6 mm sciatic nerve defect [150].  
These results are disappointing for the potential therapeutic use of nerve guides with human 
Schwann cells as it is not clinically feasible to isolate and expand the required number of 
Schwann cells for implantation (due to donor site morbidity and time required for Schwann cell 
culture and expansion).  However, new culture protocols that improve Schwann cell proliferation 
and expansion may allow Schwann cell seeded nerve guide to be more clinically useful someday.   
1.4.5.3 Gene therapy 
 The success of neurotrophin delivery from nerve guides toward improved nerve 
regeneration has often been cited as suboptimal due to low dosages and short delivery periods 
[151].  In addition, the stability of such growth factors is generally poor, causing the bioactivity 
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of delivered proteins to be uncertain [37].  Therefore, the transplantation of genetically modified 
cells which overexpress specified neuroregenerative proteins have been investigated with great 
interest [9].  In particular, genetically modified fibroblasts have been studied for the sustained 
delivery of  bFGF [152], CNTF [153], NGF, BDNF, and NT-3 [154].  While these cells have not 
been utilized toward peripheral nerve repair, genetically modified fibroblasts hold promise for 
both supporting axonal outgrowth and delivering neurotrophic factors directly within the site of 
nerve injury.   
 Schwann cells have also been modified to overexpress factors such as bFGF and GDNF 
and have been used in peripheral nerve studies.  When implanted in a critical size, 1.5 cm, sciatic 
nerve defect, silicone tubes filled with matrigel and Schwann cells overexpressing bFGF 
improved both the number and length of regenerated myelinated axons when compared to 
controls [132].  Schwann cells have also been genetically modified to overexpress GDNF [155].  
In the rat animal model, 1 cm sciatic nerve defects were bridged with silicone tubes filled with 
saline, Schwann cells, or Schwann cells overexpressing GDNF.  Histological analysis of 
regenerated nerves showed an increase in myelinated fiber number and density, myelin sheath 
thickness, and the overall nerve area as highest in animals with GDNF expressing Schwann cells.  
Additionally, nerve conduction velocity and compound muscle action potential were greater with 
the experimental GDNF group.  It was not noted in this study if transfected cells migrated from 
the implanted nerve conduit or if any adverse consequences of using genetically modified cells 
were observed.   
 While results with genetically engineered cells have shown great potential for delivering 
a continual supply of active growth factors which promote nerve regeneration, challenges with 
gene therapy use in humans remain.  It would be beneficial if modified cells implanted within 
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nerve guide could respond to environmental cues to cease protein overexpression.  In this 
manner, neurotrophin expression could be used to lead regenerating axons into the a graft and 
then expression could be stopped once it is no longer necessary [9].    
1.5 SUMMARY AND LIMITATIONS OF PREVIOUS RESEARCH 
A difficulty in human nerve regeneration is that the axon length that must be regrown is not just 
the length of the gap, but is the length from the lesion to the innervated muscle. Consequently, 
end organs (such as muscle) may become atrophied before the axon can reinnervate them. 
Therefore, it is insignificant if the axon reaches the correct location in the periphery or not as the 
resulting nerve remains nonfunctional. While nerve guides serve as a barrier to infiltrating 
fibroblasts and inflammatory cells for scar minimization, guides are not successful for gaps 
greater than 3 cm because nothing within commercially available nerve guides actively promotes 
axonal growth.  And so, any manipulation that speeds axonal growth would have an enormous 
impact on large gap PNS repair as it would improve the likelihood of serviceable motor and 
sensory control, which is the end goal of surgeons and patients.  
 The methods for improving nerve guides for repairing long nerve defects described 
within this chapter have included: 1) optimization of nerve guide materials and fabrication 
techniques for obtaining high porosity, low immunogenicity and slow degradation rates, 2) 
delivery of chemotrophic factors for promoting axon and Schwann cell survival and 3) 
supplementing nerve guides with extracellular matrix components or genetically engineered cells 
in tissue engineered nerve guides.  In terms of commercial success, it is highly desirable that a 
nerve guide be manufactured such that it is an off-the-shelf product that does not require seeding 
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of cell populations at the time of implantation.  For this reason, nerve guides that serve as a drug 
delivery vehicle for neurotrophic factors to enhance nerve regeneration may be more clinically 
relevant.  However, the nerve guide delivery systems described herein are plagued by short 
release periods and low concentrations of delivered growth factors.  Therefore, a current 
limitation within nerve guide design is the ability of nerve guides to deliver a physiologically 
relevant concentration of neurotrophic factors over the entire regeneration period required for 
repairing long nerve defects.   
1.6 HYPOTHESIS AND SPECIFIC AIMS 
Our underlying hypothesis is that delivery of Glial Cell Line-Derived Neurotrophic 
Factor (GDNF) from nerve guides using microsphere technology will result in functional 
recovery in the in vivo environment following large axonal defects in the peripheral nervous 
system.  This hypothesis is based on the following observations.  First, GDNF is expressed by 
Schwann cells, and injury results in rapid up-regulation in distal segments of lesioned sciatic 
nerve [156].  However, with increasing gap length, the GDNF levels at the site of the injury are 
not sufficient to compensate for the lack of target derived neurotrophic factors to maintain cell 
survival [157].  Second, GDNF has been shown to prevent avulsion-induced motorneuron death 
following complete nerve transection whereas NGF, BDNF, and IGF have all failed to enhance 
cell survival or cell size [126].  Third, GDNF treatment with guidance channels following spinal 
cord injury resulted in a reduction of reactive astrocytosis and macrophage accumulation [120]. 
Finally, histological comparison of nerve guides implanted with and without added GDNF 
showed that nerve guides releasing GDNF increased nerve fiber number, fiber diameter, and 
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additionally myelin thickness was improved, an indication of improved nerve regeneration [103, 
158].   
The specific aims presented here were designed to systematically evaluate key design 
parameters of a polymer nerve guide prototype and assess GDNF therapies in regards to 
functional recovery following large lesions in peripheral nerve trunks. 
 
Specific Aim 1:  To quantify the in vitro effect of nerve guide wall porosity percentage and wall 
thickness on growth factor and nutrient diffusion through PCL nerve guide walls.  The work 
performed towards this aim is described within chapter 2. 
 
Specific Aim 2:  To develop a nerve guide that can deliver encapsulated proteins for the duration 
required for the regenerating peripheral nerve axon to reach the distal nerve stump following 
transection.  The performed towards this aim is presented within chapters 3 and 4. 
 
Specific Aim 3:  To quantify the in vivo effect of GDNF delivery from a PCL nerve guide in 
terms of histological and functional regeneration of the sciatic nerve across a critical size (1.5 
cm) defect.  The work performed towards this aim is presented within chapter 5.  
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2.0  DIFFUSION OF SOLUBLE FACTORS THROUGH DEGRADABLE POLYMER 
NERVE GUIDES: CONTROLLING MANUFACTURING PARAMETERS 
2.1 INTRODUCTION 
2.1.1 Structural requirements 
While some of the mechanical requirements of implantable nerve guides are obvious, for 
example the guide must be of the proper dimensions (the length must be long enough to bridge 
the gap without tension and the width must house the nerve stumps without compression) and the 
material must be strong enough to resist tearing from sutures yet soft enough to avoid tissue 
inflammation, other design aspects are less clear. As shown as early as 1985, a critical facet in 
nerve regeneration is the delivery of oxygen and nutrients to the surviving nerve tissue [159]. 
Presumably, the nerve guide should maximize the influx of oxygen and nutrients through pores 
in the guide wall. However, there is a limit in wall porosity because of opposing needs to allow 
interstitial fluids into the guide, prevent inflammatory cells from migrating into the lumen, and 
minimize the diffusion of growth factors out of the guide lumen. 
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2.1.2 Optimization of nerve guide wall porosity parameters: previous studies 
It was initially presumed beneficial to place transected nerve stumps in nonporous silicon tubes 
because the guide would contain the fluid and cells that come from the regenerating nerve 
stumps to the injury site.  However, a 1985 study by Jenq and Coggeshall showed that by 
allowing the extracellular fluid and its cells into the lumen of the guide through macroscopic 
holes in the guide wall, the number of both myelinated and unmyelinated axons was significantly 
increased [159].  In a subsequent study, the authors further specified that pore size was an 
important factor in determining nerve repair.  Using two pore diameters, 1.2 micron and 5 
microns, the authors saw 8/8 rats had full recovery using the 5 micron pore size while only 4/9 
rats recovered using the 1.2 micron pore size in an 8 mm gap.  It is important to note here that 
the authors defined successful regeneration as producing nerve cables with at least 1000 axons 
uniting the proximal and distal nerve stumps [160].  The most dramatic change that occurred in 
the nerve tissue was the extensive development of the perineurium, the layer of fibroblasts and 
collagen that surrounds axons and forms fascicles. The authors hypothesized that the significant 
increase in both myelinated and unmyelinated axon counts that were seen in silicone tubes with 
macroscopic holes in the walls was a result of an increase in the number of support cells lining 
each fascicle and supporting the axon. Though the authors do not speculate how this would 
impact the functional outcome of the nerve regeneration (the authors did not indicate if the 
animal regained use of the muscle), it was left to determine if the increased number of axons 
were beneficial, or if they merely indicated greater axonal branching. Finally, in 1989 the effect 
of two pore sizes that varied in molecular weight cut off were examined in 4 or 8 mm gaps in 
LVG hamsters [161]. The authors concluded that molecular weight cut off of the guide wall 
made a significant difference and lower numbers of myelinated axons were seen in pores 
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permeable to proteins with a molecular weight of 106 Da versus 105 Da.  This was presumably 
because the type of growth factor that could escape the lumen of the tubes was restricted. 
Unfortunately, functional recovery of the animals was not addressed.    
 A 2002 study by Rutkowski and Heath used computer models of diffusion to predict 
maximum axonal growth from experimental data on diffusivities, uptake rates, and nerve growth 
factor production rates [162]. This publication demonstrated the impact of certain variables, one 
of which was the supply of oxygen and nutrients, on axonal and Schwann cell growth. The 
effects of both porosity and wall thickness were examined to determine their impact on the 
luminal concentrations of a secreted growth factor and oxygen. Pore size was controlled by using 
a salt leaching technique using salt crystals ≤ 106 microns in diameter.  Porosity percentage was 
altered by the salt content in the polymer solution which was then poured into molds. The final 
porosity percentage was therefore an estimate. As expected, it was determined that lower 
porosity better retains secreted growth factors but at the expense of oxygen, a critical factor in 
the survival of Schwann cells and other support cells. Conclusions obtained from the computer 
model were that larger porosity allows for more oxygen diffusion and an increasing wall 
thickness reduces the diffusion of soluble factors out of the guide. 
Nerve guide porosity and wall thickness have been evaluated in an in vitro system in 
which parameters were evaluated for their ability to influence nerve growth in excised dorsal 
root ganglia [163]. Conduits were made with varying porosity, (0, 55%, 65%, 75% and 85%) and 
wall thicknesses (0.56 mm, 0.81 mm, 1.10 mm, 1.28 mm, and 1.44 mm). From this in vitro work 
it was shown that axon growth was slightly increased with increasing porosity and was 
significantly reduced in conduits with wall thicknesses greater than 0.8 mm. When these 
conduits were seeded with Schwann cells, nonporous conduits had much lower growth compared 
 38 
to the porous ones.  Such in vitro findings correlate well with results obtained from diffusion 
models described above.    
2.1.3 Chapter aims 
The purpose of Specific Aim 1 was to optimize nerve guide fabrication parameters such that 
lysozyme diffusion through poly(caprolactone) (PCL) conduit walls was minimized while 
nutrient (glucose) permeability was maximized.  To achieve this, the effect of three fabrication 
variables (wall thickness, pore size and porosity percentage) on both glucose and protein 
diffusion was tested.  While it is unlikely that protein loss from a porous scaffold will be entirely 
eliminated, it was determined that a 10% loss of protein payload would be acceptable.  However, 
because Schwann cell survival has been indicated as being limited by blood nutrient diffusion, 
we also aimed to determine the maximum nerve guide permeability to soluble glucose.  Though 
glucose is a small, hydrophilic molecule and as such cannot be used to model the inward 
diffusion of large biomolecules such as polysaccharides or triglycerides, it was hypothesized that 
modeling glucose permeability was an adequate method of approximating critical blood nutrient 
diffusion for molecules such as oxygen and blood glucose.       
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2.2 METHODS 
2.2.1 Reagents 
All chemicals were analytical grade or purer and were purchased from commercial suppliers.  
Poly(caprolactone) (average Mw ~65,000, average Mn ~42,500, pellets), ethyl acetate, 
ninhydrin, sodium chloride (crystalline, fine), poly(vinyl alcohol) (average Mw 9,000-10,000, 
80% hydrolyzed), poly(DL-lactide-co-glycolide) (lactide:glycolide (50:50), mol wt 40,000-
75,000 units), lysozyme from chicken egg white, glucose assay kit (GAGO-20), tetrahydrofuran, 
1,6-hexanediamine, and D-(+)-Glucose were all purchased from Sigma-Aldrich (St. Louis, MO).  
Glass capillary tubes, premium glass microscope slides, and Tissue-Tek Cryo-OCT Compound 
were purchased from Thermo Fisher Scientific (Waltham, MA).  The Micro Bicinchoninic Acid 
(BCA) Protein Assay Kit (23235) was purchased from Pierce (Rockford, IL).  26G Needles were 
purchased from Becton Dickinson (Franklin lakes, NJ).  Poly(L-lactide) was purchased from 
Durect Corporation (Pelham, AL). 
2.2.2 Polymer nerve guide fabrication 
Permeable nerve guides were created by dissolving PCL in ethyl acetate.   To the dissolved 
polymer solution, sodium chloride impregnation was accomplished by adding NaCl in a 
specified v/v% (NaCl:PCL) amount.  Large crystals of NaCl were first ground into a fine powder 
with a mortar and pestle and then sifted through sieves of known mesh diameter.  Glass capillary 
mandrels 1.5 mm in diameter were coated with a 17% w/v% aqueous solution of poly(vinyl 
alcohol) (PVA), air dried and then immersed into the polymer slurry creating NaCl/PCL mandrel 
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coatings.  The ethyl acetate was allowed to evaporate for a minimum of ten minutes between 
successive mandrel immersions into the polymer slurry.  After the completion of the dip-coating 
process, the resulting polymer conduits were submerged in distilled water to allow for salt and 
PVA dissolution, and the glass mandrels were removed.  Porosity percentage was varied through 
altering volume percentages of sodium chloride in the polymer-solvent slurry.  The nerve guide 
wall thickness was varied by the number of immersions performed in the dip-coating technique 
used to create the guides.   
2.2.3 Nerve guide porosity measurement 
Wall porosity percentage was determined after scanning electron microscopy (SEM) image 
analysis.  PCL nerve guides were dried, cut into thin sections with a razor blade and mounted on 
metal stubs covered in copper double sided tape.  The guides were then gold-coated to 3.5 nm 
thick using a Cressington 108 auto sputter-coater (Cressington, Watford UK), and viewed with a 
JEM-6330f (Jeol, Peabody, Ma) scanning electron microscope operated at 5kv acceleration.  
Low magnification images were used for image analysis as previous literature has shown better 
agreement of image analysis of material porosity with actual porosity values (Figure 4A) [164].  
To determine the guide porosity, the proportion of pixels dedicated to ‘wall area’ versus ‘pore 
area’ was determined with ImageJ software [165].  Because of the subjective nature of 
thresholding grey-scale images, Otsu’s method of thresholding was employed to decipher 
grayscale levels within the image that were considered polymer or empty space, creating a binary 
image from which pixel areas could be calculated (Figure 4B) [164].  For bi-level thresholding, 
Otsu’s method optimizes the threshold such that the variance between light and dark pixels is 
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maximized [166] and as a result, the variance in pixels associated with the pores and walls is 
minimized. 
 
 
 
 
Figure 4.  Scanning electron image of 50% porous PCL nerve guide in original format (A) and as 
processed with Otsu thresholding by ImageJ (B). 
 
 
2.2.4 Nerve guide wall thickness measurements 
To determine the wall thickness of PCL nerve guides, 5 lots of six nerve guides were fabricated 
using the dip-coating manufacturing technique described above.  Within each batch of nerve 
guides, the number of immersions of the glass mandrel into the polymer slurry varied between a 
single immersion and seven consecutive immersions.  After the nerve guides were detached from 
the mandrel and dried, each guide (2 cm in length) was cut into six sections of similar length and 
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submerged in Optimal Cutting Temperature (O.C.T.) compound and frozen for sectioning with a 
cryostat.  The nerve guides were then sectioned (15 µm) and mounted onto glass slides.  Optical 
microscopy and a stage micrometer were then used to determine the wall thickness of PCL nerve 
guides.  For each image of a nerve guide cross section, over 15 radial measurements were taken, 
perpendicular to the tangent of the inner wall, (at approximately 24 degrees apart) and were 
averaged to obtain the mean wall thickness for each nerve guide (Figure 5A - B).  Averages were 
used to assess the influence of the number of mandrel immersions on the wall thickness of the 
final nerve guide as well as to ensure reproducibility of our fabrication methods over a number of 
nerve guide batches. 
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Figure 5.  Image of a PCL nerve guide divided longitudinally into six lengths (A).  Each length of nerve 
guide was placed vertically into a square mold, sectioned (15 µm) using a cryostat, mounted onto a glass slide and 
viewed with a light microscope (B).  From each cross section, 15 radial wall measurements (tangential to the 
circumference) were averaged to determine the mean and standard deviation of nerve guide wall thicknesses.   
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2.2.5 Optimization of nerve guide porosity and wall thickness 
PCL nerve guides were fabricated as described above and the effect of each variable (wall 
thickness, pore size and porosity percentage) on glucose and protein diffusion was tested using 
factorial analysis (Table 3).  To measure the diffusion of glucose or protein through the guide 
wall, both ends of the guide were sealed with a water-proof sealant E-6000 craft adhesive.  Nerve 
guides were discarded if the sealant extended more than 1 mm onto the surface of the nerve 
guide wall, thus eliminating any guides from the study which might have a significantly reduced 
porosity due to the experimental design.  After the sealant was allowed to dry, 50 μl of solution 
with dissolved glucose (10 mg/mL) (to mimic blood nutrient diffusion) or lysozyme (8 mg/mL) 
was injected through a 26G needle into the PCL nerve guide lumen through a sealed end.  Any 
opening that was created with the needle was securely closed and the guide was submerged in 
5.0 mL of phosphate buffered saline. After 4 hours, the extraluminal solution was aspirated and 
the concentration of diffused solution was measured with an appropriate assay (glucose: Glucose 
Assay Kit; lysozyme: bicinchoninic acid protein assay).  Preliminary experiments for comparing 
nerve guide permeability over time indicated that a 24 hour period of solute diffusion through 
nerve guide walls allowed all experimental groups with transluminal flow to reach system 
equilibrium and thus all external solutions contained an identical concentration of measured 
solute.  4 hours was therefore chosen as a time point for measuring initial significant differences 
in nerve guide permeability.  Considering the physiological concentration of blood glucose is 
~0.9 mg/mL [167] and our anticipated neurotrophic factor dosage is 100 ng/mL [103, 125], the 
initial glucose or lysozyme solutions are not physiologically relevant.  The injected solution 
concentrations were adjusted to match the minimum working range of the glucose assay (20 
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µg/mL) and the Micro BCA protein assay (0.5 µg/mL) with consideration to the dilution of 
solutes caused by submerging the fluid-filled nerve guide in saline solution.   
  
 
Table 3.  Fabrication Parameters Used to Create Nerve Guide Standards. 
 
Standard Number Wall Thickness (mm) Porosity (%) Pore Size (µm) 
1 0.2 50% 10 – 38 
2 0.6 50% 10 – 38 
3 0.2 50% 75 – 150 
4 0.6 50% 75 – 150 
5 0.2 80% 10 – 38 
6 0.6 80% 10 – 38 
7 0.2 80% 75 – 150 
8 0.6 80% 75 – 150 
 
 
The numerical response resulting from each experimental group was the percentage of 
material that diffused from the PBS solution inside the guide through the guide wall and into 
extra-luminal solution.  The solute was considered to have 100% permeability if the 
concentration of the solute inside the lumen of the nerve guide and the aqueous external PBS 
solution were equal (the system was in equilibrium).   While the initial diffusion studies were 
useful for evaluating key fabrication parameters that limit growth factor loss from the guide 
lumen, this preliminary study was an estimate for the behavior of such solutes through the guide 
after implantation.  For example, protein fouling would be expected to occur immediately 
following guide implantation in vivo and could have an effect on the guide wall permeability.  
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Therefore, the diffusion of lysozyme and glucose were subsequently modeled after the nerve 
guides were incubated in a 10% FBS saline solution for 24 hours prior to performing similar 
diffusion studies as described above. 
2.2.6 Ninhydrin assay 
A ninhydrin assay was used to verify the presence of amine groups on the surface of 
poly(caprolactone) nerve guides.  Ninhydrin (triketohydrindene hydrate) is a chemical that reacts 
with free amine groups creating a solution colored Ruhemann's purple that can be compared to 
samples of known protein concentration [168].  Following protein fouling diffusion experiments, 
each nerve guide was immersed in a 1.0 M ninhydrin solution for 1 minute and then transferred 
to a glass vial that was heated at 75°C for 15 minutes. The treated guide was then dissolved in 4 
mL of tetrahydrofuran (THF). The absorbance of the final solution was measured at 560 nm 
using a SpectraFluor Plus plate reader (Tecan, Switzerland).  A standard curve was prepared 
using known concentrations of 1,6-hexanediamine. 
2.2.7 Statistical analysis 
Multiple nerve guide batches were created for each measurement with a minimum repetition of 
five.  Results are expressed as the mean ± standard deviation or standard error where indicated.  
Analysis of variance (ANOVA) was used to determine statistical significance between 
experimental groups.  The least significant difference method was used for multiple comparisons 
with p < 0.05. 
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2.3 RESULTS 
2.3.1 Scanning electron microscopic analysis of PCL nerve guides 
Porous poly(caprolactone) nerve guides were created using a dip-coating, salt-leaching 
technique.  The resulting nerve guides were 2-3 cm in length and flexible (Figure 6 A - B).  SEM 
analysis revealed that nerve guides of low porosity (50% porous) displayed smooth inner walls 
and several blind-ended (pores that are exposed only at a surface) or closed pores (pores that are 
isolated within the polymer matrix).  In contrast, highly porous nerve guides (80% porous) 
consisted of walls that were less smooth with highly interconnected pores for transluminal flow 
and solute diffusion (Figure 7). 
 
 
 
 
Figure 6.  Photo of a flexible PCL nerve guide (A).  Image of nerve guide after fabrication (B). 
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Figure 7.  Scanning electron images of low porosity (50%) nerve guides revealed guides with smooth 
luminal surfaces (A) and blind-ended and closed pores (B).  In contrast, highly porous nerve guides (80% porous) 
had walls that were less smooth (C) with highly interconnected through-pores (D). 
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2.3.2 Validation of nerve guide porosity 
Photographs of SEM images of nerve guide cross-sections were used with ImageJ software to 
determine the porosity percentage of the nerve guide walls.  The theoretical porosity was 
determined by the addition of a known volume of NaCl (density: 2.16 g/cm3) to a known volume 
of PCL (density: 1.145 g/cm3). NaCl crystal diameter ranged between 10 – 38 µm.  Results 
obtained from binary image analysis of the percentage of open space compared to guide wall are 
shown in Figure 8.  Nerve guide porosity was measured for guides of 50% NaCl/PCL 
composition to 70% NaCl/PCL in 5% increments.  For all nerve guides, the measured average 
porosity was within 3% of the theoretical porosity, with the greatest variation seen in the 60% 
porous nerve guides where 57.2% was measured.  Standard deviation in guide porosity averages 
ranged between 6% and 11%, indicating an acceptable rate of consistency between nerve guide 
batches. 
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Figure 8.  Porosity of the PCL conduits as determined by the percentage of open space in nerve guide 
walls.  Error bars represent mean ± standard deviation for n=5.  Significance between groups is indicated by 
asterisks (p<.05). 
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2.3.3 Validation of nerve guide wall thickness 
Wall thickness varied depending on the number of immersions used to create each nerve 
guide.  PCL nerve guides were fabricated with two wall porosities (50% and 80%) and a variable 
number of immersions of the mandrel into the polymer slurry.  At least 6 cross sections of each 
guide from all batches were analyzed to obtain mean wall thickness (Figure 9).  Results indicated 
that the nerve guide wall thickness was proportional to the number of mandrel immersions into 
the polymer slurry.  Furthermore, the 80% porous nerve guides required more mandrel 
immersions into the polymer slurry to create a nerve guide of similar thickness to the 50% 
porous guides.  This difference in thickness was caused by the change in viscosity of the polymer 
solution required to create the original PCL/NaCl slurry.  When guides of 50% porosity were 
fabricated, a polymer solution of 20% (w/v) PCL was originally prepared.  To this solution, 
5.659 g of sodium chloride was added.  However, in order to create an 80% porous nerve guide 
of the same original polymer solution concentration, 22.638 g of NaCl would have been 
required.  Because porosity percentage was due to a volume ratio of NaCl to PCL, a more 
reasonable weight of NaCl (7.92 g) was instead added to a 7% polymer solution to manufacture 
80% porous nerve guides.  However, these two polymer/NaCl slurries had slightly different 
viscosities which contributed to the difference in nerve guide wall thickness due to the number of 
mandrel immersions. 
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Figure 9.  Wall thickness of PCL nerve guides as measured with light microscopy and a stage micrometer 
from 5 batches of samples.   50% porosity,  80% porosity.  Statistical significance between porosity percentage 
groups and between successive immersions was achieved (asterisks represent p<.0001).  Results are expressed as 
mean ± SE for n=5 guide lots. 
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2.3.4  Optimization of nerve guide wall parameters 
Parameters of a nerve guide that affect diffusion include wall thickness, pore size (creating pore 
tortuosity), and pore percentage. The effect of each variable on glucose and protein diffusion 
through PCL nerve guides was tested using factorial analysis.  This type of analysis allows all 
three parameters to be tested simultaneously instead of modifying each factor at discrete values 
one at a time [169].  Each parameter was tested at a low and high value to provide a contrast of 
averages.  The effect of each possible value between the selected ranges on lysozyme or glucose 
diffusion for all three parameters was then estimated.  Additionally, simple effects, potential 
parameter interactions, and main effects are revealed through this type of analysis.   
 The low and high porosity percentages were chosen specifically because 50% porous 
guides are the lowest porosity percentage with interconnected pores when using the lowest pore 
diameter and thus transluminal flow, while porosities greater than 80% produced mechanically 
unstable guides. Wall thicknesses were chosen as 200 μm for the low variable range because this 
thickness is considered sufficient for nutrient diffusion [170], and 600 μm was considered the 
high endpoint for the wall thickness range because this is a wall thickness that minimizes 
diffusion [162].  Finally, pore sizes were selected because 10-38 μm is the minimum salt crystal 
diameter that can be successfully sieved and 75-150 μm is the largest crystal range that can be 
impregnated into PCL that would not disrupt the wall continuity upon leaching in the 0.2 mm 
thick guide. These three parameters were varied to determine which combination most 
successfully contained lysozyme within the lumen of the guide while simultaneously permitting 
glucose to diffuse freely through the guide walls. 
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2.3.4.1 Nerve guide porosity percentage 
The results indicate that porosity percentage is the main parameter affecting lysozyme 
and glucose diffusion through PCL nerve guides (Figure 10A).  For the period during which 
solute diffusion was measured for nerve guides made of 10-38 µm pores and wall thicknesses of 
0.6 mm, nerve guides which are 50% porous appeared to be almost impermeable for both 
glucose and lysozyme.  However, when the porosity was increased to 80%, nearly 50% of the 
concentration of glucose was able to diffuse through the nerve guide wall and into the 
surrounding aqueous environment.  Under similar conditions, approximately 44% of the 
lysozyme concentration was lost.  When the pore diameter was increased, it was observed that 
lysozyme diffusion increased to a small extent while glucose diffusion was not affected (Figures 
10B and 10C).  At low porosity percentages, such as 50%, a pore size increase from 10-38 µm to 
75-150 µm produced no effect on the diffusion of solutes through the guide wall.  This was most 
likely caused by the large number of closed pores seen in the 50% porous nerve guide SEM 
images.  However, for more highly porous guides, the pores are interconnected and protein 
diffusion is slightly increased.  The diffusion of the small molecule, glucose, does not appear to 
be affected by the diameter of the pores and thus subsequent experiments involved a smaller 
diameter pore size so as to minimize lysozyme loss (Figure 10B). 
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Figure 10.  A) Percentage of material that diffused through PCL nerve guides as determined by glucose 
assay kit and bicinchoninic acid protein assay.  Guide wall was 100% permeable to solute if the concentration of the 
solute inside the lumen of the nerve guide and the aqueous external PBS solution were equal.   lysozyme,             
  glucose.  B) Porosity percentage and pore size interact to increase lysozyme diffusion when both parameters are 
simultaneously increased. The red line indicates 75-150 µm pore diameter while the black line is 10 – 38 µm pore 
diameter.  C) Diffusion of glucose increased with porosity percentage regardless of an increase in pore size.  
Differences between solute permeability due to wall porosity percentage are significant (p<.0001).  Results are 
expressed as mean ± standard deviation for n=5. 
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2.3.4.2 Nerve guide wall thickness 
Increasing nerve guide wall thickness is an additional manufacturing parameter that 
limits the diffusivity of both lysozyme and glucose.  As expected, when the wall thickness of the 
nerve guide was increased, the permeability of both lysozyme and glucose was decreased 
through the nerve guide walls (Figure 11A).  The impact of wall thickness was most significant 
on the diffusion of glucose, which decreased from ~82% permeable with a 0.2 mm thick nerve  
guide wall to ~53% permeable in a nerve guide of 0.6 mm thickness (Figure 11B).  This is a 
significant decrease of 29% (p < .0001).  The results indicated that there was a smaller decrease 
in lysozyme wall permeability with a 25% reduction of solute diffusion (Figure 11C, p < .05).  
Because nutrient diffusion is critical to nerve regeneration and glucose diffusion was 
significantly increased by maximizing the wall porosity percentage, nerve guide wall porosity 
percentages were not considered adequate below 80%.  Furthermore, pore diameter was a useful 
parameter for minimizing lysozyme diffusion in highly porous guides (80% porous) while 
glucose diffusion was not affected.  Therefore, further studies were performed using guides of 10 
– 38 µm pore diameter.  Optimization experiments indicated that the thickness of the nerve guide 
wall needed to be analyzed using discrete parameter values in increments between the initial 
minimum and maximum ranges of 0.2 and 0.6 mm.  Therefore, analysis in protein diffusion 
using nerve guides of variable wall thickness were performed to determine the wall thickness 
parameter that would best restrict lysozyme permeability while simultaneously allowing for 
adequate glucose diffusion (Figure 12A). 
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Figure 11.  A) Percentage of material that diffused through PCL nerve guides as determined by glucose 
assay kit and bicinchoninic acid protein assay.     lysozyme,   glucose.  B) The permeability of PCL nerve guides 
to lysozyme as affected by nerve guide wall thickness. C) The permeability of PCL nerve guides to glucose as 
affected by nerve guide wall thickness.   Results are expressed as mean ± standard deviation for n=5.  (* p < 0.05) 
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Figure 12.  A) Percentage of material that diffused through PCL nerve guides as determined by glucose 
assay kit and bicinchoninic acid protein assay.    lysozyme,  glucose.  Results are expressed as mean ± standard 
deviation.  Asterisks indicate significant differences at 0.2 and 0.6 mm wall thicknesses for lysozyme diffusion 
(p<.0001).  There was no significance between any of the glucose measurements (p > 0.05).   B) Ninhydrin analysis 
of PCL nerve guides of 5 wall thicknesses following protein adsorbtion.  Results are expressed as mean ± standard 
error for n=3.  There was no significant difference between groups (p > .05). 
 
 
2.3.5 Effects of protein fouling on PCL nerve guide permeability 
To determine the effect of protein fouling on solute diffusion through the nerve guide wall, nerve 
guides were incubated in 10% FBS in phosphate buffered saline solution for 24 hours prior to 
performing a diffusion study as described above.  Protein fouling caused a decrease in lysozyme 
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diffusion from within the nerve guide (Figure 12B).  Initial diffusion studies indicated that nerve 
guides of 10 – 38 µm pore diameter and 80% porosity that were not coated with protein allowed 
approximately 45% of the lysozyme concentration originally contained within the lumen of the 
nerve guide to diffuse through the polymer wall.  After the PCL surface was treated with a 
protein rich solution, the percentage of lysozyme that diffused from the internal, luminal 
environment of the nerve guide significantly decreased to approximately 10% (p<.0001).  A 
ninhydrin anaylsis of protein deposition on the nerve guide surface suggested that proteins 
adhered not only to the external surfaces of the nerve guides but also throughout the internal pore 
surface of the polymer conduit, though experimental values were not statistically significantly 
different between groups (p > .05). 
2.4 DISCUSSION 
Polycaprolactone was initially chosen for use in nerve guides because it is a slowly degrading 
polymer that can provide sound mechanical support for the regenerating nerve for over one year.  
In addition, the degradation products, succinic acid, butyric acid, valeric acid, and caproic acid, 
are nontoxic and do not cause inflammation [171].  Furthermore, though PCL is typically a very 
rigid polymer (elastic modulus of 206 – 345 MPa), high porosity has been shown to decrease 
rigidity and allows for the creation of soft, flexible nerve guides [172].  While it is highly 
desirable for the implanted nerve guide to move fluidly within an animal as the animal regains 
mobility, previous studies performed with our PCL nerve guides shows that the PCL guides are 
also easily sutured across a sciatic nerve gap and maintain mechanical stability for the duration 
of 16 week in vivo.  Finally, the hydrophobic properties of PCL would enhance the capacity of 
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the nerve guide to contain both delivered and secreted neurotrophic factors within the area of the 
nerve injury due to the low diffusivity of hydrophilic proteins through the material [173].   
 It is well known that the peripheral nervous system is abundantly vascularized throughout 
axonal trunk lengths by vasa nervorum. Nerve trunks are supplied by blood vessels along their 
course by arteriae nervorum, which are intimately related to the nerve, and supply not only the 
supporting tissues of nerve trunks with oxygen and nutrients, but also contribute to the nutrition 
of the nerve fiber itself [14]. The importance of nerve vasculature is evident from literature 
reporting improved regeneration by nerve gap bridging devices that are porous when compared 
to identical but nonporous guides [21, 174].  Creating a porous nerve guide that permits adequate 
metabolic exchange across the tube wall while retaining growth factors to the internal lumen of 
the guide is a substantial challenge.  The goal of Specific Aim 1 was to optimize nerve guide 
fabrication parameters such that lysozyme diffusion through poly(caprolactone) (PCL) conduit 
walls was minimized while nutrient (glucose) permeability was maximized.  
 Nerve guide porosity was increased through increasing porosity percentage and pore 
diameter, which created tortuosity, and by decreasing nerve guide wall thickness.  The results 
indicate that in a hydrophobic material, such as PCL, porosity percentage is the main effect 
determining both hydrophilic protein diffusion as well as the permeability of small molecules 
such as glucose.  When PCL nerve guides were increased in porosity from 50% to 80%, with 
other parameters held constant, the permeability of the nerve guides to lysozyme increased from 
3% to 45% (p < .05), an increase of 42%.  Glucose diffusion was also improved with an increase 
in wall porosity percentage, with permeability increases of nearly 9% for every 10% increase in 
wall porosity percentage. 
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 Because lysozyme must diffuse through the PCL nerve guide walls through water-filled 
interconnected channels, an increase in pore size would be expected to decrease the pore 
tortuosity (the ratio of the length of a curved path to the direct distance between the ends of the 
path) when porosity percentage is held constant.  Previous literature has shown that as the 
tortuosity of porous PCL is decreased, the diffusion of lysozyme that permeates through PCL 
membranes increases [173].  Therefore, the diffusion of lysozyme in this system was expected to 
decrease with a decrease in pore diameter.  Our results confirm this hypothesis; however, the 
effects of pore diameter were seen as an interaction effect with porosity percentage.  As pore 
diameter and porosity percentage were simultaneously increased, the permeability of PCL to 
lysozyme also increased.  The permeability of PCL to glucose, a smaller molecule, was not 
affected by pore diameter.  This parameter interaction is especially helpful for our optimization 
purposes as high porosity percentage nerve guides allow for more glucose diffusion, while 
protein loss can be minimized by reducing the nerve guide pore diameter.  Wall thickness studies 
indicated that by increasing the guide wall thickness, both glucose and lysozyme diffusion would 
be reduced.  
 In the early stages of nerve regeneration, prior to the fibrous encapsulation of the nerve 
guide that occurs due to the foreign body response, proteins from biological fluids such as blood 
plasma would be expected to adsorb onto the PCL guide surface.  It was initially hypothesized 
that protein adsorption would limit the diffusion of lysozyme through the nerve guide wall 
because small pores would limit solute diffusion through the guide walls.  As indicated by Figure 
8, protein fouling greatly decreased the diffusion of lysozyme through the guide wall while 
glucose diffusion was not significantly affected.  The dramatic decrease in lysozyme 
permeability was most likely caused by protein adsorption that occurred throughout the entire 
 62 
surface area of the internal pore channels, decreasing the available pore diameter.   Furthermore, 
proteins have a large number of both negative and positive charges and an adsorbed protein 
monolayer would present a modified surface to the diffusing lysozyme.  Because lysozyme has a 
high surface activity on negatively charged surfaces [175], large amounts of lysozyme may 
adhere to the internal luminal surfaces, effectively limiting channel passageways from further 
protein diffusion.  Glucose (Mw 180 Da), a molecule roughly 81 times smaller than lysozyme 
(Mw 14,600 Da), does not appear to be significantly affected by protein fouling [73].   
 In addition to protein fouling, a fibrous capsule surrounding the nerve guide would also 
be expected to form after in vivo implantation thus further reducing the capacity of growth 
factors to diffuse outward. At longer time points, it would be expected that the majority of 
released protein would be retained in the injury site within the lumen of the nerve guide.  
2.4.1 Limitations 
In this study, PCL nerve guides were fabricated according to specifications for wall thickness, 
pore size and porosity percentage.  However, there are some considerable limitations within the 
manufacturing procedure that limit the precision of the final measured nerve guide parameters.  
First, the nerve guides are prepared using a dip coating technique, which does not result in a 
constant wall thickness along the entire length of the final guide.  The analysis performed on the 
effect of wall thickness as a result of the number of immersions of the glass mandrel into the 
polymer solution resulted in an average thickness value for the range of potential measurements 
distributed along the length of the guide.  The information obtained from the wall thickness 
evaluation provides a guide for an end user to approximate the number of immersions required 
for a nerve guide to be of a specified wall thickness range, however it is suggested that a nerve 
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guide be measured using calipers to ensure that the final nerve guide has been produced with the 
final desired wall thickness. 
A second limitation within the manufacturing protocol for PCL nerve guides is inherent 
in the method used to obtain the range of salt crystals for creation of pores.  While sodium 
chloride was first ground to a fine powder and then separated into particle size ranges using 
sieves, this process does not distinguish between individual pieces of NaCl and agglomerates 
[164].  Analysis of this type of preparation and measurement of NaCl by Grant et al., has shown 
that NaCl separated through sieving results in a distribution in the equivalent volume diameter of 
salt samples with fractions containing a significant proportion of small diameter particles due to 
the passage of agglomerates through the salt sieve [164].  Alternative porogens include lipid 
microparticles such as Softispan 154 or Witepsol H42 as discussed in Section 1.4.2.1. 
An additional limitation within studies performed toward nerve guide optimization 
concerns the use of nonphysiologically relevant concentrations of solutes required for the 
diffusion analysis of glucose and lysozyme from the interior of the PCL nerve guides.  While 
normal blood levels of glucose are ~0.9 mg/mL [167] and our anticipated neurotrophic factor 
dosage is 100 ng/mL [103, 125], the assays used to measure each solute required that much more 
concentrations of each be used.  The use of highly concentrated solutions of both glucose and 
lysozyme may cause the effects of nerve guide manufacturing on solute diffusion to be over 
estimated.  Furthermore, the diffusion studies performed within this study aim do not assess the 
diffusion of protein released from a delivery device incorporated within the polymer nerve guide 
scaffold.  The goal of Specific Aim 1 was to conduct optimization studies on nerve guide 
manufacturing parameters to maximize the percentage of a potential neurotrophic factor retained 
within the lumen of the nerve guides.  However, such studies do not account for proteins 
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delivered over several weeks.  It is anticipated that because the external surface of the nerve 
guide will have been exposed to blood for a sufficient period for the development of a fibrous 
capsule surrounding the material, the flux of proteins from the nerve guide lumen will be 
severely limited.           
2.5 CONCLUSIONS 
PCL nerve guides were reproducibly manufactured with tailored porosity percentage, wall 
thickness, and pore diameter through a dip-coating salt leaching technique.  For factorial 
analysis, these three parameters were varied across ranges to measure the response of glucose 
and lysozyme diffusion through the guide wall.  Initial optimization experiments resulted in the 
highest glucose diffusion from guides of 80% porosity.  Because initial nutrient and oxygen 
delivery is so critical to axon and Schwann cell survival at the site of nerve injury, nerve guide 
porosity was not considered adequate below 80%.  Additionally, it was determined that at high 
porosity percentages, decreasing the pore diameter was a measurable method of decreasing the 
lysozyme permeability of PCL nerve guides while not creating a loss of glucose permeability.  
PCL fouling studies were used to fine tune the desirable nerve guide wall thickness.  Results 
indicated that nerve guides of 0.6 mm thickness decreased the loss of lysozyme to ~10% without 
significantly diminishing glucose permeability.  Based on the results of this study, nerve guides 
of 80% porosity percentage with 10 – 38 µm pore diameter and 0.6 mm wall thickness will be 
used for in vivo studies. 
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3.0  DEVELOPMENT OF A DOUBLE WALLED MICROSPHERE DELIVERY 
SYSTEM FOR GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR 
3.1 INTRODUCTION 
Conventional methods of drug administration include oral formulations or bolus application via 
injection (e.g. intravenous, intramuscular, subcutaneous, or intrathecal) [176].  The benefits of 
using simple administration routes such as oral formulations include the ease of use, patient 
comfort and low expense, all factors which lead to high patient compliance.  However, there are 
limitations in the use of these traditional delivery methods for therapeutics targeting peripheral 
nerve repair.  Oral administration of proteins such as Glial Cell Line-Derived Neurotrophic 
Factor (GDNF) is not a suitable mechanism for investigating potential benefits of the drug due to 
the potential for drug degradation in the intestinal tract and low epithelial permeability to large 
proteins [177].  Furthermore, oral or injected administration of GDNF allows for the possibility 
of unwanted side effects from systemic administration of high dosages necessary for therapeutic 
efficacy at the site of nerve ligation [178].   
 As an alternative to systemic administration, early investigations of neurotrophic factors 
in peripheral nerve defects applied a direct application of protein growth factor at the site of 
nerve injury immediately following surgical repair [179, 180].  However, because of the short 
half life (e.g. minutes) of proteins such as GDNF, this method of delivery is not optimal for 
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treatment of a large nerve defects considering the slow growth rate of axons across critical size 
nerve gaps which can take several weeks.  Therefore, when evaluating the efficacy of 
neurotrophic factors toward improving nerve regeneration, it may be beneficial to use a 
controlled release system that is capable of delivering neurotrophins to Schwann cells and nerve 
stumps at the site of ligation in the sciatic nerve over a sustained period.  With such a delivery 
system, GDNF could be administered in a localized manner, allowing for higher concentrations 
of the growth factor to be administered and potentially avoiding systemic side effects. 
 Encapsulation of proteins within polymeric microspheres is a well documented method of 
controlled drug delivery [181-185].  Benefits of microsphere delivery systems include non-
invasive placement and localized release of large amounts of therapeutic agents, circumventing 
deleterious side effects from systemic administration [186].  Because of this, larger, more 
effective dosages can be administered.  Furthermore, microspheres can be administered through 
injection and thus avoiding surgical procedures or microspheres can be embedded within gels or 
constructs for combined tissue engineered therapies [184, 187, 188].  Finally, microspheres can 
be manufactured with biodegradable materials which eliminate the need for device recovery 
[182]. 
3.1.1 Single walled microsphere delivery systems 
Single walled microspheres are produced from a single polymer or copolymer phase and can be 
produced in a wide range of sizes (1 – 100 nm for nanospheres and 1 – 100 μm for microspheres) 
[187].    Single walled biodegradable microspheres are most often fabricated using polymers or 
copolymers of lactic and glycolic acids due to their proven safety and biocompatibility [5].  
Microspheres have been used to successfully encapsulate a variety of growth factors including 
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Transforming Growth Factor – β (TGF-β) [184, 189], CNTF [190], FGF-1 [185], NGF [97, 100, 
191], and GDNF [192, 193].   
 There are several advantages to using single walled microspheres for the delivery of 
either hydrophobic or hydrophilic drugs in vivo.  Single polymer microspheres are easy to 
fabricate and can be manufactured with materials that are well characterized and relatively 
inexpensive.  In addition, it is possible to encapsulate a wide range of protein macromolecular 
sizes including high molecular weight globular proteins such as BSA as well as small molecular 
weight proteins such as lysozyme.  Furthermore, when biodegradable polymers are utilized for 
microsphere production, removal of the drug delivery device is not necessary.  Finally, polymer 
microspheres can be made with a mean diameter range below 10 μm, a size that allows for in situ 
injection, and thus allows for an easy method of localized drug delivery. 
3.1.1.1 Materials and fabrication techniques 
 Fabrication techniques for single walled microspheres include emulsification-solvent 
evaporation, polymer phase separation (coacervation), spray drying, or techniques employing 
supercritical fluids (e.g. rapid expansion of supercritical solutions) [194].  Emulsification – 
solvent evaporation processes have been used frequently for microencapsulation processes 
because of the ease in fabrication and therefore the technique is discussed in detail in the 
following paragraphs.  Fabrication of microspheres through coacervation requires a change in 
polymer phase from one of soluble to insoluble.  This can be accomplished by altering the 
temperature of the solvent in which the polymer of choice is dissolved or by adding a third 
component which interacts with the organic solvent but not with the polymer.  This method 
requires large quantities of organic components which can prove difficult to remove completely 
from the final microspheres.  Spray drying has been used to create microspheres through 
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atomization of a solution using compressed air through a dessicating chamber.  This method is 
typically used to create porous microspheres and is most successful when the polymer and drug 
are dispersed in the same solution.  The use of fluids such as carbon dioxide at supercritical 
pressures or temperatures are an alternative microencapsulation technique that avoid large 
amounts of residual solvents and have thus been recently explored as an alternative to solvent 
evaporation techniques.  However, the nucleation of particles occurs during expansion, which 
typically occurs at a rate of 10-7 seconds, producing high shear stress which can denature 
dissolved molecules such as proteins [194]. 
 Production of microspheres through the solvent evaporation method has been studied 
extensively and can be used to encapsulate apolar, hydrophobic molecules as well as hydrophilic 
molecules such as proteins.  Initially, polymers are dissolved in a poorly water soluble, volatile 
solvent such as dichloromethane or chloroform.  This mixture is then emulsified in a large 
volume of aqueous solution containing a surfactant such as poly(vinyl alcohol).  For apolar 
molecules, the drug to be encapsulated is dispersed within the organic solvent in which the 
polymer is dissolved.  Therefore, when the polymer/drug mixture is emulsified within the 
aqueous solution, the solvent evaporates allowing the polymer to harden while entrapping some 
portion of the dissolved drug within the polymer matrix.   
 Encapsulation of hydrophilic proteins such as GDNF requires an additional emulsion step 
resulting in a water-oil-water (W/O/W) double emulsion system.  In this process, the protein to 
be delivered is dissolved in an aqueous solution and emulsified within the polymer/organic 
solvent solution.  This emulsion is then added to a large quantity of poly(vinyl alcohol) (PVA) in 
water and the resulting solution is stirred until the solvent evaporates and the polymer droplets 
solidify.   
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Materials with which microspheres have been produced include a variety of polyesters 
and polyanhydrides.  The encapsulation of highly water soluble proteins within aliphatic 
polyesters based on lactic and glycolic acids have received considerable attention due to the 
proven biocompatibility, predictability of degradation kinetics, ease of fabrication, and past 
regulatory approval in suture applications [195].  Generally, PLA, PGA and copolymers thereof 
are hydrophilic and thus undergo bulk degradation of the polymer backbone through hydrolytic 
cleavage of ester linkages (Figure 13, from [187]).  Unlike large PLA or PGA implants, 
microspheres that are 300 μms or less in diameter undergo a homogenous degradation in terms of 
core and surface degradation rates [182].  
 
 
 
 
Figure 13.  Common polyesters for microsphere fabrication with predicted degradation products.  (Image 
modified from [187]) 
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Poly(lactide) (PLA) exists as both D- or L- stereoisomers, allowing for considerable 
versatility in the performance characteristics (e.g. glass transition temperature, melting point, 
degradation rate) of PLA/PGA copolymers.  DL-PLA is more sterically hindered and therefore 
less crystalline than either D-PLA or L-PLA.  In addition, lactic acid has a side methyl group 
which causes lactide monomers to have more hydrophobicity than glycolide monomers.  Finally, 
the copolymers of PGA and PLA are less crystalline than either of the homopolymers.  Factors 
which affect rate of polymer hydration and thus biodegradation include: monomer 
stereochemistry, co-monomer ratio, polymer chain linearity, and polymer molecular weight.  
Table 4 lists the approximate biodegradation times for PLA, PGA and commonly used PLGA 
polymers.  Biodegradation time varies depending on microsphere surface area and porosity, and 
has a large impact on encapsulate release kinetics from microspheres in solution. 
 
 
Table 4.  Biodegradation of lactide/glycolide polymers.  Reproduced from [195]. 
 
Polymer Biodegradation Time Months 
(approx.) 
Poly(L-lactide) 18 – 24 
Poly(DL-lactide) 12 – 16 
Poly(glycolide) 2 – 4 
50:50 (DL-lactide-co-glycolide) 2 
85:15 (DL-lactide-co-glycolide) 5 
90:10 (DL-lactide-co-glycolide) 2 
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3.1.1.2 Limitations of single walled microsphere encapsulation 
 While there are many advantages to microsphere delivery methods, there are also several 
disadvantages inherent to the encapsulation process.  Large hydrophilic proteins are difficult to 
encapsulate within hydrophobic polymers.  Therefore, high energy mixing is used to entrap the 
protein within nearly spherical occlusions of aqueous solution inside the hardened polymer 
microspheres (Figure 14A) [181].  These discrete occlusions remain following polymer 
hardening and water removal during the lyophilization process, which results in macropores in 
the microsphere structure [196].  This results in microsphere release kinetics of an initial burst of 
protein within the first 24 hours of placement in aqueous solution either in vitro or in vivo 
(Figure 14C) [197, 198].  Depending on the size of the microspheres and the type of polymer, the 
liberated protein within the first 24 hours can be over 50% of the total encapsulated material 
[181]. 
 Additionally, the solvent evaporation method results in a considerable loss of hydrophilic 
protein material to the aqueous solution and therefore manufacturing procedures result in low 
encapsulation efficiency and a considerable loss of expensive growth factors during fabrication 
[9].  Finally, there are several mechanisms through which encapsulated proteins may become 
denatured during the encapsulation process as discussed in Section 3.1.3. 
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Figure 14.  Comparison of single walled and double walled microspheres.  A) Three dimensional confocal 
micrograph depicting the spherical occlusions of fluorescently labeled protein within a single PLGA microsphere 
(edge is marked with red circle) (Image modified from [196]).  B) Scanning electron micrograph of a double walled 
PLGA/PLLA microsphere.  C)  Cumulative release profile of GDNF from a single walled PLGA microsphere in 
vitro.  D)  Cumulative release profile of BSA from double walled PLGA/PLLA microspheres (Image from [199]). 
 
3.1.2 Double-walled microsphere delivery system 
The technique for preparing double-walled (DW) microspheres was first patented by Edith 
Mathiowitz and Robert Langer in 1989 as a novel method of creating a controlled delivery 
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system [200].  In this type of delivery system, a substance to be delivered is encapsulated within 
a polymeric sphere and a second, unique polymer forms a capsule around that inner sphere.  By 
localizing the growth factor to the core of double-walled microspheres, the amount of material 
through which the drug must diffuse is increased thus slowing the drug release rate (Figure 14B).  
DW microspheres have been used to encapsulate bovine serum albumin (BSA) [199], 
doxorubicin [201], piroxicam [202] and etanidazole [203].  With these double-walled 
microsphere systems, in vitro release profiles ranged between 60 days for etanidazole and ~240 
days for BSA (Figure 14D).      
3.1.2.1 Materials and fabrication techniques 
 Double-walled microspheres are primarily fabricated through a single step manufacturing 
process in which two polymers form a core and shell morphology through phase separation.  The 
fabrication process requires the addition of a non-solvent or a second polymer that is 
incompatible with the first polymer to a two-polymer continuous phase solution, which is mixed 
briefly and then added to a nonsolvent aqueous solution.  As the solvent slowly evaporates, the 
homogenous mixture separates resulting in one polymer precipitating around a core [204].  
Alternatively, double walled microspheres have been produced by coating single walled 
microspheres following microsphere formation and hardening with a second unique polymer 
[199], employing multiple concentric nozzles which create dual polymer jets of the microsphere 
core polymer surrounded by an annular stream of the shell polymer [205], and through solvent 
removal with a non-solvent solution [206]. 
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3.1.2.2 Limitations for double-walled microsphere encapsulation 
 Despite the improved release kinetics that DW microspheres present as compared to 
standard, single-walled double emulsion microspheres, some of the drawbacks of encapsulating 
proteins with a solvent evaporation method continue to exist.  During the DW microsphere 
fabrication process, the protein to be encapsulated is added directly to PLGA dissolved in an 
organic solvent, potentially denaturing the protein.  Furthermore, high energy mixing and 
addition of the dissolved protein and polymer solution to a large aqueous volume is still required.  
Therefore, the encapsulation procedure results in a substantial loss of expensive drug or protein 
materials.   
3.1.3 Instability of proteins during the microencapsulation process 
Proteins are particularly sensitive to destabilization during fabrication of both single and double 
walled microspheres because of the globular structure, the complex internal architecture which 
may dictate the activity of ligand binding sites, the numerous chemically active side chain 
moieties, as well as the structural dependence on numerous labile bonds [207].  Protein  stability 
in relationship to proteins is defined as the retention of the tertiary structure of the protein 
conformation such that an enzyme, for example, retains the active site for natural substrate 
binding and is therefore functionally stable [207].   
There are a variety of mechanisms through which encapsulated proteins may denature 
during the microsphere fabrication process (Figure 15).  In the manufacturing process of 
microsphere formation, proteins may be denatured due to the use of organic solvents for polymer 
dissolution, the employment of high energy mixing necessary to encapsulate the protein and 
create the oil in water emulsions [181], exposure of the protein at the organic/aqueous interface 
 75 
[208], as well as by lyophilization of the microspheres (and therefore, the encapsulated protein) 
to remove moisture.  Additionally, proteins may denature due to hydration and erosion of the 
polymer during protein liberation.  Microspheres are typically stored under desiccation and then 
rewetted in a manner that reconstitutes the protein in aqueous solution much more slowly then 
would occur in direct solubilization.  This process, termed moisture induced aggregation, is 
known to cause denaturation of encapsulated proteins [209].  Other potential sources for protein 
denaturation during release periods include the acidic microenvironment that results from 
polymer degradation and the accumulation of free carboxylic acid end groups and the presence 
of hydrophobic polymer surfaces [207].  Finally, depending on the intrinsic stability of the 
protein, the functional protein structure may be lost due to natural degradation occurring during 
storage and release. 
 
 
 
 
Figure 15.  Potential mechanisms for protein denaturation during microsphere fabrication and protein 
release (Image modified from [207]). 
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3.1.4 Modeling GDNF release with Lysozyme 
Lysozyme was chosen as a model for characterizing protein delivery from DW microspheres 
because of its small size (14.6 kD), which is similar to several neurotrophic factors (GDNF: 15 
kDa [181], NGF: 26 kDa [182], BDNF: 12.3 kDa [183], and CNTF: 20.4 [184]).  Additionally, 
the bioactivity of lysozyme can be easily quantified by measuring the enzymatic lytic activity on 
Micrococcus lysodeikticus.  Because lysozyme bioactivity is easily measured and lysozyme has a 
similar size and isoelectric point to neurotrophic factors, lysozyme is an ideal protein for 
optimizing microsphere fabrication protocols.  
3.1.5 Chapter Aims 
It is hypothesized that a sustained delivery of GDNF applied directly to the site of nerve injury 
will result in an improved regeneration of lost nerve tissue.  To evaluate this hypothesis, it was 
necessary to develop a delivery system that would release bioactive GDNF for a sustained 
period.  With this goal, the purpose of the work described within this chapter was to optimize a 
microsphere delivery system such that GDNF was delivered for at least 60 days, the approximate 
period required for proximal nerve stumps to transverse the 1.5 cm interstump gap assuming a 
growth rate of 0.25 mm per day. 
 Investigation of microsphere delivery included the preparation of both single walled and 
DW microspheres.  Two model proteins, BSA and lysozyme were encapsulated in single walled 
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microspheres.  Release kinetics were evaluated from microspheres of variable PLGA 
comonomer ratio and molecular weight as well as microspheres encapsulating additives for 
protein stabilization.  DW microspheres were prepared from PLGA and PLLA and encapsulated 
the model protein lysozyme.  Design specifications for double walled microspheres included a 
PLGA core and PLLA shell with encapsulated protein localized to the microsphere core.  To 
confirm the distribution of lysozyme within the polymer core, fluorescently labeled bovine 
serum albumin was encapsulated and localization to a particular polymer component was 
confirmed through fluorescent microscopy.  Release studies were conducted to determine the 
long term release kinetics of the DW microspheres and the bioactivity of lysozyme was 
confirmed for the extended release period.  In addition, co-encapsulates were evaluated as a 
method of protecting and stabilizing encapsulated model proteins during microsphere fabrication 
in order to improve liberated protein bioactivity. 
3.2 METHODS 
3.2.1 Reagents 
All chemicals were analytical grade or purer and were purchased from commercial suppliers.  
Poly(vinyl alcohol) (average Mw 9,000-10,000, 80% hydrolyzed), poly(DL-lactide-co-glycolide) 
(lactide:glycolide (50:50), mol wt 40,000-75,000 units), Fluorescein Isothiocyanate Conjugated 
Bovine Albumin (FITC-BSA) (A9771), lysozyme from chicken egg white, Docusate Sodium 
Salt (AOT) (D1685), Dichloromethane, Ethyl Acetate, Phosphate Buffered Saline (PBS), 
Potassium Phosphate (Anhydrous, P-5379) and Micrococcus lysodeikticus (ATCC 4698), 
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sodium dodecyl sulfate (SDS) (minimum 98.5%, L4509), polyethylene glycol (avg mol wt 400, 
P3265) were all purchased from Sigma-Aldrich (St. Louis, MO). Poly-L-lactide (0.90 – 1.20 
dL/g) was purchased from DURECT Corporation (Pelham, AL).  The Micro Bicinchoninic Acid 
(BCA) Protein Assay Kit (23235) was purchased from Pierce (Rockford, IL).  228 mm Pasteur 
Pipettes were purchased from Wheaton (Millville, NJ).  Dimethyl Sulfoxide (DMSO) was 
purchased from Thermo Fisher Scientific (Pittsburgh, PA). 
3.2.2 Preparation of single walled, PLGA microspheres  
Single walled microspheres were prepared using a standard double-emulsion (W/O/W) technique 
(Figure 16).  The primary emulsion was formed by adding protein (20 mg of either BSA or 
lysozyme in 200 μL aqueous solution) to PLGA dissolved in dichloromethane (200 mg in 4 mL).  
The mixture was immediately sonicated for 10 seconds at 35% power using a 750 Watt probe 
sonicator.  The second emulsion was formed by addition of the first emulsion to a 60 mLs of a 
2% (w/v) solution of aqueous Poly(vinyl alcohol) (PVA).  The solution was homogenized for 1 
minute at 5,200 rpm using a Silverson homogenizer.  The resulting emulsion was added to 80 
mLs of a 1% PVA solution stirring continuously for 3 hours at 600 rpm.  The resulting 
microspheres were washed 4 times with water and freeze dried using a Labconco freeze dry 
system (Kansas City, MO). 
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Figure 16. Preparation of single walled PLGA microspheres 
 
 
3.2.2.1 Optimization of process parameters on single walled microsphere encapsulation 
To determine the effect of polymer properties on microspheres prepared with constant 
operating conditions (e.g. geometry of beakers, agitation rate, and temperature), PLGA of 
varying co-monomer ratio and molecular weight was investigated with a primary emulsion of 
BSA in 2% aqueous PVA (Table 5).  Microspheres were prepared with each PLGA ratio as 
described in Section 3.2.2.     
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Table 5.  PLGA polymers used for fabricating single walled microspheres 
 
PLGA lactide:glycolide 
monomer ratio Molecular Weight (Mw) Inherent Viscosity (dL /g) 
50:50 5,000 – 15,000 0.15 – 0.25 
50:50 40,000 – 75,000 0.61 
65:35 40,000 – 75,000 0.61 
75:25 66,000 – 107,000 0.63 
 
 
The effect of additives on lysozyme encapsulation efficiency and release kinetics was 
investigated using stabilizing proteins such as human serum albumin (HSA) and surfactants such 
as poly(ethylene glycol) and docusate sodium salt (AOT).  Microsphere preparation followed 
standard protocol as described in Section 3.2.2 with the exception that the primary emulsion of 
protein dissolved in 200 μL of PBS additionally contained coencapsulates as described in Table 
6. 
 
 
Table 6.  Additives used in single walled microsphere fabrication 
 
Coencapsulates Primary aqueous phase Rationale Reference 
HSA (10 mg),  
PEG 400 (120 μl) 
16 mM Citrate Buffer 
(pH = 5.0) 
Large protein for improved 
lysozyme stabilization 
[183] 
AOT (10 mg) dI H2O 
Improves lysozyme solubility in 
DCM 
[181] 
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Finally, single walled microspheres encapsulating GDNF were prepared using PLGA 
(65:35) and the surfactant AOT in a 1:30 molar ratio of GDNF (5 μg) to AOT (1.09 mg).  The 
primary emulsion of GDNF and AOT contained DI water instead of either PBS or PVA as was 
used in previous microsphere formulations.   
3.2.2.2 Microsphere characterization 
Microspheres were examined morphologically by scanning electron microscopy (SEM). 
Microspheres were mounted on metal stubs using double-sided copper tape, coated with gold 
using a Cressington 108 Auto (Cressington, Watford UK) and then viewed with a JEM-6330F 
(JEOL, Peabody, MA) scanning electron microscope operating at 5 kV acceleration.  The 
diameter distribution was measured using a Multisizer 3 Coulter Counter. 
For each batch of microspheres, the final product weight (MSfinal) was recorded.  
Microsphere batch efficiency (final batch yield as compared to initial product input, MSinitial) was 
calculated using equation 1.   
 
     (1) 
 
The drug loading of single walled PLGA microspheres was determined using methods 
described by Sah et al., [210].  A known weight of microspheres was first dissolved in 2 mL 
dimethyl sulfoxide (DMSO) for 1 hour.  A 10 mL solution of 0.05 N NaOH solution in 0.5% 
(w/v) sodium dodecyl sulfate (SDS) was then added to the DMSO solution and mixed for an 
additional hour.  Fractions of the clear DMSO/NaOH/SDS protein solution were then evaluated 
with a BCA assay.  Known concentrations of protein dissolved in DMSO/NaOh/SDS were used 
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for standard curve production.  From the standard curve, the total amount of loaded protein 
(WeightDrug) was determined.  Drug loading was then calculated using equation 2. 
 
     (2) 
3.2.2.3 In vitro release of encapsulated proteins 
 10 mg PLGA microspheres were incubated in 1mL PBS at 37°C.  Following incubation, 
the microspheres were centrifuged for 10 minutes at 1000 rpm and the PBS was removed, 
leaving a microsphere pellet at the bottom of the eppendorf tube.  The PBS was refreshed 
following each time point and the released protein concentration within the collected PBS was 
determined using a BCA assay. 
3.2.3 Preparation of double-walled microspheres 
3.2.3.1 Selection of PLGA and PLLA solvent for DW microsphere preparation 
 Microspheres were fabricated using the three solvents listed in Table 7.  Two distinct 
polymer solutions of (50:50) PLGA and PLLA were prepared in glass vials.  A single phase 
emulsion was then created by adding a 10% (w/v) PLGA (0.15 grams) solution in organic 
solvent to a 10% PLLA solution (1:1 polymer mass ratio) and sonicated for 20 seconds. This 
homogenous oil-in-oil emulsion was added drop-wise through a Pasteur pipette to 200mL of 
aqueous 0.5% poly(vinyl alcohol) solution stirring at 900 rpm for three hours. After this time, the 
polymer microspheres were collected through centrifugation (1000 rpm for 10 minutes) and 
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washed three times. Finally, the microspheres were lyophilized and stored in a desiccant at          
-20ºC.   
 
 
Table 7.  Properties of solvents for microsphere preparation 
 
Solvent Chemical Formula 
Boiling 
Point (°C) 
Dielectric 
Constant 
Ethyl Acetate (EA) CH3C(=O)-O-CH2CH3 77 0.894 
Dichloromethane (DCM) CH2Cl2 40 1.326 
Tetrahydrofuran (THF) (CH2)4O 66 0.886 
 
 
 Table 8 describes the three polymer combinations used for double walled microsphere 
preparation as ordered in increasing polarity.  Microspheres prepared with THF as the solvent for 
PLLA could not be produced with a 10% (w/v) solution due to the low solubility of polymer in 
solvent.  Therefore, a 3.5% (w/v) PLLA solution in THF was utilized while maintaining the 1:1  
mass ratio of PLGA to PLLA.  Resulting microspheres were sectioned and examined for 
evidence of polymer separation using SEM as described in Section 3.2.4.1.  To determine the 
localization of encapsulated protein within the polymer compartments, microsphere batches 1 
through 3 were prepared by encapsulating 4 mg of fluorescently labeled albumin (FITC-BSA).  
To evaluate release kinetics, microspheres of identical solvent formulation were prepared 
encapsulating 20 mg lysozyme.  When encapsulating protein within microspheres, protein in dry, 
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lyophilized form was added directly to the PLGA dissolved completely in solvent, vortexed, and 
placed in ice for 20 minutes before the PLGA and PLLA solutions were mixed.     
 
 
Table 8.  Solvent combinations for PLGA and PLLA in DW microsphere fabrication 
 
Batch  Number PLGA Solvent PLLA Solvent 
1 DCM (17.5% w/v) DCM (10% w/v) 
2 EA (17.5% w/v) DCM (10% w/v) 
3 DCM (17.5% w/v) THF (3.5% w/v) 
 
 
3.2.3.2 Effect of PLGA solution concentration on polymer phase separation   
 To determine how PLGA solution concentration (w/v) affects polymer phase separation 
between the microsphere core and shell, double walled microspheres were prepared with varying 
PLGA solution concentrations ranging from 10% to 20% in 2.5% increments (batch numbers 4 – 
8).  A 10% PLLA solution in dichloromethane (0.15 grams PLLA in 1.5 mL DCM) was used for 
all microsphere batches.  The PLGA to PLLA mass ratio was held constant at 1:1.  For 
evaluation of PLGA solution concentration on microsphere release kinetics, lysozyme was 
encapsulated by adding 20 mg of protein (as a dry powder) directly to PLGA dissolved in 
dichloromethane. 
 Following microsphere preparation, the batch yield was calculated for each microsphere 
formulation using equation 1.  Additionally, the external surface and internal architecture of 
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microspheres was observed through SEM (detailed methods in Section 3.2.4.1).  Due to the 
limited capacity of coulter counters to measure large particles, the diameter distribution of 
microspheres prepared with a 20% PLGA solution was determined using Image-J analysis of 
SEM photo images [165].  Finally, in vitro microsphere release studies were performed as 
described in Section 3.2.4.3.     
3.2.3.3 Co-encapsulation of additives for improved protein bioactivity 
 To improve the bioactivity of released protein samples, additives (Table 7) were used as 
coencapsulates with lysoyme, or subsequently GDNF.  Because AOT and HSA both interact 
with the structure of lysozyme, possibly obstructing the enzyme ligand binding site prior to 
encapsulation and thus reducing lysozyme bioactivity upon release, preliminary studies were 
performed to determine the optimal molar ratios of additive to model protein such that the 
bioactivity of encapsulant was maintained. 
Optimization of AOT and HSA molar ratio for lysozyme bioactivity  
An initial bioactivity assay was performed on varying molar ratios of lysozyme:additive 
(AOT or HSA) to determine the optimum amount for encapsulation.  This bioactivity assay was 
developed on the principle that the enzyme, lysozyme, causes the lysis of intact Micrococcus 
lysodeikticus cells.  Therefore, the units of active lysozyme per mL solution were calculated by 
determining the solution turbidimetric rate.  To accomplish this, three reagents were created: 1) 
66 mM potassium phosphate buffer, pH 6.24 at 25ºC (Potassium phosphate in D.I. water), 2) 
0.015% (w/v) Micrococcus lysodeikticus cell suspension in reagent 1, and 3) A range of 0 - 1000 
units/mL in 100 unit increments of lysozyme enzyme solution in reagent 1.  Previous analysis of 
lysozyme bioactivity revealed that the measured turbidmetric rate is highly temperature sensitive.  
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Therefore, all bioactivity measurements of lysozyme solutions were taken after the samples had 
reached a temperature of 37°C.  For measuring the turbidimetirc rate, 0.1 mL of lysozyme 
solution was added to 2.5 mLs of solution (2) in a cuvette.  The cuvette was immediately 
covered, mixed well and placed in a spectrophotometer.  The change in measured absorbance at 
A450nm was recorded for the initial 5 minutes (Thermo Spectronic GENESYS 10 Bio 
spectrophotometer). 
 For determining the percent activity of each lysozyme/additive solution, 200 units of 
lysozyme (0.0957 mg/mL) were dissolved in 1 mL of PBS (positive control) or PBS containing a 
specified amount of AOT or HSA in eppendorf tubes (molar ratios of lysozyme : AOT tested: 
1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:20.  Molar ratios of lysozyme:HSA tested: 1:50, 1:100, in addition 
to those ratios listed for AOT).  The solutions were mixed well and incubated at 37°C for 48 
hours.  This time period was required as the bioactivity of lysozyme was significantly affected by 
the protein binding of additive and no additional activity affects were seen after this time.  After 
the initial incubation period, the eppendorf tubes were maintained at 37°C in a water bath as the 
bioactivity assay was performed as described above.  The activity of fresh lysozyme dissolved in 
PBS alone was normalized to 100% and the activity of each additive / lysozyme solution was 
normalized to this value. 
Preparation of microspheres encapsulating lysozyme with AOT 
  Four unique batches of DW microspheres were prepared encapsulating protein (either 
FITC-BSA or lysozyme) alone (batch 9) or in a 1:2 molar ratio with AOT (batch 10).  Because 
AOT is stored as a thick waxy solid, lysozyme could not be mixed homogeneously with AOT in 
solid form.  Therefore, lysozyme and AOT were mixed thoroughly in sterile water and 
lyophilized to produce a well mixed protein powder.  For consistency, lysozyme was prepared in 
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an identical manner when microspheres were prepared without surfactant.  The bioactivity of 
lyophilized lysozyme immediately prior to encapsulation was confirmed using the analysis 
method described above.  Following protein solution lyophilization, either lysozyme or lysozyme 
with AOT solids were added to a 20% PLGA (50:50) solution (0.2 grams in 1 mL of 
dichloromethane).  The protein/PLGA product was vortexed for ~30 seconds to achieve a 
homogenous mixture.  The PLGA mixture was then poured into a glass vial containing a 20% 
PLLA solution (0.2 grams in 1 mL of dichloromethane) and sonicated for an additional 20 
seconds. This oil-in-oil emulsion was added drop-wise through a Pasteur pipette to 200mL of 
aqueous 0.5% poly(vinyl alcohol) solution stirring at 900 rpm for three hours. After this time, the 
polymer microspheres were collected through centrifugation (1000 rpm for 10 minutes) and 
washed three times. Finally, the microspheres were lyophilized and stored in a desiccant at -
20ºC. 
3.2.3.4 Double walled microencapsulation of Glial Cell Line-Derived Neurotrophic Factor 
 Preliminary batches of double walled microspheres encapsulating GDNF were fabricated 
with GDNF, AOT and HSA as described by Jiang et al., [211] (batch 11).  To create a single, 
homogenous protein/additive powder, 100 mg of AOT, 7 mg of HSA and 40 μl of GDNF (0.1 
mg/mL) were combined in 3 mL of sterile dI H2O.  The solution was mixed well and added drop 
wise into a glass dish supported by a floatation device immediately above liquid nitrogen.  After 
solidification, the dish was immediately placed in a container for lyophilization.  Once all of the 
liquid had completely sublimed from the protein/additive mixture, the solid powder was added to 
a 10% (w/v) solution of PLGA dissolved in DCM and microspheres were prepared as described 
in Section 3.2.3.  Additional microspheres were prepared using a reduced volume of AOT, with 
the final molar ratio of GDNF to AOT being 1:2 (batch 12). 
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 Double walled microspheres were subsequently prepared encapsulating GDNF and HSA 
in a 1:10 molar ratio.  Protein and stabilizer were combined in solution as described above and 
lyophilized, creating a single protein powder.  This powder was then added to a 17.5% (w/v) 
solution of PLGA in DCM over ice.  The polymer and GDNF mixture were allowed to 
thoroughly mix for 20 minutes before the PLGA was combined with a 10% PLLA solution and 
microspheres were prepared as previously described.  To determine if cloud point induction of 
the two polymers combined in a single oil phase would improve encapsulation, a second batch of 
double walled microsphere were prepared using an identical GDNF / HSA powder (batch 13).  
After the two polymer solutions and protein were mixed in a single glass vial through vortexing, 
100% ethanol was added drop wise to the oil emulsion until the solution was slightly turbid, 
indicating that the polymers had begun to phase separate.  This polymer solution was 
immediately vortexed for 20 seconds and then added drop-wise to the aqueous PVA solution, 
forming microspheres as previously described.  Identical microspheres were prepared without 
cloud point induction (batch 14). 
3.2.4  Microsphere characterization 
3.2.4.1  Morphological assessment with scanning electron microscopy 
 Double walled microspheres were examined morphologically by scanning electron 
microscopy (SEM). Microspheres were mounted on metal stubs using double-sided copper tape, 
coated with gold using a Cressington 108 Auto (Cressington, Watford UK) and then viewed with 
a JEM-6330F (JEOL, Peabody, MA) scanning electron microscope operating at 5 kV 
acceleration.  Microsphere diameter distribution was determined using Image-J analysis of SEM 
photo images [165].   
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 To view the internal architecture of the DW microspheres, the microspheres were 
suspended in an aqueous solution of 20% gelatin, 5% glycerin for 2-3 hours at 37ºC as described 
by Rosner et al [97].  The suspension was then placed into a mold and frozen over liquid 
nitrogen. The gelled suspension was removed from the mold, sectioned to 40 µm sections using a 
cryotome at -30ºC and mounted onto a metal SEM stub. Sections were dehydrated, coated as 
described above and imaged using SEM. 
3.2.4.2 Determining protein localization and microsphere polymer orientation 
 Fluorescence microscopy was used to observe protein localization within the DW 
microspheres.   Microspheres encapsulating FITC-BSA were sectioned to 30 µm sections as 
described in 3.2.4.1 and mounted onto glass slides for visualization.  Fluorescent light 
microscopy was then employed to visualize the encapsulated FITC-BSA within the microsphere 
sections. 
 In order to confirm the polymer composition of the microsphere core and shell, a solvent-
specific dissolution study was conducted. The polymer PLLA is insoluble in ethyl acetate (EA), 
while PLGA is soluble in EA. Therefore, DW microspheres were sectioned as described above 
and mounted onto metal stubs using double-sided copper tape.  After the microsphere samples 
were secured onto the metal stubs, the samples were inverted, exposing the microspheres to EA 
for 2 days.  The copper tape was not affected by this procedure.  After this period the stubs were 
thoroughly dehydrated and imaged with SEM.  Because the PLGA component of the DW 
microsphere was dissolved, either PLLA spherical cores or PLLA hemispheres were expected to 
remain. 
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3.2.4.3 In vitro protein release studies 
 To determine the protein release kinetics from DW microspheres, 10 mg of microspheres 
were incubated in 1mL PBS at 37°C. Following incubation, the microspheres were centrifuged 
for 10 minutes at 1000 rpm and the supernatant was removed.  For measuring the lysozyme 
content of the releasate, a micro BCA protein analysis assay was performed.  For this assay, 1 
mL of lysozyme standard (or sample solution) and 1 mL of the micro BCA working reagent were 
combined in a test tube and mixed well.  All of the standard lysozyme samples as well as the 
release samples were incubated simultaneously in a water bath for 1 hour at 60°C.  After this 
period, the protein solutions were cooled to room temperature and 200 µL from each sample 
were transferred to a 48 well plate and read with a plate reader at 562 nm (Tecan Spectraflour).  
Lysozyme bioactivity 
To ensure the encapsulated lysozyme remained active following release from the DW 
microspheres, a lysozyme bioactivity assay was performed as described in Section 3.2.3.3 for 
each time point of supernatant collection.  To determine the percent bioactivity, the known 
protein concentration of each microsphere release sample was calculated through Micro BCA 
analysis.  The lysozyme stock solution used to create the standard curve for determining the 
lysozyme concentration with the BCA assay was identical to the solution used to produce the 
standard curve for the lysozyme bioactivity assay.  Therefore, for each sample assayed, the 
known protein concentration and the measured protein bioactivity were determined.  To calculate 
the percent bioactivity, the measured bioactivity was divided by the theoretical bioactivity based 
on the known protein concentration and this number was multiplied by 100%. 
 
 91 
In vitro GDNF release 
To determine the release kinetics of GDNF from the PLGA/PLA double-walled 
microspheres, 10mg of microspheres were placed into eppendorf tubes and incubated in 1 mL 
PBS at 37°C.  At specified time points, the microspheres were vortexed, centrifuged for 10 
minutes at 1000 rpm and the supernatant was replaced with fresh PBS.  The amount of soluble 
GDNF in the collected samples was analyzed using an enzyme linked immunosorbent assay 
(ELISA) manufacturer’s instructions. The optical density was recorded at 450 nm in an ELISA 
plate reader (Tecan, NC). The GDNF concentrations were calculated against a 6-point standard 
curve, then adjusted to picograms of GDNF per milligram of microspheres. 
3.2.4.4 In vitro degradation of double walled microspheres 
 Degradation of DW microspheres was analyzed under the same conditions as the protein 
release studies in Section 3.2.4.3.  Microspheres were incubated in PBS at 37°C for 6 months.  
At 1 week and subsequent monthly intervals the microspheres were collected through 
centrifugation and examined through SEM using the protocol described in Section 3.2.4.1. 
3.2.5 Statistical analysis 
Results are expressed as the mean ± standard deviation.  Analysis of variance (ANOVA) was 
used to determine statistical significance between experimental groups.  The least significant 
difference method was used for multiple comparisons with p < 0.05.      
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3.3 RESULTS 
3.3.1 Single walled microspheres: effect of PLGA on microsphere properties and BSA 
release 
Single walled PLGA microspheres were fabricated using a double emulsion (W/O/W) solvent 
evaporation method, with the primary emulsion containing BSA dissolved in 2% PVA solution.  
Microspheres were prepared using PLGA of 3 different lactide to glycolide monomer ratios and 
2 polymer molecular weights.  Drug loading for microsphere batches was 13.5 %, 11.1 %, 7.5 % 
and 9.0 % for batch A, B, C, and D respectively.  The average batch yield and mean diameter are 
recorded in Table 9.  The external surface of microspheres comprised of 50:50 high molecular 
weight (HMW) PLGA appeared smooth and nonporous.  Encapsulation of BSA did not alter the 
external microsphere morphology (Figure 17).   
 
 
Table 9.  Properties of single walled microspheres prepared of variable PLGA 
 
Batch ID PLGA Batch Yield % (w/o BSA); (w/ BSA) Diameter Range μm 
(w/o BSA); (w/ BSA) 
A 50:50, LMW 65.3 (1 batch) ;    78.4 ± 18.6 6.08 ± 2.52 ;   8.61 ± 4.05 
B 50:50, HMW 79.4 ± 6.9 ;    67.9 ± 7.0 7.26 ± 2.43 ;   7.88 ± 3.13 
C 65:35 64.4 (1 batch) ;    74.4 ± 8.5 10.01 ± 4.40 ; 10.50 ± 9.44 
D 75:25 77.7 ± (1 batch) ;    84.0 ± 2.6 10.12 ± 3.95 ; 11.58 ± 5.29 
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Figure 17.  Scanning electron micrograph of single walled PLGA (50:50, HMW) microspheres (A) and 
microspheres of identical formulation encapsulating BSA (B). 
 
 
3.3.1.1 In vitro release kinetics as affected by varying PLGA monomer ratio 
The liberation of BSA from single walled PLGA microspheres was evaluated by 
measuring the protein concentration of PBS solution following microsphere suspension and 
incubation at 37°C.  An initial burst of BSA release was seen in all four batches of PLGA 
microspheres (Figure 18).  The percent released following 1 day incubation was 22.3%, 78.9%, 
72.3%, and 70.1% of the total encapsulated protein for batch A, B, C, and D (respectively).  
While microsphere release from batch B, C, and D plateaued following 7 days of release, BSA 
release from batch A was nearly linear between day 1 and day 22.  Following day 25 of the 
release period, microspheres of batch B released an additional 2.5% of the total encapsulated 
protein.  Similarly, batch C released 3% and batch D released 0.2% beyond day 25.  However, 
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batch A consisting of microspheres prepared with 50:50 low molecular weight (LMW) PLGA 
released an additional 20% of total encapsulated protein beyond day 25. 
 
 
    
 
Figure 18.  Cumulative release of BSA from single walled microspheres of variable PLGA physical 
properties.  ( ) batch A, ( ) batch B, ( ) batch C, and (X) represents batch D.  Data is presented as mean ± 
standard deviation (n = 3 measurements for each batch of microspheres).   
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3.3.2 Single walled microspheres: effect of additives on lysozyme release kinetics 
Double emulsion microspheres were prepared as described in Section 3.2.2 with (65:35) 
PLGA and a primary emulsion of 20 mg of lysozyme in PBS without additives or with either 
AOT or HSA with PEG.  The average batch yield ranged between 71% and 80%, with no 
additive formulation offering a significant improvement in batch yield.  However, microspheres 
encapsulating lysozyme with HSA and PEG resulted in a decrease in protein loading (4%) as 
compared to lysozyme encapsulated alone (10.7%) or with AOT (11.0) (Table 10).   
   
 
Table 10.  Batch yield and drug loading of single walled microspheres encapsulating lysozyme with 
additives.    
 
Batch ID Encapsulate(s) Batch yield (%) Protein loading (%) 
E None 71.0 ± 19.6 NA 
F Lysozyme 76.9 ± 8.9 10.7 
G Lysozyme, AOT 71.1 ± 6.5 11.0 
H Lysozyme, HSA, PEG400 80.0 (1 batch) 4.0 
 
 
Single walled microspheres produced with all 4 formulations of encapsulants resulted in 
similarly normal distributions of microsphere diameter range as indicated in Figure 19, however 
microspheres of batch E were observed in low frequency at diameters above 20 μm.  The 
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diameter distribution of batch H shows peaks at higher diameters due to the measurement of 
aggregates of microspheres. 
 
 
Figure 19.  Diameter distributions of single walled PLGA microspheres for batch E (A), batch F (B), batch 
G (C) and batch H (D). 
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3.3.2.1 Scanning electron microscopic assessment of single walled PLGA microspheres with 
additives 
Scanning electron micrographs of the external surface of single walled (65:35) PLGA 
microspheres prepared without encapsulants, batch E, reveal that microspheres generally have a 
smooth surface and are nonporous.  However, microspheres are present in low frequency which 
possess large pores in the surface as indicated with a white arrowhead (Figure 20A).  
Additionally, large irregularly shaped microspheres are also visible as indicated with a white 
arrow.  Similar to batch E, SEM images of microspheres encapsulating only lysozyme, batch F, 
also reveal a porous microsphere surface, although the diameter distribution does not appear to 
contain large malformed microspheres as was seen with batch E.  However, microspheres of 
batch F have slightly non-spherical geometries.   
Micrographs of microspheres prepared with lysozyme and AOT (batch G) reveal a large 
number of microspheres with concave regions (white arrow).  However, unlike the alternative 
microsphere formulations, the external surface of batch G appears to be smooth and nonporous.  
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Figure 20.  Scanning electron micrographs of single walled (65:35) PLGA microspheres for batch E (A), 
batch F (B), batch G (C) and batch H (D).  Irregularities in spherical morphology is indicated with white arrow head.  
Concave regions in microsphere surface are indicated with white arrows.  
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3.3.2.2 In vitro release kinetics as affected by addition of protein coencapsulates 
Lysozyme release from single walled microspheres was evaluated over a time period of 
75 days in vitro (Figure 21).  Protein release from microspheres encapsulating lysozyme with or 
without additives resulted in an initial burst as was seen with single walled microspheres 
encapsulating BSA without co-encapsulants.  The greatest percent of total encapsulated protein 
lost following the first day on incubation in PBS occurred in microspheres of batch E, where 
86% of the total lysozyme encapsulated was lost after 1 day.  Encapsulation of lysozyme with 
AOT and HSA (batch F) does not appear to decrease the initial burst of lysozyme, as 85% of the 
total encapsulated material was lost.  However, addition of AOT in a 1:1 mass ratio to lysozyme 
in the primary emulsion (batch G) did decrease the initial percent release, with only 44% of the 
encapsulated protein being liberated on the first day of microsphere suspension.  Beyond day 1, 
batch G experienced a sustained lysozyme release that continued to day 75 after which time the 
subsequent release samples were negligible. 
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Figure 21.  Cumulative release of lysozyme from single walled microspheres.  (  ) batch F, (  ) batch G, 
(  ) batch H.  Data is presented as mean ± standard deviation (n = 3 measurements for each batch of microspheres). 
 
 
3.3.3 Single walled microspheres encapsulating GDNF 
Double emulsion (65:35) PLGA microspheres were prepared encapsulating GDNF with the 
primary emulsion containing AOT in a 1:30 molar ratio of GDNF to AOT in DI water.  
Microspheres were prepared with a batch yield of ~80% and drug loading of 2.3 * 10-5 % (or 
~230 pg GDNF per mg microspheres).    
 101 
3.3.3.1 SEM assessment of PLGA microsphere morphology and diameter distribution 
Micrographs used to visualize microsphere morphology for single walled PLGA 
microspheres encapsulating GDNF reveal a smooth, nonporous external surface (Figure 22A).  
Generally, the microspheres possess a spherical shape with an average diameter of 6.3 ± 3.8 μm 
(Figure 22B). 
3.3.3.2 In vitro release kinetics of PLGA microspheres encapsulating GDNF 
Single walled (65:35) PLGA microspheres encapsulating GDNF in a 1:30 molar ratio 
with AOT result in release kinetics of an initial burst (~70%) at day 1 followed by a sustained 
release until day 20 (Figure 22C).  Beyond this point, no measureable amount of GDNF was 
liberated from the microspheres.   
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Figure 22.  A) Scanning electron micrograph of single walled PLGA microspheres encapsulating GDNF.  
B) Diameter distribution of microspheres.  C) In vitro cumulative release of GDNF from single walled 
microspheres. 
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3.3.4 Double walled microspheres: Selection of polymer solvent on protein localization 
and polymer orientation  
DW microspheres were prepared using an oil-in-oil-in-water emulsion technique.  The 
microspheres were prepared using a 1:1 weight ratio of PLGA to PLLA in solvent.  To determine 
the appropriate organic solvent for creating a two phase microsphere with a PLGA core 
encapsulating protein and a PLLA shell, microspheres were prepared with combinations of 
dichloromethane, ethyl acetate and tetrahydrofuran (batches 1 – 3, Table 8).  Scanning electron 
micrographs of microspheres prepared with dichloromethane for dissolution of both PLGA and 
PLLA (batch 1) reveal two distinct polymer walls with the microsphere shell completely 
engulfing the microsphere core indicating complete polymer separation (Figure 23A).  
Additionally, light micrographs of batch 1 microspheres encapsulating FITC-BSA show protein 
localization within the microsphere core (Figure 23B).  SEM assessment of batch 2 microspheres 
also reveals two unique polymer walls with complete phase separation between the external shell 
and inner polymer core (Figure 23C).  Figure 23D shows protein localization within the polymer 
core as visualized with fluorescent microscopy.   
 Double walled microspheres were not produced reproducibly with the solvent 
combination of DCM (PLGA) and THF (PLLA).  SEM analysis of batch 3 microspheres 
revealed the production of microspheres with two polymer walls in low frequency as compared 
to the majority of microspheres which were non-engulfing and were composed of a single 
polymer (Figure 23E).  The internal architecture of single polymer microspheres was rough and 
appeared to have a porous structure.  In addition, for those microspheres seen which were 
composed of two polymer walls, fluorescent micrographs reveal protein localization in the outer 
polymer shell (Figure 23F). 
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Figure 23.  SEM and fluorescent visualization of cross sections of batch 1 (A, B), batch 2 (C, D) and batch 
3 (E, F) microspheres.  Fluorescent micrographs were taken at 40X.  
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3.3.4.1 Effect of polymer solvent on lysozyme release kinetics 
Long term release studies were performed on batch 1 – 3 microspheres to determine the 
release profile of the encapsulated protein lysozyme (Figure 24).  Microsphere release profiles 
for all three batches show a sustained release of lysozyme beyond 90 days of incubation in PBS 
at 37 °C.  After 1 day release, lysoayme liberation from batch 1 and 2 was 4.4% and 5.8%, 
respectively while release of lysozyme from batch 3 was 11.5% at day 1.  Beyond day 1, all three 
batches of microspheres produced a slow, gradual release of encapsulant until day 35, when 
batch 1 and 2 produced a rapid increase in lysozyme release rate.  Lysozyme release from 
microspheres of batch 1 continued at an accelerated rate until day 70, when the release rate 
leveled and only negligible amounts of protein released beyond day 91.  Lysozyme release for 
batch 2 microspheres was greatest between days 35 and 49, after which protein release slowed 
and was nearly linear until day 91, after which lysozyme release was no longer measured.  
Finally, lysozyme release from microspheres of batch 3 demonstrated a sustained, low rate of 
protein release for the duration of time over which protein samples were measured, with only a 
small increase in release rate seen between day 28 and 42.  Drug loading as calculated with 
equation 2 was 21.1% for batch 1, 14.7% for batch 2, and 3% for batch 3.  
 
 
 
 106 
 
 
Figure 24.  Cumulative in vitro release of lysozyme from microspheres of batch 1 ( ), batch 2 ( ) and 
batch 3 ( ). 
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3.3.5 Double walled microspheres: assessment of PLGA solution concentration on 
lysozyme release kinetics 
DW microspheres were fabricated with the most efficient protein loading using dichloromethane 
as the solvent for both PLGA and PLLA.  Initial microsphere batches were produced with a 20% 
PLGA solution and a 10% PLLA solution in a 1:1 polymer mass ratio.  The external surface of 
the microspheres appeared smooth and non-porous (Figure 25A).  The microspheres were 
manufactured with an average yield of ~50 ± 8 % (N = 12).  The mean microsphere diameter 
was 81 ± 34 µm with the majority of microsphere ranging between 50 – 75 µm (Figure 25B). 
 
 
 
 
Figure 25.  A) Scanning electron micrograph of 20% PLGA, 10% PLLA DW microspheres.  B) Size 
distribution of double walled microspheres. 
 
 
 To determine the effect of variable PLGA solution concentrations on polymer phase 
separation, 4 additional microsphere batches were produced using PLGA in concentrations from 
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10% to 17.5% (w/v) in 2.5% increments.  The batch yield for each microsphere formulation is 
presented in Table 11.  For each presented microsphere batch type, three replicate batches of 
microspheres were prepared except for batch 8, where n = 20.   Scanning electron micrographs of 
microsphere cross sections show a double walled microsphere morphology for all variations of 
PLGA solution concentration (Figure 26).  However, microspheres formed with a low to 
intermediately viscous PLGA solution resulted in reduced polymer phase separation between the 
core and shell microsphere components.  Microspheres prepared using 10% PLGA (Figure 26A), 
12.5% PLGA (Figure 26B) and 15% PLGA (Figure 26C) show a high frequency of PLGA 
spherulitic occlusions within the PLLA shell.  Additionally, large holes (white arrow heads) can 
be seen in both the PLLA microsphere shell and the PLGA microsphere core.  Double walled 
microspheres produced with 17.5% (Figure 26D) and 20% (Figure 26E) PLGA solutions, 
polymer phases which were more viscous when dissolved in dichloromethane, produced 
microspheres of dense polymer compartments and a low frequency of PLGA spheres within the 
PLLA shell.     
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Table 11.  Microsphere characterization: Batch Efficiency. 
 
PLGA % w/v Solution Concentration % Batch Yield 
10 % 60.16 ± 12.58 % 
12.5 % 66.96 ± 1.31 % 
15 % 60.48 ± 13.56 % 
17.5 % 61.57 ± 10.82 % 
20 % 50.25 ± 8.41 % 
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Figure 26.  Scanning electron micrographs of double walled microspheres prepared with 10% PLLA in 
DCM and A) 10% PLGA (w/v), B) 12.5% PLGA, C) 15% PLGA, D) 17.5% PLGA and E) 20% PLGA in DCM.  
White arrow heads indicate large air occlusions in microspheres following polymer hardening.    
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3.3.5.1 Internal architecture 
The scanning electron micrographs depicting microspheres treated for 48 hours with 
ethyl acetate shown in Figure 27 demonstrate a PLLA hemisphere with partial mass loss within 
the external microsphere shell, indicating incomplete polymer phase separation during the 
dynamic process of microsphere hardening.  Microspheres produced with low PLGA solution 
concentration (10% to 15%) resulted in uniform microsphere shell coatings with small diameter 
spaces where PLGA spheres had existed.  SEM images of microspheres produced with highly 
viscous PLGA solutions reveal heterogeneous microsphere shells with large holes following 
solvent removal of PLGA.  Upon incubation of microspheres in aqueous solution, PLGA 
degrades before PLLA, resulting in mass loss from the microsphere shell and the formation of 
pores.   
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Figure 27.  Scanning electron micrographs of double walled microspheres following treatment with ethyl 
acetate.  A) 10% PLGA (w/v), B) 12.5% PLGA, C) 15% PLGA, D) 17.5% PLGA and E) 20% PLGA in DCM.    
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3.3.5.2 Microsphere degradation 
Degradation studies were performed for DW microspheres prepared with 20% PLGA and 
10% PLLA in DCM with and without encapsulated lysozyme (Figure 28 and 29 respectively).  
Following 1 week incubation in vitro (Figure 28A), the external PLLA surface of the spheres 
appeared very smooth and dense.  Large quantities of adherent protein were evident on the 
surface of microspheres (Figure 29A).  The shell appeared to roughen by 1 month and large 
craters formed (Figure 28B).  Beyond 2 months of degradation, the shell continuity was 
compromised by large cracks (Figure 28C).  In contrast, the PLGA core began to degrade within 
the first month of incubation in PBS and by month 3 the PLGA material was completely absent 
(Figure 28D).  Micrographs taken after 3 months also reveal incomplete polymer separation in 
the microsphere layers as large spaces are evident within the microsphere PLLA shell due to 
PLGA degradation.  Though the PLGA core degrades within the first few months of incubation, 
the PLLA shell maintained an overall spherical structure until month 5 (Figure 28F) when the 
material began to crumble and large macropores were evident.  Following 6 months of in vitro 
degradation, a small percentage of intact PLLA microsphere shells remain while the majority of 
microspheres have broken apart (Figure 28G).  The presence of encapsulated lysozyme did not 
alter the degradation process of double walled microspheres. 
 
 
 
 114 
 
Figure 28.  Scanning electron micrographs of double walled microspheres without encapsulated proteins 
incubated in PBS for 1 week, (A) followed by monthly intervals to 6 months (B – G).   
 
 
Figure 29.  Scanning electron micrographs of double walled microspheres with encapsulated lysozyme 
incubated in PBS for 1 week, (A) followed by monthly intervals to 6 months (B – G).   
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3.3.5.3 In vitro release kinetics 
The formation of pores in the microsphere shell impacted lysozyme release kinetics as 
shown in the protein release studies (Figure 30).  The cumulative release of lysozyme from 10% 
PLGA microspheres by day 56 is 19.5 μg protein per mg microspheres, while 12.5% PLGA 
micropsheres released only 12 μg per mg microspheres.  DW microspheres produced with 15% 
and 17.5% PLGA had reduced liberation of lysozyme as compared to 12.5% and 10% PLGA.  
At day 56, 15% PLGA microspheres released only 5.7 μg protein per mg microspheres.  
Lysozyme release from 17.5% PLGA microspheres was similar to that of 15% PLGA solution, 
with 6.3 μg protein liberated per mg microspheres.  Therefore, PLGA solution concentration 
affected not only the pore structure within the PLLA shell, but also the overall protein loading of 
microsphere batches.  Encapsulation efficiency for microspheres of successively increasing 
concentrations of PLGA were: 23.5%, 14.6%, 6.5%, 6.5%, and 4.3% for batch 4 – 8 
respectively.    
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Figure 30.  Cumulative release of lysozyme from double walled microspheres prepared with 10% PLLA 
solutions and 10% PLGA ( ), 12.5% PLGA ( ), 15% PLGA ( ), 17.5% GDNF (*), 20% PLGA (X). 
 
 
 
 
 117 
3.3.6 Double walled microspheres: effect of co-encapsulates 
Additives such as the surfactant AOT and the large, stabilizing protein human serum albumin 
were investigated as co-encapsulants for double walled microsphere preparation. 
3.3.6.1 Optimization of Lysozyme : AOT molar ratio 
A bioactivity assay with specified molar ratios of lysoyme to AOT was performed using a 
Micrococcus lysodeikticus solution (Figure 31).  Results suggest that a 1:2 (93% activity) and 
1:3 (91% activity) molar ratio of lysozyme to AOT had significantly higher activity when 
compared to all other molar ratios of lysozyme:AOT tested (p < 0.05).  The activity assay further 
indicated that AOT molar ratios of 1:1, 1:4, 1:5, and 1:20 all had similarly reduced activity (85%, 
80%, 79% and 78%, respectively).   The 1:10 solution of lysozyme to AOT appeared to have the 
lowest percent activity, with only 70% measured activity as compared to identical lysozyme 
concentration in PBS solution (p < 0.003 for all compared groups).  From this study, DW 
microspheres were prepared using a 1:2 molar ratio of lysozyme to AOT. 
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Figure 31.  Measured bioactivity of lysozyme in PBS solution with varying molar ratios of lysozyme to the 
surfactant AOT.  Error bars represent mean ± standard deviation for n = 4.  Significance between groups is indicated 
by astersisks (p < 0.05).  
3.3.6.2 Effect of docusate sodium salt on protein localization and microsphere polymer 
orientation 
Light micrographs of DW microspheres encapsulating only fluorescently labeled albumin 
revealed protein localization within the polymer core (Figure 32A).  However, when FITC-BSA 
was encapsulated with the surfactant AOT, the protein was detected in the microsphere shell 
(Figure 32B).  Dissolution studies in which the microspheres were first sectioned and 
subsequently treated with ethyl acetate, a solvent which dissolves PLGA and not PLLA, revealed 
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the PLGA component of the microspheres was largely restricted to the internal microsphere core 
when AOT was not used for encapsulation.  The scanning electron micrograph depicting 
microspheres treated for 48 hours with ethyl acetate shown in Figure 32C demonstrates a PLLA 
hemisphere with partial mass loss within the external microsphere shell.  Scanning electron 
micrographs of DW microspheres encapsulating both lysozyme and AOT reveal solid polymer 
spheres remain following treatment with ethyl acetate for 48 hours (Figure 32D).   
 
 
 
 
Figure 32.  Fluorescent micrograph of double walled microsphere encapsulating FITC-BSA (A) and with 
FITC-BSA in a 1:2 molar ratio with AOT (B).  Scanning electron micrographs of double walled microspheres 
encapsulating FITC-BSA (C) and FITC-BSA with AOT (D) following treatment with ethyl acetate.  
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3.3.6.3 Microsphere degradation in vitro 
Degradation studies were performed for DW microspheres encapsulating lysozyme with 
the surfactant AOT.  The degradation of microspheres encapsulating lysozyme with AOT 
(Figure 33) was markedly different from that seen with lysozyme alone (Figure 29).  
Microsphere surfaces after 1 week incubation in vitro were very rough (Figure 33A) and it is 
evident that the PLGA/PLLA orientation was reversed.  The PLGA shell was mostly degraded 
following 1 month incubation (Figure 33B) and was almost completely absent after 2 months 
(Figure 33C).  At month 3 (Figure 33D), the PLLA core seemed to have surface adherent protein 
that was not evident at 4 months (Figure 33E).  As the degradation of the remaining PLLA core 
continued, the surface pores increased in size and by month 6 only single polymer PLLA spheres 
remained that were deeply cratered (Figure 33G). 
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Figure 33.  Scanning electron micrographs of double walled microspheres with encapsulated lysozyme and 
AOT incubated in PBS for 1 week, (A) followed by monthly intervals to 6 months (B – G).   
 
 
3.3.6.4 In vitro release kinetics 
The long-term delivery of lysozyme was measured following microsphere incubation in 
PBS at 37°C.  At specified time points, the microspheres were centrifuged and the PBS was 
aspirated and analyzed with a Micro BCA protein assay.  Protein release studies were performed 
on two unique batches of microspheres with lysozyme to assess fabrication consistency (Figure 
34).  Microspheres demonstrated an extended release of lysozyme for over 140 days.  The drug 
loading efficiency was ~12% and microsphere drug loading capacity was .005%.  The release 
profile revealed a small burst release of lysozyme within the first week of microsphere 
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incubation in vitro.  This was followed by a slower, sustained release until day 36.  At this point, 
~16% of the encapsulated lysozyme was released from the microspheres.  Between day 40 and 
day 100 of the release profile an additional 77% of encapsulated lysozyme was released.  Beyond 
day 100, only small residual amounts of lysozyme were measured.  The release profile of 
lysozyme between multiple batches of DW microspheres appeared consistent. 
Lysozyme encapsulated with the surfactant AOT in a 1:2 molar ratio produced a 
significantly different release profile (Figure 34).  Within the first week of incubation, ~37% of 
the encapsulated lysoyme was released, followed by an additional 37% before day 40.  Between 
day 40 and day 100, 17% of the encapsulated lysozyme was released in a near linear order.  Drug 
loading efficiency for lysozyme encapsulated with AOT was 12.8% and drug loading capacity 
was 0.006%. 
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Figure 34.  Release of lysozyme from double walled microspheres.  Lysozyme was encapsulated in two 
unique batches of microspheres without AOT (  and  ) and with AOT (  ).  Error bars represent standard 
deviation (n = 3 measurements for each batch of microspheres). 
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3.3.6.5 Lysozyme Bioactivity 
The bioactivity of lyophilized lysozyme was assessed immediately prior to encapsulation 
and was not significantly different from freshly dissolved lysozyme (p = 0.66). When 
microspheres were prepared with lysozyme independently, 82 ± 5 % of bioactivity was 
maintained following 1 week release from DW micropsheres (Figure 35).  The lysozyme mean 
activity decreased slightly to ~73 ± 7 % at day 13, and then increased to measured activity levels 
above 100% between day 34 and 53 of the release studies, however the release activity for 
lysozyme encapsulated alone was not significantly different between day 1 and day 60 (p > 
0.05).  Beyond day 60, the lysozyme activity decreased significantly to ~65% (p < 0.001) and 
then decreased again at day 70 to ~17.0% (p = 0.0012).  The bioactivity of lysozyme release 
beyond day 90 was no longer detectable.   
Lysozyme encapsulated with the surfactant AOT had significantly reduced bioactivity at 
day 1 (47%) and day 7 (47%) as compared to lysozyme encapsulated alone (p < 0.01) (Figure 
35).  Bioactivity of released lysozyme samples increased after this period and was not 
significantly different from lysozyme activity when encapsulated alone (p > 0.05). 
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Figure 35.  Measured percent bioactivity measurements for (  ) lysozyme samples without AOT or (  ) 
lysozyme with AOT released from double walled microspheres after incubation in PBS, mean ± standard deviation.  
Single asterisks represent statistical significance between individually compared groups.  Double asterisks represent 
significant differences between time points for both microsphere groups (p < 0.05).   
 
 
3.3.6.6 Double walled microsphere encapsulation of GDNF with AOT 
GDNF was encapsulated in double walled 15% PLGA, 15% PLLA microspheres with the 
surfactant AOT.  Batch 11 of GDNF microspheres was prepared with 7 mg HSA and 100 mg 
AOT as coencapsulants with 40 μl (0.1 mg/mL) GDNF as described by Jiang et al [193].  
Microspheres of this preparation formulation were generated with a batch efficiency of 54.6%.  
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Scanning electron micrographs of double walled microspheres reveal heterogeneity in resulting 
microsphere morphology.  Microspheres were produced with both a single polymer composition 
(Figure 36A) and a double walled morphology (Figure 36B).  DW microspheres had a thick shell 
coating and show large holes in the polymer layer continuity. 
Microspheres of batch 12 consisted of 15% PLGA, 15% PLLA with 7 mg HSA, 40 μl 
GDNF and a 1:2 molar ratio of AOT (2.37 μg).  Micrographs of microspheres reveal two 
polymer microspheres with both complete core engulfment (Figure 36C) as well as partial 
engulfment (Figure 36D).  Additionally, the external shell of double walled microspheres is 
rough and appears porous with small spheres of PLGA evident within the external shell layer.    
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Figure 36.  Scanning electron micrographs of batch 11 double walled microspheres encapsulating GDNF 
(A and B) and batch 12 double walled microspheres with GDNF in a 1:2 molar ratio with AOT (C and D). 
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 The long term liberation of GDNF from double walled microspheres was measured 
following analysis of PBS collected following microsphere incubation in vitro.  The release 
profile indicates an initial burst release of GDNF from batch 11 during the first day of 
microsphere incubation, with 4.8 ± 0.4 ng GDNF measured per mg microspheres (Figure 37).  
Following the initial burst, GDNF was released with near zero-order kinetics until day 40 and by 
day 64 had a cumulative release of 6.4 ± 0.02 ng GDNF per mg microspheres.  GDNF release 
from batch 12 microspheres consists of two periods of accelerated release.  After 1 day in 
solution, ~15% of the total encapsulated GDNF was released and by day 35, ~59% of the 
encapsulated GDNF was liberated.  After this point, there was a second period of increased 
lysozyme release until day 57, when at this time point, almost 99% of the encapsulated GDNF 
was released.  The cumulative release of GDNF for 64 days of incubation in PBS was ~4.5 ± 
0.006 ng per mg of double walled microspheres.  This represents a total drug loading of 0.0006% 
and 0.0004% for batch 11 and 12 respectively. 
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Figure 37.  In vitro release of GDNF from double walled microspheres (  , batch 11; 100 mg AOT) and  
(  , batch 12; 1:2 ratio of GDNF:AOT).  Error bars represent standard deviation, with 4 unique release 
measurements per batch of microspheres. 
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3.3.7 Optimization of lysozyme : HSA molar ratio 
A bioactivity assay with specified molar ratios of lysoyme to HSA was performed using a 
Micrococcus lysodeikticus solution (Figure 38).  Following incubation of lysozyme with HSA in 
PBS for 48 hours, the protein solution was added to a standard solution of lyophilized bacteria 
and the change in solution absorbance was measured.  All results were normalized to fresh 
lysozyme suspended in an identical PBS solution.  Results indicate that HSA improved the 
stability of lysozyme in solution and therefore increased the measured in vitro bioactivity, as all 
recorded measurements of bioactivity were above lysozyme alone in solution.  The mean 
recorded bioactivity of lysozyme with HSA was greatest at a 1:50 ratio of lysozyme to HSA, 
with the average bioactivity being ~111 ± 4.8 %, which was significantly greater than a 1:2 ratio 
(105 ± 1.63%), a 1:3 ratio (106 ± 2.8%), a 1:4 ratio (106 ± 3.2%) and a 1:20 ratio of lysozyme to 
HSA (107 ± 3.2%).  Bioactivity of lysozyme in solution was recorded with four repetitions and 
statistical significance was established with p < 0.05. 
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Figure 38.  Measured bioactivity of lysozyme in PBS solution with varying molar ratios of lysozyme to 
HSA.  Error bars represent mean ± standard deviation for n = 4.  Significance between groups is indicated by 
astersisks (p < 0.05). 
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3.3.7.1 Double walled microspheres encapsulation of GDNF with HSA 
Double walled microspheres were prepared with 17.5% PLGA, 10% PLLA and 
encapsulated GDNF with HSA as a coencapsulant.  Batch 13 microspheres were produced with 
85.7% microsphere efficiency and resulted in microspheres that had two distinct polymer walls 
(Figure 39 A and B).  Large holes are evident within the PLGA core while the PLLA shell 
appears smooth and dense.  The external surface of the microsphere shell is rough, with a large 
number of protuberances.  Batch 14 microspheres were produced with 84.7% yield efficiency 
and also produced microspheres of two distinct polymer layers in high frequency.  As was 
evident with batch 13, large holes are evident in the PLGA core.  However, the external 
microsphere shell is smooth and dense and appears to contain only small traces of PLGA that 
was not able to fully phase separate.   
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Figure 39.  Scanning electron micrographs of double walled microspheres encapsulating GDNF with HSA.  
A and B) Double walled microspheres produced with cloud point induction.  C and D) Double walled microspheres 
produced without induction of phase separation. 
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Long term release studies of GDNF encapsulated with HSA reveal two phase protein 
release for both batches 13 and 14 of microspheres.  For those microspheres produced with cloud 
point induction (batch 13), protein release following 1 day incubation resulted in a burst with 
~53% of the total encapsulated GDNF released into solution.  GDNF release between day 1 and 
28 was nearly continuous with ~80% of GDNF released by day 28.  Following a second period 
of accerlerated protein release, all measurable amounts of GDNF were released by day 63 in 
vitro.  Protein release from batch 14 microspheres showed two periods of rapid protein release 
with little to negligible GDNF liberation in between   At day 1, ~29% of the total encapsulated 
protein was released followed by a plateau until day 35, when the release profile appears nearly 
zero order.  This period of release occurred between day 35 and day 50, when ~98.5% of the 
encapsulated GDNF was released.  The drug loading for batch 13 and 14 respectively was 
8.2x10-4 %  and 4.5x10-4 %.     
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Figure 40.  In vitro release of GDNF from double walled microspheres (  , batch 13; cloud point 
induction) and (  , batch 14; no cloud point induction).  Error bars represent standard deviation, with 4 unique 
release measurements per batch of microspheres. 
3.4 DISCUSSION 
There are several manufacturing factors within solvent evaporation methods for 
microsphere fabrication that influence the physical properties of the microsphere product and 
thus the drug release profile.  Such factors include the selection of fabrication materials such as 
polymer type, solvent, encapsulated protein and surfactant choice.  Depending on the selected 
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permeation of these manufacturing factors, microsphere size distribution, surface morphology, 
porosity, encapsulation efficiency and protein release kinetics can all be influenced [212].   
GDNF has been successfully encapsulated in single walled microspheres by Ward et al., 
[192], Fu et al., [181],  Aubert-Pouessel et al., [183] and Tatard et al., [213].  By using single 
emulsion and double emulsion PLGA microspheres, Fu et al., were not able to avoid burst 
release of GDNF such that blood serum levels in rats showed significant protein delivery beyond 
2 days.  Our results show that even with optimization of PLGA selection (65:35 lactide to 
glycolide molar ratio) and coencapsulation of surfactants shown to delay model protein release, 
the burst release of GDNF from single walled microspheres was not improved upon.  Therefore, 
the use of double walled microspheres as a method for improved GDNF release kinetics was 
investigated. 
 While DW microspheres were originally formed from poly(1,3-bis(p-
carboxyphenoxypropane)-co-sebacic anhydride) 20:80 and poly(lactic acid) [204] more 
chemically similar polymer pairs such as PLLA and PLGA have also been used [199, 201, 203, 
214, 215].  The benefit of using PLGA and PLLA for DW microspheres includes the polymers 
proven biocompatibility and toxicologically safe degradation products (lactic and glycolic acid) 
[182].  Furthermore, PLGA and PLLA used in combination create a DW microsphere that is both 
a reservoir and bioerodible matrix system.  When the DW microsphere is added to an aqueous 
environment, the PLLA microsphere shell presents a barrier and suppresses water diffusion 
throughout the microsphere, limiting the initial protein release [216].  Within the two polymer 
microsphere layers, the PLGA microsphere core undergoes bulk erosion first (Figures 28 and 
29), allowing water molecules to permeate into the amorphous regions of the polymer matrix and 
release the encapsulated protein through diffusion.  However, the degradation of PLLA is much 
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slower than PLGA (50:50) due to increased polymer crystallinity and hydrophobicity [217], 
which results in a temporary reservoir system from which the protein diffuses outward through 
the PLLA pores and is released with kinetics approaching first order [199]. 
 Double walled microspheres were produced using an oil-in-water single emulsion 
process.  This method depends on the creation of a two polymer solution in a single, continuous 
phase in which phase separation occurs.  The two polymers used for microsphere preparation 
were PLGA and PLLA.  The desired polymer configuration for the microsphere core and shell 
was one of PLGA engulfed by PLLA.  The effect of three volatile solvents on polymer phase 
separation was investigated as a method of engineering polymer orientation within the double 
walled microspheres.  After the selection of appropriate polymer solvents, separate solutions of 
PLGA (10 – 17.5% w/v) and PLLA were prepared in order to dictate the extent to which the two 
polymers were able to phase separate within each droplet of the single emulsion solution.  
Finally, additives were investigated as a method of protecting the encapsulated protein and thus 
improve the bioactivity of liberated proteins in vitro. 
 For selection of polymer solvent for DW microsphere preparation, it was hypothesized 
that the polymer dissolved in the more hydrophilic solvent would phase separate toward the 
aqueous environment and would therefore become the microsphere shell.  Therefore, solvent 
combinations of Table 8 were selected such that the most hydrophobic solvent within 
combinations was used for PLGA dissolution.  Polymer combinations of PLGA and PLLA 
dissolved in dichloromethane or PLGA in ethyl acetate and PLLA in DCM resulted in the 
desired polymer orientation and protein localization with the PLGA core.  However, the solvent 
combination of DCM for PLGA and THF for PLLA was used, the resulting microspheres were 
heterogeneous in polymer orientation with the majority of microspheres having a PLLA core and 
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a PLGA shell.  Although, the encapsulated protein remained within the PLGA microsphere layer, 
because the PLGA composed the microsphere shell, the localization of protein was not optimal 
for our purposes.  Because the protein loading within microspheres prepared with only DCM 
(21.1%), was greatly improved over microspheres prepared with ethyl acetate and 
dichloromethane (14.7%), future microspheres were produced using dichloromethane for both 
PLGA and PLLA.  
 The percent concentration of PLGA was further investigated as a method of tailoring the 
release kinetics of lysozyme from microspheres.  As shown in Figure 27, the degree of phase 
separation between PLGA and PLLA during the dynamic process of polymer separation and 
hardening is affected by the concentration of PLGA in dichloromethane used for the primary oil-
in-oil emulsion.  Low concentrations of PLGA, 10% and 12.5% PLGA, result in the formation of 
small, interconnected pores upon PLGA degradation form the microsphere shell.  Accordingly, 
when the PLGA degrades during protein release studies at day 35, there is an increase in 
lysozyme liberation seen in microspheres prepared with 10% and 12.5% PLGA solutions.  
However, DW microspheres prepared with higher concentrations of PLGA showed large 
occlusions of PLGA within the PLLA shell due to an increase in polymer solution viscosity.  As 
a result, large, isolated pores remained following PLGA degradation.  Therefore, the liberation of 
lysozyme into release media was slowed from microspheres produced with highly viscous 
solutions of PLGA during the initial oil-in-oil emulsion preparation.     
Despite the improved release kinetics that DW microspheres present as compared to 
standard, single-walled double emulsion microspheres, some of the drawbacks of encapsulating 
proteins with a solvent evaporation method continue to exist.  During the DW microsphere 
fabrication process, the protein to be encapsulated is added directly to PLGA dissolved in an 
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organic solvent, potentially denaturing the protein.  Furthermore, high energy mixing and 
addition of the dissolved protein and polymer solution to a large aqueous volume is still required.  
Therefore, the encapsulation procedure results in a substantial loss of expensive drug or protein 
materials.  Because of this, additives for protein encapsulation have been investigated to 
maximize the recovered protein bioactivity following encapsulation.   
Protein stabilizers such as cyclodextrins [218], poly(ethylene glycol) (PEG) [219], Rat 
Serum Albumin (RSA) [208] and AOT [181, 192, 193] have all been investigated as potential 
compounds for protecting a protein during the encapsulation procedure.  For this study, docusate 
sodium salt was chosen because it was hypothesized that a continuous distribution of protein 
within the initial PLGA solution would lead to a decrease in protein aggregation and therefore an 
improvement in released lysozyme bioactivity.  While other stabilizers were shown effective in 
minimizing protein denaturation during manufacturing of single polymer double-emulsion 
microspheres, protein encapsulation in DW microspheres required that lyophilized protein 
powder solubilize in a single-phase polymer solution.  Fu et al., have shown previously that AOT 
dramatically increases the solubility of lysozyme in dichloromethane and when used to fabricate 
single-walled microspheres resulted in enhanced protein partitioning within PLGA in organic 
solvent [181].   
However, it has also been documented that anionic surfactants, such as AOT, can cause a 
decrease in enzyme stability at temperatures near 37°C [220].  Literature reports that there is an 
initial interaction between the negatively charged regions of surfactants (such as the two 
negatively charged arms of AOT) with the cationic amino-acid residues of lysine, histidine and 
arginine [221].  In an oil-based solution, such as dichloromethane, the conformation of lysozyme 
changes slowly to maximize the number of exposed hydrophobic regions.  If an abundance of 
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AOT is added to the lysozyme solution such that the cationic sites of lysozyme are saturated, 
AOT will also bind to the exposed hydrophobic regions of lysozyme and can disrupt the 
secondary structure of the protein folding, especially the α-helices [221].  In an effort to 
determine the optimal concentration of AOT for encapsulation, a bioactivity study was 
conducted using various molar ratios of lysozyme to AOT.  While Fu et al., reported that a 1:30 
molar ratio of protein to AOT was optimal for protein solubility in the single phase of PLGA and 
solvent, our bioactivity studies of lysozyme in solution with various molar ratios of AOT 
revealed that an excess of surfactant decreased the protein bioactivity.  Because we consider 
protein bioactivity a priority for our delivery system, we chose to conduct our experiments with a 
1:2 molar ratio of lysozyme to AOT. 
DW microsphere degradation studies revealed an unexpected effect of AOT on the 
process of polymer phase separation (Figures 29 and 33).  After one week in vitro, microspheres 
encapsulating lysozyme alone displayed a smooth surface with adherent lysozyme.  However, 
microspheres encapsulating both lysozyme and AOT resulted in a surface covered with 
protuberances indicating incomplete phase separation between PLLA and PLGA.  By validating 
the polymer orientation through dissolution studies (Figure 32) and from the progression of 
microsphere degradation micrographs, it is evident that the polymer orientation seen previously 
with lysozyme-loaded microspheres had reversed.  Instead of DW microspheres containing a 
core of PLGA and a PLLA shell, microspheres encapsulating lysozyme and AOT resulted in a 
core composed mostly of PLLA and a PLGA shell.   
Lysozyme release kinetics from the two microsphere samples reflect the reversal of 
polymer core and shell orientation.  The release profile of lysoyme encapsulated alone from DW 
microspheres reveals that protein was delivered first from the surface of the microsphere, 
 141 
followed by a slow rupture and formation of macropores in the PLLA microsphere shells.  The 
slow, steady-state release of lysozyme between day 7 and day 35 reflects the high water uptake 
of the inner PLGA core and the slow release of lysozyme through PLLA micropores [215].  
Lysozyme release between day 40 and day 100 is nearly zero-order and indicates that the PLGA 
core has undergone bulk degradation and the PLLA shell served as a rate-limiting barrier for 
continued lysozyme release.   
Lysozyme encapsulated with the surfactant AOT in a 1:2 molar ratio resulted in an initial 
burst of lysozyme release within the first week.  Therefore, there was a large amount of protein 
adherent to the surface of the microspheres during fabrication.  Furthermore, within the first 40 
days of microsphere incubation, nearly two-thirds of the encapsulated protein was lost.  Because 
the PLGA shell degradation profile (Figure 29) closely matches the lysozyme release profile, it is 
most likely that a majority of lysozyme was encapsulated within the PLGA microsphere shell.  
Furthermore, the release profile of lysozyme beyond day 40 until day 100 was nearly zero order.  
This indicates that an additional quantity of lysozyme was also encapsulated within the PLLA 
microsphere core and was released through matrix diffusion. 
Although we hypothesize that the inversion of microsphere release kinetics between 
sustained, nearly constant release from microspheres encapsulating only lysozyme and an initial 
lysozyme release within 20 days from microspheres with AOT is caused by the inversion of 
polymer orientation, additional mechanisms may be responsible.  For example, it is possible that 
AOT interrupts the interaction between polymer and protein and allows for an increased 
concentration of non-adsorbed, soluble lysozyme within the DW microspheres.  Because similar 
overall concentrations of lysozyme are released cumulatively, we feel that the primary 
mechanism affecting the lysozyme release kinetics is polymer orientation.   
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At present, the exact mechanism for reversal of the polymer orientation in the 
microsphere core and shell is not clear.  We hypothesize that the increase in charge of the PLGA 
solution caused the polymer to reposition toward the aqueous solution and thus became the 
microsphere shell.  During fabrication, the protein and surfactant were added as a powder to 
PLGA dissolved in dichloromethane; the solution was then vortexed very well and allowed to sit 
on ice for ~20 minutes.  Therefore, lysozyme and AOT were adsorbed onto the PLGA prior to 
addition of PLLA.  In dichloromethane, the PLGA with adsorbed protein would arrange itself to 
get an energy minimum and would hide the hydrophilic elements in the center of the polymer – 
protein aggregate.  Because PLLA is a more hydrophobic polymer and because PLGA contained 
charged molecules, the PLGA most likely separated to the interior of polymer.  However, when 
the PLGA – PLLA oil phase was emulsified with the aqueous solution for microsphere 
formation, PLGA with bound protein and AOT rearranged toward the water interface.  This 
hypothesis is supported by both the initial burst release of protein adherent to the surface of the 
DW microspheres as well as the measured bioactivity of released lysozyme (Figure 35). 
Alternatively, it is possible that polymer rearrangement occurred during emulsification of 
PLGA – PLLA in aqueous solution is due to a reduction in polymer viscosity because of AOT 
and not because AOT binds to PLGA.  In addition to creating DW microspheres of 10% PLGA 
solution, we have also investigated fabricating microspheres using more concentrated polymer 
solutions with an increased viscosity.  Microspheres of similar polymer orientation to those used 
in assessment of AOT have been constructed from both dilute PLGA solutions (10% w/v) and 
highly viscous polymer solutions (20% w/v) (Section 3.3.5; Figure 26).  Therefore, a decrease in 
polymer solution viscosity is likely not responsible for the inversion of polymer orientation. 
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Within the first week of protein release from microspheres, the bioactivity of lysozyme 
encapsulated with the surfactant AOT was significantly reduced at both day 1 and day 7.  
Possible mechanisms of protein denaturation include damage to protein structure by the 
organic/aqueous interface as well as an increased molar ratio of lysozyme to AOT.  Results from 
activity data from lysozyme encapsulated alone and the microsphere release profile present 
evidence that both mechanisms are responsible for the lysozyme/AOT decrease in activity.  AOT 
caused an increase in surface adherent lysozyme (as indicated by the initial burst release from 
microspheres) which exposed a greater concentration of lysozyme to interface damage.  
Additionally, lysozyme released from microspheres encapsulating both protein and surfactant 
regained activity that was similar to protein encapsulated alone after 7 days.  Therefore, it is 
probable that nearly all of the AOT encapsulated in microspheres was located near the surface 
and was released within the first week of in vitro studies.   
 Encapsulation of lysozyme with HSA did not appear to affect the bioactivity of lysozyme 
(Figure 38).  Additionally, SEM assessment of microspheres encapsulating protein with HSA 
showed that two layered microsphere morphology was consistently produced within two unique 
batches of microspheres.  Induction of polymer cloud point using ethyl acetate resulted in an 
increased drug loading 8.2x10-4 % as compared to 4.5x10-4 % for microspheres prepared without 
cloud point induction.  However, GDNF release from microspheres prepared through cloud point 
induction resulted in an initial burst of protein from the microspheres followed by a sustained 
release until day 50.  This release profile was distinct from microspheres prepared without cloud 
point induction, in which GDNF release closely resembled typical double walled release profiles 
as modeled with lysozyme. 
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3.4.1  Conclusions 
DW microspheres were fabricated from two polymers of a similar chemical structure, PLGA and 
PLLA.  Initial studies with microspheres encapsulating a fluorescent protein, FITC-BSA, 
indicated that protein localization was restricted to the PLGA core.  In addition, protein release 
studies were performed using microspheres with the model protein lysozyme encapsulated alone 
or with the surfactant AOT.  Degradation studies indicated that microspheres encapsulating 
lysozyme alone resulted in a microsphere core composition of PLGA and a shell composed of 
PLLA.  In contrast, the polymer configuration for the microsphere core and shell were reversed 
due to AOT addition in the PLGA solution phase.  The reversal of polymer orientation was 
evident in both the microsphere release kinetics as well as the bioactivity assay of lysozyme 
released from both microsphere samples.  Lysozyme encapsulated with AOT caused the majority 
of encapsulated elements to be released from DW microspheres within the first 40 days of 
microsphere incubation in vitro.  Alternatively, lysozyme encapsulated alone resulted in the 
majority of encapsulated protein release occurring between day 40 and day 100.  The overall 
improvement in drug delivery through DW microspheres is promising.  Because of the potential 
for scale-up with this simple manufacturing technique, the DW microparticles presented herein 
represent a method of encapsulation with great utility in an array of delivery applications.            
3.5 FUTURE DIRECTIONS 
Though DW microspheres encapsulating protein with AOT resulted in an improvement in 
protein release kinetics such that the initial burst release of protein was avoided, the DW 
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microsphere formulations described herein do not yet meet our requirements of delivery 
bioactive protein for the entire duration of long term studies for long gap peripheral nerve repair.  
Therefore, additional studies with alternative protein stabilizers such as trehalose or antacids 
such as magnesium hydroxide are currently under investigation.  Trehalose has been shown to 
thermostabilize proteins such as BSA or other globular proteins composed mainly of α-helices 
such as lysozyme [222, 223].  By stabilizing the intermolecular O-H interactions responsible for 
the stability of the protein tertiary structure, Trehalose may prove fruitful as a method of 
improving encapsulated protein bioactivity following the initial freeze-drying procedure required 
for protein mixing with PLGA [223]).   
 Magnesium Hydroxide (Mg(OH)2) has been used by several groups as a method of 
increasing the pH within the microsphere microenvironment during PLGA degradation and 
accumulation of acidic end groups [224].  Within PLGA microspheres, the acidic 
microenvironment has been shown to fall to as low as pH = 2 [225].  Previous work performed 
with lysozyme has shown that the bioactivity is decreased at such a low pH, and certainly less 
stabile proteins such as neurotrophic factors would be denatured at such a low pH.  Therefore, 
Mg(OH)2 will be investigated as a coencapsulate for improved bioactivity of lysozyme upon 
release form microspheres.  The effect of antacid encapsulation will be investigated for protein 
release kinetics, microsphere degradation, and the long term bioactivity of released lysozyme.      
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4.0  INCORPORATION OF DOUBLE-WALLED MICROSPHERES INTO 
POLYMER NERVE GUIDES  
4.1 INTRODUCTION 
Though there has been a considerable amount of research in improving peripheral nerve 
guide design, commercially available nerve guides have not equaled the regenerative capacity of 
the nerve autograft in long gap peripheral nerve repair.  While autografts (e.g. the sural nerve) 
have been used to bridge nerve defects of 6 cm or more [13], polymer based nerve guides are 
effectively used to regenerate nerves in gaps that span only 3 cm or less [8].  This barrier in gap 
length may reflect the unmet necessity for nerve guides to actively promote nerve regeneration 
through the lumen of the guide from the proximal to the distal nerve stump [151].  Therefore, in 
addition to providing mechanical support for regenerating nerves, nerve guides must also provide 
cues that guide axonal growth and, as a consequence, increase the rate at which nerves 
regenerate.        
4.1.1.1 Substrate delivery from polymer nerve guides 
 The complex problem of targeting axonal outgrowth has led to the investigation of a 
variety of nerve guide materials, luminal fillers, cell therapies and combinations thereof [133].  
One additional pathway toward enhancing axonal growth involves locally delivering drugs or 
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neurotrophic factors that promote nerve growth and survival.  Growth factors have been 
delivered from nerve guides through several methods detailed in Table 12 (for review of these 
techniques, see [151] and [226]).  Results from these preclinical studies have shown many 
beneficial effects of delivered growth factors for nerve regeneration.  For example, the delivery 
of nerve growth factor (NGF) promotes sensory neuron survival, outgrowth and branching [102], 
ciliary neurotrophic factor (CNTF) aids in motor neuron survival and outgrowth [227] and glial 
cell line-derived neurotrophic (GDNF) has been shown to promote the regeneration of fibers 
originating from the spinal cord beyond what has been measured with NGF [228].  Because of 
the numerous promising reports following treatment of nerve injuries with neurotrophic factors, 
the delivery of such factors may be a potential method of surpassing the current length 
limitations in nerve regeneration.   
 
 
 
Table 12.  Methods of delivering growth factors within nerve guides. 
 
Method of Protein Delivery from Nerve Guides Reference(s) 
Growth factor adsorbed to the nerve guide scaffold [229] 
Growth factors combined with the scaffold material during fabrication [72] 
Growth factor encapsulated in  additional delivery system (rods or 
microspheres) that is incorporated into  the nerve guide 
[97, 99, 102, 228, 
230-232] 
Growth factor covalently immobilized onto the nerve guide surface [101, 125, 233] 
Co-implantation of an osmotic pump releasing growth factor [234, 235] 
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4.1.2 Limitations of previous art 
While strategies have been developed for protein delivery from polymer nerve guides, many 
conduit delivery systems lack a sustained and controlled release rate of bioactive proteins for the 
entire duration required for the axon to cross from the proximal to the distal nerve stump [72].  
For example, Dodla and Bellamkonda implanted polysulfone nerve guides across a 20 mm defect 
with lipid microtubules capable of delivery NGF for only 18 days and saw no improvement in 
axonal elongation after 4 months [99].  Furthermore, because typical microspheres have low 
drug loading, Rosner et al., noted that a significant limitation for microsphere loading in the 
center lumen of guides was adequate space.  For a target drug release of 1 ng/mL, the authors 
stated that for a nerve guide 1 mm in diameter, the construct’s capacity prevented microsphere 
loading and transfected cells were used instead [97].  Therefore, several groups have constructed 
nerve guides with microspheres embedded in the nerve guide wall and have shown that growth 
factors can be delivered from nerve guides in this manner for almost 30 days [72, 100, 231]. 
4.1.3 Chapter Aims 
In this chapter, double-walled microspheres comprised of poly(L-lactide) / poly(lactic-co-
glycolic acid) were reproducibly incorporated into porous poly(caprolactone) nerve guides in a 
manufacturer controlled distribution.  To confirm the distribution of microspheres within the 
nerve guide, fluorescently labeled bovine serum albumin (BSA) was encapsulated and visualized 
through fluorescent microscopy.  Because particulate leaching is required to create the porous 
nerve guide walls, the minimum period required for sodium chloride removal was determined.  
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In vitro release studies were performed to determine the effect of the nerve guide macrostructure 
on release of a model protein, lysozyme.   
4.2 METHODS 
4.2.1 Reagents 
All chemicals were analytical grade or purer and were purchased from commercial suppliers.  
Poly(vinyl alcohol) (average Mw 9,000-10,000, 80% hydrolyzed), poly(DL-lactide-co-glycolide) 
(lactide:glycolide (50:50), mol wt 40,000-75,000 units), Fluorescein isothiocyanate Conjugated 
Bovine Albumin (A9771) (FITC-BSA), lysozyme from chicken egg white, Dichloromethane, 
Ethyl Acetate, and Phosphate Buffered Saline (PBS) were all purchased from Sigma-Aldrich (St. 
Louis, MO). Poly-L-lactide (0.90 – 1.20 dL/g) was purchased from DURECT Corporation 
(Pelham, AL).  The Micro Bicinchoninic Acid (BCA) Protein Assay Kit (23235) was purchased 
from Pierce (Rockford, IL).   
 
4.2.2 Fabrication of poly(caprolactone) disks and nerve guides 
4.2.2.1 PCL Disks 
PCL disks were prepared to determine the effect of nerve guide macrostructure on 
lysozyme release from double walled microspheres.  Briefly, 15 mg of double walled 
microspheres (detailed fabrication description in Section 3.2.3) were added to a circular well 
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(diameter = 1 cm, depth = 0.5 cm) of a custom made silicone mold (Figure 41A).  Porous disks 
were created by dissolving 1.35 g PCL in 15 mL ethyl acetate.   To the dissolved polymer 
solution, sodium chloride impregnation was accomplished by adding NaCl in a 80% (v/v) 
amount.  200 μl of the polymer slurry was added to each mold and mixed well to distribute the 
microspheres within the disk space.  The ethyl acetate was allowed to evaporate and the sodium 
chloride was leached with distilled water.   
4.2.2.2 Nerve Guides 
PCL nerve guides were fabricated using a modification of previously reported methods 
(Section 2.2.2 and [236]).  Glass capillary mandrels 1.5 mm in diameter were coated with a 17% 
w/v% aqueous solution of poly(vinyl alcohol) (PVA), air dried and then immersed into the 
polymer slurry (as described above) creating NaCl/PCL mandrel coatings.  The ethyl acetate was 
allowed to evaporate for a minimum of ten minutes between successive mandrel immersions into 
the polymer slurry.  After the completion of the dip-coating process, the resulting polymer 
conduits were submerged in distilled water for 5 hours to allow for salt and PVA dissolution, and 
the guides were removed from the glass mandrels.  The final wall thickness after 6 successive 
immersions of the mandrels into the polymer solutions was 600 - 700 μms. 
 To incorporate double-walled microspheres into the inner half of the nerve guide wall 
(Figure 41B), 15 mg of double walled microspheres encapsulating either FITC-BSA (for 
visualization) or lysozyme (for protein release kinetics) were evenly spread onto a drawn grid on 
parchment paper (Figure 41C).  After the first immersion of the glass mandrel into the PCL 
slurry, the ethyl acetate was allowed to evaporate for only 30 seconds leaving a semi-hardened 
polymer layer on the mandrel.  The mandrel with semi-hardened polymer was then smoothly 
rolled across the microspheres on parchment paper.  The PCL with embedded microspheres was 
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allowed to dry for ten minutes and then repeatedly coated with additional layers of polymer as 
done in nerve guides without microspheres. 
 
 
 
 
Figure 41.  (A) Photograph of PCL disks following fabrication in custom made silicone mold.  (B) 
Schematic of polymer orientation in double-walled microsphere.  (C) Schematic of fabrication technique for 
incorporating double-walled microspheres into PCL nerve guide. 
 
 
4.2.3 Evaluation of sodium chloride leaching from nerve guide walls 
To determine the minimum amount of time required to leach the sodium chloride from 
the nerve guide walls, nerve guides were fabricated as described above (n = 5).  After ethyl 
acetate evaporation overnight, each mandrel with the attached polymer guide was weighed.  The 
mandrels were then immersed in distilled water in one hour increments.  The dry weight of each 
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guide was recorded between successive salt leaching periods.  Previous work has indicated that 
in an 80% porous nerve guide, very few closed pores exist from which remaining salt crystals 
could not dissolve [22]. 
4.2.4  In vitro release of lysozyme from PCL disks and nerve guides 
To determine the effect of the nerve guide material on lysozyme release from double-
walled microspheres, protein release kinetics were compared between a known weight of 
microspheres embedded in PCL disks to an equal weight of free microspheres in solution.  To 
accomplish this, 15 mg of microspheres were first immersed in water for a period identical to 
that used to remove the salt particulates from the PCL disks.  The microspheres were then 
collected and incubated in 1 mL PBS at 37°C. Following incubation, the microspheres were 
centrifuged for 10 minutes at 1000 rpm and the supernatant was removed.  Five PCL disks 
prepared as described above were individually placed into wells of a 48 well plate.  To each disk, 
0.6 mL of PBS solution was added and the well plate was incubated for equal time periods as 
microsphere samples.  To collect the releasate, the disks were removed using sterile forceps and 
transferred into clean wells where the PBS was refreshed. 
To measure the release of lysozyme from double-walled microspheres in PCL nerve 
guides, nerve guides were fabricated as described in Section 2.4.2.  After the guides were 
immersed in distilled water for 10 hours, the guides were cut to 2 cm lengths and added to a 
clean eppendorf tube.  To each tube, 0.6 cm of PBS was added and the guides were incubated at 
37°C for specified time increments.  To collect the releasate, the guides were removed from each 
eppendorf tube using clean forceps and added to new tubes in which the PBS was refreshed. 
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For measuring the lysozyme content of the releasate, a micro BCA protein analysis assay 
was performed.  Lysozyme standard or sample solution (1 mL) and 1 mL of the Micro BCA 
working reagent were combined in a test tube and mixed well.  All of the standard lysozyme 
samples as well as the release samples were incubated simultaneously in a water bath for 1 hour 
at 60°C.  After this period, the protein solutions were cooled to room temperature and 200 µL 
from each sample were transferred to a 48 well plate and measured with a plate reader at 562 nm 
(Tecan Spectrafluor, NC). 
4.2.4.1 Statistical Methods 
 A minimum repetition value of five was used when measuring lysozyme release from 
PCL disks and nerve guides.  Results are expressed as the mean ± standard deviation.  Analysis 
of variance (ANOVA) was used to determine statistical significance between experimental 
groups.  The least significant difference method was used for multiple comparisons with p < 
0.05. 
4.3 RESULTS 
4.3.1 Minimization of salt leaching period 
Leaching of sodium chloride from the nerve guide walls also results in a loss of protein from the 
microspheres.  Therefore, it is desirable to minimize the immersion of nerve guides in water.  
Following fabrication of PCL nerve guides impregnated sodium chloride, the PCL guides were 
immersed in distilled water for one hour increments.  Figure 42 indicates that the majority (97%) 
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of NaCl was removed from the nerve guide wall after one hour of immersion in water.  Beyond 5 
hours, no amount of measurable NaCl was further removed.  To validate the final PCL nerve 
guide weight, the guides were weighed after 60 hours of immersion in water and the final weight 
was unchanged. 
 
 
 
Figure 42.  Weight of nerve guides following NaCl impregnation and removal by leaching in distilled 
water for specified time points.  (Mean ± std dev, N=5). 
 
 
4.3.2 Incorporation of double-walled microspheres into PCL nerve guides  
A novel rolling technique was used to embed double-walled microspheres into PCL nerve guides 
for sustained protein release.  Fluorescently labeled BSA was encapsulated in the double-walled 
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microsphere to visualize microsphere distribution within the nerve guide wall.  Fluorescent 
microscopy images were then taken of the microspheres and overlaid with light microscopy 
images of the polymer nerve guide.  As seen in Figure 43A, by smoothly rolling the nerve guide 
mandrel across the microspheres and performing several consecutive immersions of the mandrel 
into the polymer solution, a nerve guide was created with microspheres distributed evenly along 
the luminal wall of the nerve guide.  Because PLA is not soluble in ethyl acetate, the rounded 
morphology of the microspheres was maintained following nerve guide fabrication (Figure 43B). 
 
 
 
 
Figure 43.  (A) Compilation of brightfield and fluorescent micrographs taken at 10X.  Multiple images of 
both the nerve guide and FITC-BSA encapsulated in double-walled microspheres were used to overlay fluorescent 
images on brightfield prior to realignment of figures.  (B)  Scanning electron micrograph of double-walled 
microsphere following incorporation into PCL nerve guides. 
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4.3.3 Lysozyme release from double-walled microspheres embedded in PCL 
A known weight of double-walled microspheres was incorporated into PCL disks to measure the 
effects of nerve guide macrostructure on protein release.  Lysozyme was released from 
microspheres in a significantly higher concentration than from microspheres embedded in PCL 
(p < 0.05, n=5).  The cumulative amount of protein released at day 35 was not significantly 
different between free floating microspheres and microspheres in disks (p > 0.05) (Figure 44A). 
 To analyze the long-term release of protein from PCL nerve guides, 15 mg of double-
walled microspheres identical to those used in the disks were embedded into the walls of 5 
individually prepared nerve guides.  The lysozyme release pattern from nerve guides was similar 
to that from microspheres alone (Figure 44B).  There was a gradual, sustained release of 
lysozyme until day 36 when ~45% of the total lysozyme was released.  After this period, there 
was an increase in release rate and by day 49, 90% of lysozyme was released.  No detectable 
amount of lysozyme was measured beyond day 56. 
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Figure 44.  (A) Cumulative release of lysozyme from PCL disks (  ) and microspheres suspended in 
buffer solution (  ) (mean ± std dev, N=5).  Asterisks indicate statistical differences between microspheres that 
were suspended in solution and those embedded in disks (p < 0.05).  (B)  Cumulative release of lysozyme from 
nerve guides with double-walled microspheres (mean ± std dev, n = 5). 
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4.4 DISCUSSION 
Typical microsphere release kinetics include an initial burst release of protein within the first 24 
hours of placement in aqueous solution either in vitro or in vivo.  To increase the time over 
which protein is released, PLGA microspheres were coated with an additional layer of polymer 
(e.g. PLLA), creating a double-walled microsphere.  With this technique, the encapsulated 
growth factor is protected in the core of the two-layered core-shell microsphere structure. 
Furthermore, by localizing a growth factor to the core of the double-walled microsphere, the 
amount of material through which the protein must diffuse through is increased thus slowing the 
protein release rate.  In addition, double-walled microspheres with a core of PLGA and a PLLA 
shell is an effective method of incorporating the microspheres into PCL nerve guide walls.  
PLLA is not soluble in ethyl acetate, the solvent used to create the PCL / NaCl slurry for nerve 
guide fabrication and therefore protects the microspheres from dissolution during nerve guide 
fabrication. 
In the present study, we have demonstrated that microspheres can be reproducibly 
incorporated into PCL nerve guides in a distribution that was easily tailored to manufacturer 
specifications.  While the nerve guide with FITC-BSA microspheres in Figure 43A depicts 
microspheres embedded along the luminal edge of the guide, it would also be possible to create a 
homogeneous distribution of microspheres in the nerve guide wall.  Furthermore, microspheres 
encapsulating multiple growth factors could be used such that the inside layer of microspheres 
releases neurotrophic factors while the external microspheres release vascular endothelial growth 
factor (VEGF) for promotion of revascularization of the injured nerve.  Additionally, because the 
microspheres are organized by distribution on parchment paper, it would also be possible to 
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create gradient distributions of microspheres along the longitudinal axis to mimic the release of 
growth factors from Schwann cells within the distal nerve stump.  
Because the initial release of protein from double walled microspheres at day 1 is 
typically less than 25% of the total encapsulated material, the required leaching period of 5 hours 
appears adequate for our nerve guide delivery system.  Additionally, lysozyme release studies 
from microspheres embedded in PCL disks suggest that the nerve guide material delays the 
initial release of protein into the aqueous environment, presumably because the protein is trapped 
within the porous architecture of the nerve guide wall.   
4.4.1 Limitations 
In the creation of our PCL nerve guides, it was initially hypothesized that this effect of nerve 
guide macrostructure on the initial protein release kinetics would be of benefit for our 
application, as the initial burst of protein from the microspheres (Figure 44A) would be delayed 
and closer to first-order.  However, lysozyme release from DW microspheres within nerve guide 
walls was no longer detectable after 54 days while previous work has shown that microspheres 
suspended in PBS release protein for >80 days (Figure 34).  It is possible that released protein 
adsorbs to the PCL surface upon release and is entrapped within the nerve guide wall.  Initial 
exposure of the PCL guide surface to blood proteins following implantation in vivo would likely 
minimize protein adsorption upon release from microspheres.       
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4.5 CONCLUSIONS 
The polymer orientation of double-walled microspheres protected the microsphere morphology 
during PCL nerve guide fabrication.  The microsphere core was composed of PLGA while the 
shell was PLLA, a polymer that is insoluble in ethyl acetate which was used to create the PCL / 
NaCl slurry.  Nerve guides embedded with microspheres encapsulated with FITC-BSA show a 
homogeneous distribution of microspheres along the inner luminal circumference of the guide 
and SEM analysis indicate that the mechanical integrity of the microspheres was maintained.  
The nerve guides created within this experiment indicate potential for examining the effect of a 
variety of growth factors within long gap peripheral nerve defects. 
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5.0  IN VIVO DELIVERY OF GLIAL CELL LINE-DERIVED NEUROTROPHIC 
FACTOR WITHIN A DEGRADABLE POLYMER NERVE CONDUITS FOR LONG 
GAP PERIPHERAL NERVE REPAIR IN THE RODENT ANIMAL MODEL 
5.1 INTRODUCTION 
Glial cell line-derived neurotrophic factor (GDNF) is related structurally to the transforming 
growth factor beta (TGF–β) superfamily and was first identified as a survival factor for 
dopaminergic neurons of the midbrain [156].  GDNF signals through a multicomponent receptor 
complex consisting of a glycosyl-phosphatidylinositol (GPI-) anchored coreceptor (GFRα1 
through 4) as a ligand binding component and a receptor tyrosine kinase (RET) signaling 
component [237].  Following homodimeric binding of GDNF with GFRα1, the RET receptor 
further dimerizes and initiates several canonical signaling pathways including the Ras-MAPK 
(mitogen activated protein kinase), the phosphatidylinositol-3 kinase (PI3K)-Akt, the PLC-γ and 
the Src pathways [238].       
 In addition to the crucial role GDNF has within the development and function of the 
central nervous system, GDNF has further demonstrated efficacy in promoting the survival of 
motor and sensory neurons [239, 240].  Knock-out mice lacking GDNF die at birth with a 40% 
loss in viscerosensory neurons and a postnatal loss of myelinated mechanoceptors [240].  
Furthermore, GDNF may have an important role in motor neuron target innervations, as an 
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overexpression has been shown to induce a hyperinnervation of neuromuscular junctions [241].  
In addition to serving as a survival factor for neurons, GDNF also promotes proliferation, 
migration and differentiation of Schwann cells [242].   
5.1.1 In vivo use of GDNF in animal models for peripheral nerve repair 
The efficacy of GDNF toward improving peripheral nerve regeneration through nerve guidance 
conduits has been evaluated in preclinical studies (Table 13).  In a 2007 study by Patel et al., 
chitosan scaffolds blended with laminin-1 and 5µg GDNF were implanted across a 10 mm gap in 
the Lewis rat sciatic nerve [123].  After 12 weeks, the chitosan / GDNF guides resulted in 
decreased gastrocnemius muscle atrophy and restoration of functional strength that was 
comparable to autograft controls.  Behavioral testing indicated GDNF treatment groups regained 
sensation and improved gait kinematics.  In addition, silicone conduits filled with GDNF gene 
modified Schwann cells have resulted in significantly improved nerve conduction velocity, 
number and density of regenerated nerves, and the thickness of the myelin sheath of regenerated 
nerves than that seen in controls across a 10 mm defect in the Wistar rat [155].  Finally, nerve 
guides with a GDNF releasing rod increased the number of myelinated axons and the overall 
number of regenerated axons was four-fold higher than nerve guides with NGF [103]. 
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Table 13.  Investigation of GDNF for peripheral nerve repair in vivo. 
 
Animal Model Conclusion Reference 
8 mm sciatic nerve gap in 
adult Sprague-Dawley rats 
GDNF increased motor neuron survival and 
regenerated myelinated axons. 
Chen et al., 
2001 [117] 
1 mm gap in Wistar rat facial 
nerve 
GDNF promoted axonal branching from 
motor neurons. 
Streppel et al., 
2002 [118] 
8 mm gap in Wistar rat facial 
nerve 
GDNF promoted axonal maturation. Barras et al., 
2002 [119] 
15 mm gap in Wistar rat 
sciatic nerve 
GDNF increased the number of myelinated 
axons and the overall number of regenerated 
axons was four-fold higher than with NGF. 
Fine et al., 2002 
[103] 
Transection and coaptation 
in Sprague-Dawley rat sciatic 
nerve 
GDNF increased the rate of sensory recovery 
than with NGF and aFGF. 
Jubran et al., 
2003 [121] 
10 mm gap in Wistar rat 
sciatic nerve 
GDNF improved nerve conduction velocity, 
the number and density of reinnervated 
axons, the area of regenerated nerve and the 
thickness of myelin sheath of the regenerated 
nerves. 
Ping et al., 2003 
[122] 
10 mm gap in Lewis rat 
sciatic nerve 
GDNF resulted in decreased gastrocnemius 
muscle atrophy and restoration of functional 
strength that was comparable to autograft 
controls. GDNF treatment groups regained 
sensation and improved gait kinematics. 
Patel et al., 
2007 [123] 
3 mm gap in sciatic nerve of 
adult male Wistar rats 
GDNF resulted in improved nerve fiber 
diameter. 
Piquilloud et al., 
2007 [124] 
13 mm gap in Lewis rat 
sciatic nerve 
GDNF-containing fibrin resulted larger 
nerve fiber diameters compared to NGF-
containing guides. 
Wood et al., 
2009 [125] 
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5.1.2 Rationale of using the 1.5 cm rat sciatic nerve model for evaluating nerve 
regeneration 
Transection of the sciatic nerve in the rat is the most often employed animal model for peripheral 
nerve regeneration studies [243]. Therefore, it is advantageous for the investigation presented 
within this dissertation to use the rat sciatic nerve gap model so that a fair comparison can be 
made between the regenerative capabilities of our guide to those documented for animal models.  
In addition, strain differences in the rodent model have been carefully considered and the Lewis 
rat was selected as a model specifically because of the length of available sciatic nerve tissue 
available for removal in the Lewis rat. A 2007 study by Rupp et al., showed that the distance 
from the most proximal visible point of the sciatic nerve to the point at which the sciatic nerve 
divides into the tibial and peroneal nerves is longer on average in the Lewis rat compared to 
Sprague-Dawley, Fischer 344, Wistar-Han, Lewis or Nude rats [243]. Therefore, the sciatic 
nerve can be transected as a single epineuria which simplifies the path for the regenerating nerve 
fibers within the guidance conduit.   
 Though many authors initially state the limitations in currently employed nerve guides 
(guides are only useful for bridging short defects), there is a conflict that arises in the animal 
models used to test the efficacy of nerve guides under investigation. The criteria often used to 
determine success in terms of axon regeneration and functional recovery of the muscle are tested 
in rat sciatic nerve gaps of 1 cm or less. However, it is well known that the probability of 
observing regeneration depends strongly on the gap length and regeneration can occur in an 
unfilled nonporous silicone tube in a defect model of this size. Therefore, it is difficult to 
extrapolate the impact of involved factors being tested when regeneration is also present without 
such altered combinations of porosity, delivery of growth factors, incorporation of Schwann cells 
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or extracellular matrix. As such, a 1.5 cm defect was used in the described in vivo studies 
because regeneration is not observed in empty defects. 
5.1.3 GDNF in human clinical trials  
Currently, four clinical trials have been performed utilizing GDNF for the treatment of 
Parkinson’s disease [244] or Progressive Supranuclear Palsy [245].  Within these studies, GDNF 
was continuously infused via catheter either intracerebrally or intraputaminally.  Side effects of 
GDNF therapy included nausea, loss of appetite, cutaneous sensory disturbances and psychiatric 
symptoms [246].  Post study evaluation of the delivery method utilized in the clinical trials 
performed in rhesus monkeys determined that GDNF delivery by a point source (catheter) led to 
an uneven distribution of the administered growth factor, with tissue levels of GDNF dropping 
exponentially from distances beyond the single opening in the catheter [244].  Therefore, the 
development of an improved GDNF delivery system would have utility in not only our nerve 
guide application discussed here, but also within the broader field of growth factor delivery for 
treatment of a variety of neurodegenerative diseases. 
5.1.4 Chapter aims 
It is hypothesized that a sustained delivery of GDNF applied directly to the site of injury will 
result in an improved regeneration of lost nerve tissue.  This hypothesis is based on the following 
observations. First, nerve injury results in rapid up-regulation of GDNF by Schwann cells in 
distal segments of lesioned sciatic nerve [156]. Second, GDNF has been shown to prevent 
avulsion-induced motorneuron death following complete nerve transection whereas nerve growth 
 166 
factor (NGF), brain-derived neurotrophic factor (BDNF), and insulin-like growth factor (IGF) all 
failed to enhance cell survival or cell size [126]. Third, GDNF treatment with guidance channels 
following spinal cord injury resulted in a reduction of reactive astrocytosis and macrophage 
accumulation [120]. Finally, histological comparison of nerve guides implanted with and without 
added GDNF showed that nerve guides releasing GDNF increased nerve fiber number, fiber 
diameter, and additionally myelin thickness was improved, an indication of improved nerve 
regeneration [103, 119]. 
 To evaluate this hypothesis, poly(caprolactone) (PCL) nerve guides were fabricated as 
described within Section 4.2.2.2 with double walled microspheres encapsulating GDNF 
described in Section 3.3.7.1.  To approximate the dosage of GDNF released from the PCL nerve 
guides, in vitro release studies were performed using the complete nerve guide/microsphere 
system.  Nerve guides delivering GDNF were then implanted into a 1.5 critical size nerve defect 
in the adult rat sciatic nerve.   
 To assess the initial efficacy of the nerve guide design, a short-term, 6 week pilot study 
was performed to ensure that bioactive GDNF was delivered to the site of nerve ligation.  
Subsequently, a long-term, 16 week assessment of nerve regeneration across a similar long gap 
defect with GDNF therapy was performed.  Nerve repair was evaluated through functional 
assessment of toe-spread, joint angle range of motion, gastrocnemius contraction force and 
gastrocnemius wet weight.  Histological evaluation of nerve repair included assessment of 
Schwann cell and neurofilament location with immunohistochemistry, evaluation of tissue 
integration and organization throughout the lumen of the regenerated nerve with Masson’s 
trichrome stain, and quantification of axon fiber density and g-ratio.  
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5.2 METHODS 
5.2.1 Reagents 
In addition to those reagents previously listed, Gel Mount (G0918), Xylene, monoclonal anti-
S100, and monoclonal anti-neurofilament were all purchased from Sigma-Aldrich (St. Louis, 
MO).  The Masson’s trichrome kit was purchased from American MasterTech (Modesto, CA).   
5.2.2 In vitro release of GDNF from Nerve guides with Double walled microspheres 
Twenty PCL nerve guides with double-walled microspheres encapsulating GDNF were prepared 
as described in Section 4.2.2.2.  Following fabrication, the PCL polymer was allowed to dry 
completely and NaCl leaching was performed by immersing the guides in sterile DI water for 5 
hours.  Nerve guides were then removed from glass mandrels used during initial preparation and 
cut to 1.7 cm lengths.  From this group of nerve guides, 4 were randomly selected for measuring 
in vitro GDNF release kinetics.  The remaining 16 were implanted into the experimental group of 
animals as described in Section 5.2.3.   
 Long term release studies were performed to approximate the amount of GDNF released 
during the duration of the in vivo studies.  To accomplish this, nerve guides were individually 
added to clean eppendorf tubes.  To each tube, 0.6 mL of PBS was added and the guides were 
incubated at 37°C for specified time increments.  To collect the releasate, the guides were 
removed from each eppendorf tube using clean forceps and added to clean tubes with fresh PBS. 
The amount of soluble GDNF from the collected samples was analyzed using an enzyme 
linked immunosorbent assay (ELISA) manufacturer’s instructions as described in Section 
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3.2.4.3.  The optical density was recorded at 450 nm in an ELISA plate reader (Tecan, NC). The 
GDNF concentrations were calculated against a 6-point standard curve, then adjusted to 
picograms of GDNF per milligram of microspheres. 
5.2.3 Surgical technique 
Following the guidelines of the University of Pittsburgh Institutional of Animal Care and Use 
Committee, 54 male Lewis rats (250-300 g, Harlan Labs) were used to evaluate the efficacy of 
GDNF released from PCL nerve guides for improved nerve regeneration.  To implant the guide, 
each rat was anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg).  
The sciatic nerve was then exposed with a muscle splitting incision of the gluteal muscle.  The 
nerve was sharply transected ~0.5 cm from the proximal bifurcation and 0.5 cm of tissue was 
excised.  After the proximal and distal nerve stumps were allowed to retract, the exposed 
fascicles were trimmed and sutured with 10-0 prolene epineurial mattress stitch 1 mm into each 
end (Figure 45A) of a 1.7 cm nerve guide, creating a 1.5 cm defect (Figure 45B).  The gluteal 
muscle and skin were then closed with 4-0 vicryl suture.   
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Figure 45.  (A) Photograph of distal sciatic nerve stump sutured 1mm into PCL conduit using a mattress 
stitch.  Prolene sutures are indicated with white arrow.  (B) Photograph of PCL guide at time of implantation.  Ruler 
indicates nerve guide is 1.7 cm in length.  Nerve stumps were inserted 1 mm into each end of nerve guide.   
 
 
 For in vivo studies, two time points were used; a 6 week time point for evaluation of 
guide design and a longer 16 week study to evaluate the effects of GDNF release on nerve 
regeneration.  For the initial 6 week pilot study, animals were randomly divided evenly amongst 
two groups, one of which received conduits with microspheres encapsulating GDNF (n = 3) and 
the other group received identical conduits with empty microspheres as a negative control (n = 
3).  Animals used for the subsequent 16 week study were divided amongst three groups, animals 
receiving an isograft (n = 16), animals receiving nerve guides with empty microspheres (n = 16), 
and animals receiving PCL guides with encapsulated GDNF (n = 16). 
 170 
5.2.4 Functional assessment of nerve regeneration 
Functional reinnervation of the lower limb muscles was assessed through four methods: Sciatic 
functional index, video gait kinematics, gastrocnemius muscle contraction force, and 
gastrocnemius wet weight.  Sensory reinnervation was evaluated with a timed response to hot 
water. 
5.2.4.1 Sciatic Functional Index 
Beginning at week 6, rats were in an enclosed walkway (30 x 100 x 15 cm) ending in a 
darkened cage/box weekly as seen in Figure 46A [247]. Baseline measurements were recorded at 
week 0, prior to surgery. The rats were initially allowed two or three conditioning trials to 
become acclimated to the track. White paper was cut to the appropriate dimensions and placed 
on the bottom of the track. The rat's hind feet were painted with nontoxic paint (Figure 46B), and 
the animal was allowed to walk down the track, leaving its hind footprints on the paper. The 
following measurements were taken from the footprints (as shown in Figure 46C and D, from 
[247] ) to determine the sciatic functional index (SFI): 
a) distance from the heel to the third toe, the print length (PL); 
b) distance from the first to the fifth toe, the toe spread (TS); 
c) distance from the second to the fourth toe, the intermediary toe spread (ITS). 
All three measurements are taken from the experimental (E) and normal (N) sides [248]. 
Several prints of each foot will be obtained on each track, and the data will then be entered into 
the SFI equation 3: 
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    (3) 
 
An SFI of 0 is normal, while an SFI of -100 indicates total impairment [249]. Total 
impairment may result from a complete transection of the sciatic nerve. The walking track 
analysis provides a direct relationship between individual hind limb muscle function and print 
measurements [250].  
 
 
 
 
Figure 46.  (A) Photo of walking track used for SFI evaluation.  (B) Photo of method used for painting 
animals’ back feet.  (C and D) Photo of animal print and hind foot with SFI variables indicated (from [247]).   
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5.2.4.2 Video Gait kinematics 
A high-speed (100 full frames per second) digital video camera (Fujinon, HF12.5HA-1B) 
was used to record motion of the hindlimb during walking along a 10 cm wide runway (Figure 
47A). Black ink marks of contrast (3 mm diameter) or reflective markers (Figure 47B) were 
positioned over the iliac crest, greater trochanter, knee, ankle, and fifth metatarsal-phalangelal 
joints.  During each test, the rat was positioned at one end and encouraged to walk the length of 
the 60 cm runway. This procedure is repeated until 15 – 20 steps were recorded with the rat 
walking straight forward (Figure 47C).  Figure 48 shows an image taken from the high-speed 
video of a rat walking on the runway.  A custom Matlab program (gratefully provided by Dr. 
Douglas Weber and Dennis Bourbeau) was used to automatically track the location of each mark 
of contrast in all frames of the video. The marker locations were then used to construct line 
segments connecting each pair of adjacent markers.  Intersegmental joint angles for the hip, 
knee, and ankle joints were calculated using equation 4. 
 
       (4) 
 
In this equation, the vectors A and B denote the line segments proximal and distal to the 
joint. The intersegmental angle (θ) was computed as the inverse cosine of the dot product of 
vectors A and B, normalized by their respective lengths. The joint angular position and velocity 
trajectories were computed from the measured marker positions. The range of motion during 
both flexion and extension were measured for each joint during each step cycle.  These measures 
were then used for comparing gait kinematics across time points and treatment groups. 
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Figure 47.  (A) Photo of high speed camera with equipment for data acquisition used for recording videos 
of animal gait.  (B) Photo of anatomical placement of reflective markers for calculating joint angles during gait.  (C) 
Photo of rat traversing walkway while being video recorded for gait analysis. 
 
 
 
 
Figure 48.  Image of rat captured during plantarflexion immediately prior to initiatin the swing phase.  Line 
segments connect each of the 5 reflective markers.  Representative vectors indicated with A and B are used to 
calculate the intersegmental joint angle θ. 
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5.2.4.3 Timed response to sensory stimuli 
Sensory recovery following nerve regeneration was assessed throughout the duration of 
the 16 week animal study.  At weekly intervals, animals were observed for indications of sensory 
innervations using a preliminary behavioral test.  Animals were placed atop a raised metal grid 
and observed as they moved freely across the bars.  The non-injured foot from experimental 
animals was able to grip each bar and the corresponding leg was able to support weight.  
However, an injured foot without sensory innervations could not sense the presence of the bar.  
The behavior of each animal atop the grid was evaluated using three points of criteria: the foot 
was successfully placed on the bar, the foot responded to and gripped the metal bar, forward 
progress over the grid was made following successful placement of an injured foot on the bar.  If 
any of the following criteria were met, the sensory innervation was subsequently quantified using 
a hot water test. 
To compare the degree of sensory reinnervation within experimental groups, a hot water 
test was performed.  A glass dish with water at 60°C was prepared.  Each animal was blindfolded 
using a cotton towel and first the experimental and then the control foot was placed into the 
water bath.  The response time required by each animal to retract the foot from the bath was 
recorded and the difference in response time between injured and control legs was calculated.      
5.2.4.4 Gastrocnemius contraction force 
Immediately prior to sacrifice, animals were anesthetized with sodium pentobarbital and 
the injured sciatic nerve was exposed with a muscle splitting incision made following the scar 
line remaining from graft or guide implantation.  After freeing the isograft or regenerated nerve 
from the superficial and underlying muscle tissues, a 1.5 mm diameter nerve cuff (Microprobe, 
Inc. Gaithersburg, MD. Cat # NC(1.5)24) was placed around the nerve.  Because the implanted 
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nerve conduit enclosed the regenerated nerve, the PCL material had to be carefully removed such 
that sufficient nerve material was available for contact with the nerve cuff.  The lower 
gastrocnemius was then completely isolated from the anterior and posterior tibialis muscles and 
the Achilles tendon was cut and fastened to a force transducer using a transfixation stitch and 4-0 
silk sutures.  Finally, to completely stabilize the femur position, the animal’s foot, knee and back 
were immobilized on the data acquisition board using 16-0 gauge needles (Figure 49A).  Prior to 
obtaining the muscle contraction force, the tension of the suture used to connect the 
gastrocnemius muscle to the force transducer was optimized for obtaining the maximum force 
possible. 
The sciatic nerve was then stimulated (World Precision Instruments. Sarasota, FL. Model 
A320R) with a nerve cuff containing 4 points of contact and the generated muscle force was 
recorded from the data acquisition board (National Instruments, Model USB6009) using a 
custom Matlab program by Dennis Bourbeau and Dr. Douglas Weber (Figure 49B).  The 
difference in force between baseline and stimulated measurements for 5 consecutive recordings 
was then calculated and optimized for the strongest stimulation points of contact between the 
nerve cuff and the sciatic nerve.  
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Figure 49.  (A) Photo of rat prepared on data acquisition board for muscle contraction force recordings.  
(B) Schematic of equipment organization for stimulating the sciatic nerve and obtaining muscle contraction force 
recordings. 
 177 
5.2.4.5 Gastrocnemius muscle weight 
At the predetermined sacrifice date for each group of animals (6 weeks or 16 weeks), the 
animals were euthanized with an overdose of sodium pentobarbital (100 mg/kg IP).  A 
longitudinal incision in the lower leg, parallel to the extension of the Achilles tendon and 
gastrocnemius (gastroc) muscle, was made followed by a dissection of the skin which adequately 
exposed the gastroc muscle. The two proximal tendonous insertions of the gastroc in the femoral 
area were identification and sectioned.  The distal gastroc insertion in the heel through the 
Achilles tendon was then severed for the extraction of the gastroc muscle. The wet muscle mass 
of the unoperated contralateral control was compared to the muscle mass of the gastroc from the 
injured leg. 
5.2.5 Histological assessment of nerve regeneration 
At specified study time points, animals were sacrificed with an overdose of sodium pentobarbital 
and the implanted guides were harvested and immediately immersed in a fixative.  Nerves 
prepared for paraffin embedding for Masson’s trichrome stain (MTC) and 
immunohistochemistry (IHC) were fixed in 4% paraformaldyhyde.  Samples prepared for 
histomorphometry analysis were fixed in 2.5% gluteraldehyde.  After the tissue samples were 
immersed in fixative for at least 24 hours, the samples were washed with PBS and post-fixed in 
1% osmium tetroxide for either 2 hours in sample preparation for MTC and IHC analysis or 48 
hours for those samples prepared for histomorphometry.  Nerve specimens were then dehydrated 
with increasing concentrations of ethanol (30% to 100%) and sectioned with a sharp razor blade 
at the proximal nerve stump (PS), the proximal (PG), middle (MG) and distal (DG) regions of 
the nerve conduit, and at the distal nerve stump (DS) (Figure 50A).   The sections were then 
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embedded in paraffin or epoxy in descending order (Figure 50B) and sectioned at thicknesses of 
3 μm (IHC, MTC) or 0.5 μm (histomorphometry). 
 
 
 
 
Figure 50.  (A) Photograph of explanted nerve and conduit at 6 weeks.  Guide has been fixed and treated 
with osmium tetroxide.  Dashed likes indicate the proximal nerve stump (PS), the proximal (PG), middle (MG) and 
distal (DG) regions of the nerve conduit, and at the distal nerve stump (DS) where transverse cuts were made for 
histology.  (B) Photograph of sectioned nerve guide embedded in paraffin.   
 
 
5.2.5.1 Masson’s Trichrome 
For analysis of cellular and tissue infiltration of the nerve conduits, nerve sections from 
the negative control and experimental animals were stained for Masson’s Trichrome.  Sectioned 
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nerves were first deparaffinized with Xylene and rehydrated with decreasing percent ethanol 
solutions (100% followed by 90% and then DI water).  Solutions from a Masson’s trichrome kit 
were then used according to the protocol published by Di Scipio et al. [251]. 
5.2.5.2 Immunohistochemistry 
For fluorescent visualization of S-100 protein (Schwann cells), neurofilament proteins 
(axons), and ED1 (macrophages), IHC was performed on explanted nerve samples.  Paraffin 
embedded specimens fixed in osmium tetroxide were first deparaffinized as described above and 
then etched with H2O2 for ten minutes as described in [251].  The samples were then blocked 
with 5% FBS with 0.02% triton-X in PBS for one hour at room temperature.  Primary antibodies 
were then added overnight at 4°C (1:400, 1:200 and 1:200 respectively in 2.5% FBS and 0.02% 
triton-X in PBS).  The samples were then washed three times with PBS and the secondary 
antibody was added for one hour at room temperature (1:1000 in 2.5% FBS and 0.02% triton-X 
in PBS).  The samples were then washed thrice again and the nuclei were detected using DAPI 
(0.6 μg / mL).  The slides were then mounted with a fluorescent mounting media. 
5.2.5.3 Histomorphometry 
Nerve sections were fixed using 2.5% gluteraldehyde, embedded in epon and cut to 0.5 
μm cross-sections using an ultramicrotome (Reichert Ultracut).  Sections were then mounted 
onto glass slides and stained with 1% toluidine blue dye for imaging.  A Hitachi (model KP-
M1AN) digitizing camera was mounted on a Zeiss Primo Star microscope for image acquisition.  
A 100X oil immersion objective lens was used to produce digital images at a final magnification 
of 1000X, with a pixel size of 0.125 μm as calibrated with a stage micrometer. 
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The Leco IA32 Image Analysis System (Leco, St. Joseph, MI) with custom calculation 
routines (macros) was used as developed by Hunter et al., [252].  8-bit monochrome images were 
acquired and thresholded for determining myelin composition as detailed in Figure 51 from 
[252].  As described by Hunter et al., manual adjustments were made to photomicrographs 
displayed on an attached monitor such that debris and nonviable nerve fibers were removed 
(Figure 51D, from [252]).  Viable axons were defined as dark myelin rings enclosing clear fiber 
areas devoid of debris or cell nuclei.  Myelin width, axon width, and fiber diameter were then 
automatically calculated through software analysis of red and green bitplane identifiers. From 
these primary measurements, g-ratio (the ratio of the axonal diameter divided by the diameter of 
the axon and its myelin sheath) and nerve fiber density (fiber number/mm2) were calculated.   
5.2.6 Statistical Analysis 
Results are expressed as the mean ± standard deviation.  Analysis of variance (ANOVA) was 
used to determine statistical significance between experimental groups.  The least significant 
difference method was used for multiple comparisons with p < 0.05.     
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Figure 51.  (A) Original high magnification micrograph of native nerve. (B) Micrograph with overlaying 
red myelin bitplane as manually adjusted during the initial thresholding step for myelin identification.  (C) 
Micrograph with overlaying red and green bitplanes for axon identification.  (D) Manual elimination of nonviable 
axons as indicated with black arrows.  (Images are from [252]) 
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5.3 RESULTS 
5.3.1 In vitro release of GDNF from PCL Nerve guides 
Long term release studies of GDNF form PCL nerve guides with double-walled microspheres 
were performed to approximate the release profile of the growth factor in vivo.  Nerve guides 
embedded with double-walled microspheres encapsulating GDNF were incubated in PBS and 
released growth factor was quantified using an ELISA system.  As shown in Figure 52, the 
release of GDNF from the PCL nerve guides did not exhibit the typical burst release profile seen 
in single walled microsphere studies.  At day 3, only ~2.9% of the total released protein is 
liberated into solution.  GDNF release is nearly linear until day 56, at which point ~89.0% of the 
total growth factor is released.  After this point, GDNF release is consistent to day 112, when the 
16 week in vivo studies were complete.  Assuming that the majority of microspheres weighed for 
nerve guide preparation were successfully embedded and secured into the nerve guide walls, the 
encapsulation efficiency for GDNF nerve guide production was ~1%.  Further, using double 
walled microsphere GDNF loading as determined in Section 3.3.7.1, only ~5% of the total 
expected GDNF was released from the PCL nerve guides at the completion of the in vitro 
measurements.       
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Figure 52.  Cumulative release of GDNF (pg) from double walled microspheres embedded in PCL nerve 
guides (1.7 cm in length).  Values expressed as mean ± std dev (n = 4). 
 
 
5.3.2 Implantation of PCL nerve guides 
Upon exposure of the injured sciatic nerve at sacrifice, remaining PCL conduits were soft 
and pliable and both sutures intact.  Nerve guides were well vascularized with a soft fibrous 
coating (Figure 53A).  The proximal and distal ends of the nerve guides were completely sealed 
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with a fibrous capsule and small neuromas are apparent at both guide ends.  Prior to separating 
the nerve guide from the regenerated nerve, a pinch test was administered proximal to any 
anastamosis to determine if a muscle reflex could be observed.  In 70% of the animals treated 
with an empty PCL conduit, a lower limb reflex was observed.  However, often the regenerated 
nerve through the negative control conduits was delicate, and attempts to remove the conduit for 
placement of a nerve cuff resulted in disruption in nerve continuity.  It was also noted that the 
regenerating nerve grew adjacent or into the porous walls of the PCL conduit. 
  Nerve guides implanted with GDNF releasing microspheres were also observed as well 
vascularized and sheathed in a soft fibrous coating.  Results from a preliminary pinch test 
indicated that lower limb reinnervation was seen in 100% of the experimental animals.  
Furthermore, the nerves appeared to grow through the open lumen of the nerve guides and could 
be easily separated from the conduits for electrophysiology studies (Figure 53B). 
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Figure 53.  Photo of exposed empty PCL nerve guide 16 weeks after implantation (white arrow).  The 
proximal and distal ends of the guide are indicated with the characters P and D.  (B)  Photo of GDNF releasing PCL 
nerve guide (white arrow) that has been longitudinally sectioned revealing regenerated nerve (white arrow head).   
 
 
5.3.3 Functional analysis of nerve regeneration 
5.3.3.1 Sciatic functional index 
After 9 weeks post surgery, the sciatic functional index was recorded at weekly intervals 
(Figure 54).  Previous work has shown that no improvement in gait should be expected before 
this time point (Appendix A).  Considering that a SFI value of 0 is healthy and -100 is 
completely non-functional, animals from both the experimental treatment group (GDNF 
microspheres) and those with empty PCL guides (negative controls) showed impaired gait 
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patterns at week 9.  The SFI value for animals of the GDNF group was -71.3 ± 15 (n = 16), 
which was not statistically considered different from the empty guides which had an SFI of -80.3 
± 7 (n = 3).  There was no statistical difference in the measured SFI values throughout the 
duration of the study period.  Additionally, there was no significant improvement in SFI value 
between timepoints for the duration of the study.  
 
 
 
 
Figure 54.  Calculated SFI values for animals receiving GDNF conduits ( ), and empty control conduits 
( ).  Values are expressed as mean ± std dev. 
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5.3.3.2 Gait kinematic Analysis 
Gait kinematics from animals receiving a PCL nerve guide without growth factor (n = 3) 
and animals which received GDNF releasing guides (n=16) following sciatic nerve injury shows 
that motion of the hip joint is similar in the two animal groups within both the swing and stance 
phase of the gait cycle (Figure 55A and 55B).  Hyperflexion of the hip is required to compensate 
for weakness in the distal part of the leg, which is impaired by the injury to the sciatic nerve 
(mid-femur). Thus, dramatic differences are evident at the knee (Figures 55C and 55D) and ankle 
(Figures 55E and 55F). Injured animals are unable to generate muscle force to extend the knee, 
reaching only ~90˚ of extension during stance  (Figure 55C) compared to 130˚ in the healthy 
animal. Further evidence of muscle weakening is evident at the ankle. Normally, the ankle is 
flexed during the swing phase to lift the foot, but the ankle of an injured animal extends during 
swing (Figure 55E). This ankle extension is caused by gravity when the hip flexes to swing the 
leg forward. The range of motion (RoM) between experimental and negative control animals was 
not significantly different between groups at any time point.   
5.3.3.3 Timed response top sensory stimuli 
Rats were observed to have regained a small degree of sensory innervations beginning at 
week 14 using visual analysis of rat behavior while maneuvering a challenging metal grid.  At 
week 15, animals were further assessed for sensory recovery using a hot water test.  Animals 
receiving a GDNF guide had a mean response time to sensory stimuli of 0.93 ± 1.32 seconds (n = 
16) while animals receiving control PCL guides were significantly slower in response time with 
an average recorded time of 3.64 ± 1.93 seconds (p = 0.02, n = 3) (Figure 56). 
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Figure 55.  Hip range of motion (degrees) at baseline (week 0) and sequential timepoints following injury 
for swing phase (A) and stance phase (B) of the gait cycle.  Knee range of motion during swing (C) and stance (D).  
Ankle range of motion (degrees) in swing (E) and stance (F).  For all graphs, GDNF animals are represented with 
( ), control PCL guides are ( ) and isografts at week 15 are ( ). 
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Figure 56.  Mean response time required by animals receiving a GDNF rleasing conduit ( ) and control 
PCL guides ( ).  Values are expressed as mean ± std dev with significant differences marked with an asterisk. 
 
 
5.3.3.4 Gastrocnemius Contraction Force 
The mean measured gastroc contraction force was 0.59 ± 0.28 N, 0.44 ± 0.22 N, and 0.07 
± 0.07 N for animals treated with an isograft (n = 11), a nerve conduit with GDNF (n = 6) and 
animals treated with a PCL conduit and no growth factors (n = 7), respectively.  The average 
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contraction force between isograft animals and those within the experimental GDNF group was 
not significantly different (p = 0.1754) while both of these groups showed significantly improved 
contraction force above negative control animals (Figure 57). 
 
 
 
 
Figure 57.  Average gastrocnemius contraction force (N) with error bars representing standard deviation. 
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5.3.3.5 Gastrocnemius muscle weight 
The wet weight of recovered gastroc muscles from injured legs as normalized to 
contralateral uninjured controls are recorded in Table 14.  The normalized values of muscles 
from animals treated with isografts as a positive control for nerve regeneration were statistically 
higher than both the experimental GDNF group as well as the PCL guides without growth factor 
delivery (p < 0.01). 
 
 
Table 14.  Recorded wet weights of injured gastrocnemius muscle as normalized to contralateral control. 
(Asterisk indicates statistical significance from experimental groups, p < 0.01) 
 
Treatment Description Gastrocnemius wet weight (%) 
Isograft (positive control) 46.6 ± 12.4 * 
GDNF Nerve Guides (experimental group) 24.8 ± 5.7 
Empty PCL conduits (negative control) 21. 7 ± 4.4 
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5.3.4 Histological assessment of nerve regeneration 
5.3.4.1 Masson’s Trichrome 
6 week pilot study 
PCL nerve guides with double-walled microspheres were implanted across a 1.5 cm 
defect in the sciatic nerve to determine the initial effects of GDNF delivery on nerve 
regeneration.  The presence of cellular infiltration, tissue formation and collagen content within 
the implanted conduits was visualized through Masson’s trichrome stain.  At low magnification 
(Figure 58A), transverse images of proximal segments of PCL conduits implanted without 
encapsulated GDNF showed a thin collagen capsule surrounding the nerve guide (arrow).  
Within the lumen of the guide, there is incomplete tissue integration and a lack of intercellular 
fibers.  High magnification images (Figure 58B) reveal the presence of blood vessels (arrow 
head) and localization of cells near the inner surface of the nerve guide.  There does not appear 
to be a measureable number of nerve fibers present and the majority of infiltrating cells, such as 
fibroblasts and macrophages, are organized around the nerve guide wall and surround the 
microspheres (MS).  Neither the experimental nor control guide appear to illicit a strong 
inflammatory response.   
Visualization of nerve guides implanted with double-walled microspheres releasing 
GDNF show a higher concentration of intercellular fibers and tissue formation at the proximal 
segment of the guide (Figure 58C).  Though connective tissue does not appear to be organized, 
high magnification images of the center of the nerve guide reveal the presence of cells 
throughout the entire interior of the guide (Figure 58D).  The presence of a blood vessel located 
near a microsphere in the nerve guide wall is indicated with a white arrow head. 
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Figure 58.  (A and C) Compilation of brighfield micrographs taken of a transverse section of the proximal 
segment guides visualized with Masson’s trichrome stain.  To create the final image, a series of 10X images were 
realigned and blended using photoshop CS3.  (A) Negative control guides.  Microspheres are labeled as “MS.”  The 
collagen capsule surrounding the implanted guide is labeled with an arrow.  (C) Guides releasing GDNF.  (B and D) 
High magnification brightfield micrographs taken of the lumen of explanted nerve guides from negative controls (B) 
and guides releasing GDNF (D).  Blood vessels are labeled with an arrow head.  Scale bars are 100μm. 
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In the distal region of the implanted nerve guides, the empty conduit shows very little 
tissue formation in the lumen of the guide (Figure 59A) in comparison to guides releasing GDNF 
(Figure 59B).  Analysis of high magnification light micrograph images confirm that in negative 
control guides, there is an absence of intercellular fibers and cells in the lumen of the guide 
(Figure 59C).  In GDNF conduits (Figure 59D), tissue infiltration is not as developed as was seen 
in the same proximal nerve segment, however there was an increase in collagen content and 
intercellular fibers above the negative controls.    
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Figure 59.  (A and B) Compilation of brightfield micrographs taken of a transverse section of the distal 
segment of guides visualized with Masson’s trichrome stain.  (A) Negative control guides and (B) guides with 
GDNF.  (C and D) High magnification brightfield micrographs taken of the lumen of explanted nerve guides from 
negative controls (C) and guides releasing GDNF (D).  Scale bars are 100 μm. 
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16 Week, Long Term Study 
The regeneration of nerve across a 1.5 cm defect was also evaluated at a longer time 
point of 16 weeks.  Low magnification transverse sections of the proximal portion of negative 
control conduits reveal a high degree of collagen content within the lumen of the guide (blue) 
with tissue integration throughout the entirety of the guide lumen (Figure 60A).  Regenerated 
nerve is evident near the PCL nerve guide wall (black box) and as evident at higher 
magnification, is disorganized and sparse (Figure 60B).  Nerve tissue is also evident within the 
lumen of nerve guides releasing GDNF, however, fibers are located in the center of the lumen 
surrounded by newly formed tissue (black circle, Figure 60C).  High magnification light 
micrographs reveal a large number of small nerve fibers that are well organized and thinly 
myelinated (Figure 60D).  
Low magnification brightfield images of transverse sections from control PCL guides 
reveal that regenerated nerve tissue was not evident within mid (Figure 61A) or distal segments 
(Figure 61B).  Tissue integration appears incomplete and few blood vessels are observed.  
However, in both the mid and distal regions of conduits releasing GDNF, there was regenerated 
nerve tissue within the lumen of the guides.  Low magnification micrographs of the midline of 
explanted conduits (Figure 61C) shows collagen formation and tissue integration supporting the 
regenerated nerve fibers seen at higher magnification within Figure 61D.  Additionally, nerve 
tissue is also evident within distal regions of the GDNF releasing conduits within both low 
(Figure 61E) and high magnification (Figure 61F) micrographs.    
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Figure 60.  Transverse sections of the proximal segment of guides explanted after 16 weeks as visualized 
with Masson’s trichrome stain.  (A) Low magnification brightfield micrographs taken of negative control guides 
with regenerated nerve tissue indicated within black box.  (B) High magnification micrographs showing detailed 
nerve tissue organization.  (C) Low magnification transverse section from guides releasing GDNF with centrally 
located nerve tissue circled in black.  (D) High magnification brightfield image of nerve fiber organization following 
GDNF treatment.  Scale bars are 100 μm. 
 
 
 
 
 198 
 
 
Figure 61.  Transverse sections from guides explanted 16 weeks post injury visualized with Masson’s 
trichrome stain.  Low magnification brightfield micrographs taken of negative control guides from the mid (A) and 
distal (B) sections of the explanted guide.  (C) Low magnification mid transverse section from guides releasing.   
(D) High magnification brightfield image of nerve fiber organization following GDNF treatment. (E)  Low 
magnification distal transverse section from guides releasing.   (F) High magnification brightfield image showing 
detail nerve fiber organization from within GDNF guides.  Scale bars are 100 μm. 
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5.3.4.2 Immunohistochemical analysis 
6 week, Pilot Study 
Results from immunohistochemical analysis of nerve sections treated with anti-S100 
antibodies showed that Schwann cells were present in the proximal nerve guide segment in both 
negative control and nerves that received guides with GDNF microspheres.  However, as seen in 
Figure 62A, the distribution of Schwann cells in control guides was largely restricted to the 
middle of the nerve guide.  Within the lumen of nerve guides releasing GDNF, Schwann cells are 
evident not only in the center of the conduit, but also surrounding the microspheres (Figure 62B).  
At higher magnification, Schwann cells (red) are visualized surrounding the double-walled 
microspheres releasing GDNF (Figure 62D) but are not present around non-encapsulating 
control microspheres (Figure 62C). 
Analysis of the distal regions of the explanted nerve guide reveal the presence of 
Schwann cells in the lumen of only those guides releasing GDNF.  In Figure 62E, DAPI staining 
of nuclei reveals the presence of cell nuclei in lower frequency than in control guides as 
compared to GDNF guides (Figure 62F).  Also evident in Figure 62F is the presence of Schwann 
cells in GDNF guides not seen in the negative control guides. 
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Figure 62.  (A and B) Black and white fluorescent micrograph showing Schwann cells (visualized with 
S100).  (A) Proximal transverse section of negative control guides.  (B) Proximal section of guides release GDNF).  
(C) High magnification fluorescent micrograph of double-walled microsphere encapsulating GDNF. (E and F) 
Fluorescent micrographs from distal segment of explanted nerve tissue.  (E) negative control and (F) GDNF 
releasing nerve guides.  Red indicates S100 labeling of Schwann cells.  DAPI is blue.  Scale bars are 100 μm.   
 201 
16 week, Long Term Study 
Nerve tissue was evident in the proximal region of explanted conduits 16 weeks after 
sciatic nerve transection and conduit implantation.  Fluorescent images reveal the presence of 
both nerve fibers (neurofilament proteins: green) and Schwann cells (S-100: red) in both 
negative control PCL guides and guides releasing GDNF.  However, nerve tissue within control 
PCL guides (Figure 63A) was localized to the internal border of the nerve guide wall and appears 
disorganized, while nerve tissue was centrally located and well organized within GDNF 
releasing guides (Figure 63B).  Schwann cells and nerve fibers were not detectable within the 
middle (Figure 63C) or distal segments (Figure 63E) of control nerve guides, while robust 
Schwann cell populations were observed across the entire length of GDNF releasing guides 
(Figures 63D and F). 
To determine if macrophages were also present within and surrounding the implanted 
PCL conduits, IHC was performed using antibodies against CD68, a known macrophage marker.  
Throughout each observed section from control PCL guides, macrophages were not observed to 
preferentially localize around double walled microspheres were instead found in higher 
frequency throughout the conduit wall and surround blood vessels (Figure 64A).  However, in 
nerve guides with microspheres encapsulating GDNF, macrophages, like Schwann cells were 
seen in high frequency immediately surrounding the double walled microspheres (Figure 64B).  
This observation suggests that bioactive GDNF was delivered and had a chemotactic affect on 
endogenous macrophages. 
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Figure 63.  Fluorescent micrographs of proximal transverse sections of negative control guides (A) and 
guides releasing GDNF (B).  Fluorescent micrograph from middle segment of control (C) and GDNF (D) nerve 
guides.  Distal transverse section from negative control (E) and GDNF releasing nerve guides (F).  Red indicates 
S100 labeling of Schwann cells.  Neurofilament proteins within nerve fibers are green.  DAPI is blue.  Scale bars are 
100 μm.   
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Figure 64.  Fluorescent micrograph of transverse sections of explanted PCL conduits.  Distribution of 
macrophages (CD68, green) within control PCL guides (A) and guides releasing GDNF (B).  Microspheres are 
indicated with the characters “MS” while the nerve guide luminal edge is marked with “NG.”  Scale bars represent 
100 μm.     
5.3.4.3 Axon morphometric and histological analysis 
Monochrome images of the proximal nerve stump, proximal isograft or nerve guide, 
distal isograft or nerve guide, and distal nerve stump were acquired and thresholded to identify 
viable axons.  Using semi-automated software, myelin width, axon width, and fiber diameter 
were calculated. From these primary measurements g-ratio and nerve fiber density (fiber 
number/mm2) were determined.  Within the isograft, positive control nerve samples, the g-ratio 
of axons was consistent within each section from the proximal nerve stump to the distal nerve 
stump with a measured range of 0.40 to 0.42 (Figure 65A).  The g-ratio of nerve fibers within 
GDNF releasing guides were higher for all measured transverse sections, with average values of 
0.53, 0.54, 0.55, and 0.44 for the PNS, PG, MG and DNS sections respectively.  These measured 
values from GDNF guides approach an uninjured g-ratio range of 0.6 to 0.7 (gray bar).  Fibers 
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from control PCL guides were observed to have a lower g-ratio value within both the proximal 
nerve stump (0.47) and the proximal segment (0.45) of the explanted nerve guide.  No fibers 
were evident in the mid or distal regions of negative control PCL guides for measurement 
calculations.      
Evaluation of nerve fiber density throughout the length of explanted nerve samples 
shown in Figure 65B reveals an increased density of fibers per mm2 for both the GDNF and 
control nerve guides as compared to isograft positive controls, an indication of axonal sprouting 
from regenerating nerves (Figure 65B).  As seen in fiber g-ratio results, isograft sections had a 
small range of fiber densities (~11,300 to 12,200) progressing from the proximal to the distal 
nerve stumps indicating limited axonal sprouting occurred within the graft.  Within GDNF and 
control nerve guides, nerve fiber densities were calculated confirmed early Masson’s trichrome 
observation of improved nerve regeneration through PCL conduits releasing GDNF.  The density 
of fibers within GDNF releasing guides was higher than negative control guides for all measured 
segments and there were no viable nerve fibers in negative control nerve guides beyond the mid 
region of the explanted conduits (Figure 66).  
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Figure 65.  (A) Calculated g-ratio of fibers within transverse segments of the proximal nerve stump (PNS), 
proximal graft or guide (PG), distal graft or guide (DG) and distal nerve stump (DNS). (B) Calculated nerve fiber 
density (fibers per mm2).  Treatment groups are isograft ( ), GDNF nerve guide ( ) and control nerve guide ( ).  
Values are expressed as mean ± std dev.  Gray horizontal bar indicates normal, uninjured g-ratio values. 
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Figure 66.  High magnification (100X) light micrographs of transverse sections of explanted nerve 
following 16 weeks in vivo.  Mid-conduit nerve tissue from negative control PCL guides (A) and guides releasing 
GDNF (B).  Distal-conduit nerve tissue from negative control PCL guides (C) and guides releasing GDNF (D).  
Distal nerve stump of negative control PCL guides (E) and GDNF releasing guides (F).   
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5.4 DISCUSSION 
While the benefits of many different neurotrophic factors have been assessed in sciatic nerve 
defects (e.g. NGF, BDNF, CNTF) we chose to initially implant nerve guides releasing GDNF 
because of the promising results described in literature.  GDNF is a neuroprotective growth 
factor secreted by Schwann cells in distal segments of peripheral nerves following injury [156].  
In addition, GDNF has been shown to prevent avulsion-induced motorneuron death following 
complete nerve transection whereas nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), and insulin-like growth factor (IGF) all failed to enhance cell survival or cell size 
[126].  Finally, GDNF treatment with guidance channels following spinal cord injury resulted in 
a reduction of reactive astrocytosis and macrophage accumulation [120]. 
Our initial in vitro release studies suggest that GDNF was delivered throughout the 
preliminary 6 week pilot study period used to determine the efficacy of our novel nerve guide 
design.  Furthermore, histological evaluation of explanted conduits suggest that bioactive GDNF 
was delivered to endogenous cell populations and markedly improved cellular integration and 
tissue formation across the nerve injury.  While nerve gaps treated with empty microsphere 
conduits resulted in incomplete fibrotic tissue formation and scattered fibroblast – like cells in 
the center of proximal segment of the excised nerve guides, nerve guides releasing growth factor 
reveal an increase in cellular infiltration and tissue integration within the lumen of the conduits.  
In addition, tissue integration in the distal segments of nerve guides was markedly improved in 
guides releasing GDNF.  High magnification micrographs of the central portion of transverse 
segments (Figure 59C and 59D) reveal an overall increase in cellular infiltration and collagen 
content following GDNF treatment.  This increase in collagen content potentially supplied an 
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improved scaffold for Schwann cell migration and supported axonal outgrowth during longer 16 
week in vivo studies. 
  Detection of Schwann cell localization with immunofluorescence indicated that 
Schwann cells were present in proximal segments of PCL nerve guides.  Fluorescent 
micrographs of control guides show a significant number of Schwann cells within the lumen of 
the guide (Figure 62A) and Schwann cells do not appear to localize to the conduit wall or 
microspheres (Figure 62C).  Nuclear staining (DAPI) within the conduit center reveal a large 
presence of additional cell populations which most likely include fibroblasts and macrophages 
but were not positive for antibodies against neurofilament antibodies (Figure 62C).  However, 
micrographs of nerve guides with GDNF microspheres show a population of Schwann cells 
encircling the microspheres, an indication of targeted migration of Schwann cells toward a 
source of GDNF (Figure 62B and 62D).  This result is significant for two reasons.  First, a 
cellular response to the encapsulated growth factor suggests that the released GDNF is bioactive 
and has not been completely denatured through the nerve guide fabrication process.  Second, the 
migration of Schwann cells, presumably from the lumen of the conduit, indicates that GDNF is 
being delivered to the lumen of the nerve guide in a physiologically relevant concentration and is 
not entirely entrapped within the porous nerve guide structure.     
Nerve guides encapsulating GDNF also resulted in the presence of Schwann cells at the 
distal portion of transverse sections of explanted tissue that was not observed in control guides 
(Figure 62E and 62F).  Fluorescent micrographs of the central portion of the nerve guide reveal 
an increase in both cellular infiltration and cells positive for antibodies against S-100 protein in 
experimental guides while there were no detectable positive for S-100 in control guides.  The 
presence of Schwann cells in the distal segment of experimental nerve guides could be a result of 
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either Schwann cell proliferation or migration.  Though GDNF is typically utilized in nerve 
regeneration as trophic factor for nerve fibers and as a promoter of axonal growth [242] and 
branching [253, 254], GDNF also causes a marked proliferation and migration of Schwann cells 
[254, 255].  The effect of GDNF is RET (receptor tyrosine kinase) independent and instead, 
GDNF signaling mechanisms directly in Schwann cells through a GPI-anchored coreceptor 
(GFR-α1) and neural cell adhesion molecule (NCAM) [255].  Additionally, downstream 
signaling protein kinases (PKA) participates in GDNF transcription, and therefore, GDNF 
promotes a positive feedback loop for autocrine signaling in Schwann cells.  This autocrine 
feedback loop has been reported to further enhance Schwann cell migration and myelination 
[256], both of which are important events in nerve regeneration.    
Finally, not only were Schwann cells observed to localize around double-walled 
microspheres, macrophages were also seen with high frequency surrounding microspheres.  
During Wallerian degeneration, both endogenous Schwann cells and macrophages proliferate 
and phagocytose axonal debris within endoneurial tubes, an important process for providing 
regenerating axons an optimal environment for outgrowth.  In addition to this function, both cell 
types release growth factors which have chemotactic affects on directing axonal outgrowth 
[257].  Because the number of cells which secrete growth factors was improved within the 
experimental guides, the concentration of axonal growth promoting factors within the site of 
nerve injury may have been further increased in addition to exogenous GDNF delivery.  
Measured outcomes from functional analyses of nerve regeneration through nerve 
conduits also reflect improved nerve regeneration within GDNF releasing guides.  Upon the 
initial exposure of the site of nerve injury, nerve tissue was seen exiting the distal end of 
implanted conduits in only 70% of the control PCL guides, while 100% of the animals implanted 
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with GDNF releasing guides had nerve trunks throughout the length of the conduits and 
integrating into the distal target muscles.  In addition, the measured gastrocnemius contraction 
force, an indication of muscle atrophy and reinnervation, was significantly improved by a 
difference of 6-fold in animals treated with GDNF releasing conduits as opposed to those which 
received empty PCL conduits.  Markedly, the contraction force between animals treated with 
isografts, considered to be the gold standard for nerve repair, was not significantly different from 
animals receiving GDNF releasing conduits. 
Analysis of muscle reinnervation through quantification techniques of rat gait proved 
challenging using the techniques described herein.  No significant difference in SFI 
measurements or joint angle range of motion was measured between the GDNF experimental 
group and the negative control.  Partly, this is due to the early time points at which rat gait was 
assessed.  Because the experiments described here were designed to detect improvement in nerve 
regeneration due to growth factor delivery, it was necessary to use an animal sacrifice date that 
would preclude the natural ability of rats to regenerate nerve without treatment, known as the 
blow-through effect.  While rats have a number of positive attributes which make them ideal for 
evaluating therapies for nerve regeneration, they also have been reported in literature as having a 
superior capacity for regenerating nerve across large defects [258].  Therefore, if lengthy time 
points are used, given enough time, nerve regeneration in negative control groups will eventually 
catch up to experimental groups.  Therefore, it may have been possible to see improvements in 
animal toe spread or joint angle range of motion given more time for muscle reinnervation in 
experimental animals. 
In addition to evaluating animal recovery at early time points within the long term 16 
week study, several experimental difficulties were encountered when using SFI analysis for 
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quantifying nerve regeneration.  The animal of experimental choice, the rat, has several 
behavioral instincts that can cause obtaining clear, easily measured footprints difficult.  The first 
innate behavior pertains to self- grooming and the rats’ natural desire to trim the toe nails with 
the teeth.  When the lower leg has lost sensation, the rat may either autotomize the toes causing 
severe mutilation or will cease to trim the nails resulting in extremely long toe nails to develop 
over time (Figure 67A).  While the strain of rat can be varied to one which has less incidence of 
autotomy, such as the Lewis rat [259], a rat that produces elongated nails can cause the print 
length to appear much longer than it should be measured (Figure 67B).  Additionally, flexion 
contractures occur in early stages of nerve regeneration and prevent any toe markings from being 
left on paper (Figure 67C).  Contractures occur when the sciatic nerve fails to reinnervate proper 
connections during nerve regeneration [260] and result in these animals being discarded from the 
data pool.  Finally, animals that have lost the ability to walk with a raised heel, as is typical rat 
gait, develop blisters and sores on the heel which cause the animal discomfort or may cause the 
resulting foot print to appear wider than it might otherwise be (Figure 67D).  The described 
examples of compounding foot deformities overtime can lead to gait compensatory behaviors 
such as foot inversion or eversion that are difficult to measure through SFI.  Therefore, a more 
global view of the rat gait kinematics throughout nerve regeneration may be used in conjunction 
or separate of SFI to more adequately describe functional recovery following nerve repair.   
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Figure 67.  (A) Photo of rat foot with lengthened toe nails which results from the cessation of self-
grooming.  (B) Photo of incomplete foot print of injured right leg.  (C) Photo of a flexion contracture, a common 
occurrence in early stages of nerve regeneration which result in an inability to evaluate animal print.  (D) Photo of a 
sore (white arrow) on the bottom of a foot on the side of sciatic nerve injury.  
 
 
The development of a technique for analyzing gait kinematics through video recording 
was undertaken as a method of circumventing those challenges seen with SFI measurement.  
However, unique obstacles were presented within this method of gait analysis.  First, animal 
behavior is fickle, and often animals were observed as walking with a unique head position, 
speed, or step pattern.  In addition, animals would traverse the walkway only a few times before 
losing interest in the activity and could not be trained to proceed with a smooth gait pattern 
despite incentives provided by the operator.  Because of this, step cycles were used for 
measuring joint angles from only those steps which were consecutive and were determined to be 
of a walking nature (at least one foot always on the ground).  The use of a treadmill would 
greatly improve the consistency seen in joint angle measurements and may allow this technique 
 213 
to be a more robust method for detecting early improvements in gait kinematics following lower 
limb nerve injury.  
Because of the unique difficulties that occur within each of the various methods used for 
assessment of functional recovery following nerve injury, it is suggested here that multiple 
techniques be employed such that diverse measurements are pooled to provide the strongest 
indicators of lower limb muscle control.  SFI is a simple method of obtaining gross estimations 
of lower limb muscle control.  Video assessment of gait kinematics provides a much deeper 
understanding of animal behavior and uncovers compensatory behavior.  With further 
optimization, these tools may prove invaluable when used with sensory evaluation to track 
animal recovery throughout the duration of in vivo studies of therapeutics for nerve repair.  In 
addition to these tests which can be performed across multiple time points, end point assessment 
of muscle contraction force is a critical method of quantifying muscle reinnervation that does not 
depend on animal behavior.  When these tools are used in combination with the multiple 
histological techniques described herein, it is possible to strongly support or dismiss claims of 
regenerative effects of a wide number or therapeutics. 
5.4.1 Conclusions 
GDNF was successfully encapsulated in double-walled microspheres and released in a controlled 
manner for over 100 days in vitro.  The overall efficacy of incorporating microspheres into the 
luminal wall of PCL nerve guides was confirmed with GDNF in the rat sciatic nerve model.  
Functional evaluation of animals at weekly intervals revealed no significant differences in toe 
spread measurements between animals treated with the GDNF releasing conduits or the control 
conduits.  Furthermore, though calculated joint angles showed an overall improvement in animal 
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gait toward baseline levels, no significant difference between the experimental group and 
negative controls were measured.  However, evaluation of sensory reinnervation following nerve 
injury showed a significant increase in animal response time to stimuli within the group of 
animals treated with GDNF releasing guides.  Furthermore, the measured gastrocnemius 
contraction force in animals treated with GDNF was significantly higher than negative controls 
and was not significantly different from the isograft positive control group. 
 Histological assessment of explanted conduits after 16 weeks further showed that tissue 
integration within GDNF releasing nerve guides was improved above negative controls and 
resulted in a greater concentration of intercellular fibers and collagen content within the lumen of 
the guides.  In addition, fluorescent and brightfield images showed nerve fibers throughout the 
entire length of guides releasing GDNF, while no nerve fibers were detectable beyond the middle 
region of negative control guides.  Furthermore, a localization of Schwann cells and 
macrophages around microspheres encapsulating GDNF indicates that bioactive GDNF was 
being released from our delivery system.  Therefore, the results reported within this dissertation 
support our original hypothesis that; the delivery of Glial Cell Line-Derived Neurotrophic Factor 
(GDNF) from nerve guides results in improved functional recovery above negative controls in 
the in vivo environment following large axonal defects in the peripheral nervous system.   
5.5 FUTURE DIRECTIONS 
While initial studies for evaluating nerve repair have been conducted with a single growth factor, 
this technique could lend itself useful for evaluating delivery systems for additional growth 
factors or combinations thereof.  The nerve guide delivery system described within this 
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dissertation has been optimized in terms of guide manufacturing parameters for the sustained 
delivery of small proteins in general.  Additionally, both large (BSA) and small proteins 
(lysozyme, GDNF) were successfully encapsulated within double walled microspheres.  As the 
nerve guide design is modular, the PCL conduits described herein lend themselves easily toward 
investigation of a variety of different therapeutics for improved nerve regeneration. 
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6.0  DISCUSSION 
The work described within this dissertation presents a novel method for delivering growth 
factors from biodegradable polymeric nerve guides for peripheral nerve repair.  To accomplish 
this, a poly(caprolactone) (PCL) scaffold was combined with microspheres composed of 
poly(lactic-co-glycolic acid) (PLGA) and poly(l-lactide) (PLLA) in a novel fabrication method 
that utilized physical properties unique to each polymer.  A brief summary of each specific aim 
required to produce the final engineered nerve conduit for sustained protein delivery is presented 
below.  Future studies involving the nerve guide delivery device are then discussed. 
6.1 SUMMARY OF RESULTS 
6.1.1 Specific Aim 1: Optimizing Nerve Guide Manufacturing Parameters 
 The objective of Specific Aim 1 was to quantify the in vitro effect of nerve guide porosity 
percentage and wall thickness on growth factor and nutrient diffusion through PCL nerve guide 
walls.  This work was necessary as highly porous nerve guide walls have been shown as a 
necessary feature of nerve guide design because it is critical to allow for the diffusion of blood 
nutrients and oxygen into the site of nerve injury.  However, as the guide was also intended to 
deliver and maintain small molecular weight proteins at high concentration within the lumen of 
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the guide, wall porosity had to be limited to prevent growth factor loss.  Lysozyme was used as a 
representative small molecular weight protein to model growth factor diffusion and glucose, a 
small hydrophilic molecule was used to model blood nutrients.   
 Initial optimization experiments resulted in the highest glucose diffusion from guides of 
80% porosity with pore diameter ranging between 10 - 38 μm.  Additionally, it was determined 
that at high porosity percentages, decreasing the pore diameter was a measurable method of 
decreasing the lysozyme permeability of PCL nerve guides while not creating a loss of glucose 
permeability.  PCL fouling studies were used to optimize the desirable nerve guide wall 
thickness.  Results indicated that nerve guides of 0.6 mm thickness decreased the loss of 
lysozyme to almost 10% without significantly diminishing glucose permeability.  Based on the 
results of this study, nerve guides of 80% porosity percentage with 10 – 38 µm pore diameter 
and 0.6 mm wall thickness were used for subsequent in vivo studies. 
 
6.1.2 Specific Aim 2: Development of a Microsphere Based GDNF Delivery System 
The objective of specific aim 2 was to develop a nerve guide that delivers encapsulated proteins 
for the duration required for regenerating peripheral nerve axons to reach the distal nerve stump 
following transection and creation of a long gap nerve defect (1.5 cm).  This was accomplished 
by first developing a microsphere delivery system for sustained protein release and then 
incorporating the microspheres into the polymer nerve guide wall such that the mechanical 
integrity of both polymer components, the nerve guide and the microspheres, was maintained.   
 Double walled microspheres encapsulate proteins within a polymeric core that is encased 
by a second polymer, thus increasing the amount of material through which the liberated protein 
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must diffuse, and subsequently slowing the release rate.  To delivery bioactive proteins over a 
sustained period (at least 60 days), microspheres were prepared with various polymer solvents, 
polymer solution concentrations and co-encapsulants.  Results demonstrate that double walled 
microspheres with a poly(lactic-co-glycolic acid) core containing the encapsulated protein and a 
poly(L-lactide) shell are produced when dichloromethane is selected as the solvent for both 
solubilizing both polymers.  Further, protein release from the micropsheres can be significantly 
slowed when an increased solution concentration of PLGA is used in the initial oil-in-oil phase 
of microsphere preparation.  Finally, coencapsulants such as human serum albumin can be used 
to stabilize delicate growth factors during microsphere fabrication without decreasing protein 
bioactivity or altering the microsphere polymer orientation. 
 It was important for reproducible nerve guide fabrication that microspheres were created 
with a PLGA core and PLLA shell so that microspheres could be combined with PCL for nerve 
guide preparation.  Because PLLA is not soluble in ethyl acetate, the solvent used to create the 
PCL/NaCl slurry for nerve guide fabrication, the microsphere morphology was protected from 
dissolution during nerve guide fabrication.  Our results show that we can incorporate 
microspheres into PCL nerve guides in a manner that does not harm the morphology of 
microspheres and results in reproducible protein release profiles.  Additionally, the distribution 
of microspheres within the nerve guide walls can be easily tailored.  For example, microspheres 
can be homogenously distributed along the nerve guide wall, or embedded in a gradient 
distribution to release an increasing concentration of growth factor along the longitudinal axis.  
While the nerve guides were tailored for locally delivering GDNF to injured nerves, the overall 
design with which PCL nerve guides were engineered allows for incorporation of varying 
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microsphere concentration, location and encapsulated substance.  Therefore, our guides could be 
used to test a variety of therapeutics for nerve repair.    
   
6.1.3 Specific Aim 3: In vivo Delivery of GDNF in Long Gap Peripheral Nerve Defects 
Our overall goal was to quantify the in vivo effect of GDNF delivery from a PCL nerve guide in 
terms of histological and functional regeneration of the sciatic nerve across a critical size (1.5 
cm) defect.  An in vivo pilot study was first performed to determine if bioactive GDNF was 
sufficiently delivered from implanted nerve guides and if any improvements in nerve tissue 
regeneration could be detected within the nerve guides.  In a 6 week pilot study, PCL nerve 
guides with GDNF were used to bridge a rat sciatic nerve defect and resulted in an increase in 
tissue integration in both the proximal and distal segments of the lumen of the nerve guide and 
an increase in Schwann cells in the distal region of the guide.  Migration of Schwann cells 
toward double-walled microspheres indicated that bioactive GDNF was encapsulated and 
delivered to the internal environment of the nerve guide.  Because of these positive preliminary 
outcomes, the long term effects of GDNF delivery were assessed over a 16 week period. 
Results from our 16 week in vivo study supported our initial hypothesis that localized 
GDNF delivery to an injured nerve would improve nerve regeneration in terms of both functional 
recovery and nerve histomorphometry. Four methods of functional evaluation were used to 
assess recovery of animals following nerve injury.  Two of these methods, sciatic functional 
index and video assessment of gait kinematics, were used to track behavioral changes in rats at 
defined time points throughout the duration of the study.  Neither of these methods was able to 
detect significant improvements in rat gait between experimental and negative control nerve 
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guides.  However, recordings of gastrocnemius contraction force of anesthetized rats showed a 6-
fold increase in contraction force of animals treated with GDNF above the negative control 
guides.  Because the wet weights of harvested gastrocnemius muscles following the completion 
of the study were not significantly different, the improvement in contraction force suggests that 
perhaps the target muscles of animals treated with GDNF were innervated with an increased 
number of nerve fibers allowing for a greater recruitment of muscle fibers for contraction.  
Further histological analysis of explanted gastroc muscles for neuromuscular junctions could be 
performed to explore this hypothesis. 
Explanted nerves were examined with a variety of histological techniques to further 
examine the morphology of regenerated nerve tissue.  Transverse sections of proximal, middle 
and distal regions of explanted conduits were visualized with Masson’s trichrome stain and 
showed an overall increase in tissue integration at the middle and distal lengths of GDNF 
releasing guides as compared to PCL guides containing DW microspheres without encapsulated 
GDNF controls.  Semi-thin (500 nm) sections of tissue architecture from within PCL guides 
further confirmed that nerve fiber density was greater in the middle and distal regions of GDNF 
releasing guides.  Finally, visualization of Schwann cells and Neurofilament proteins with 
immunofluorescence revealed a higher degree of nerve tissue organization within nerve guides 
releasing GDNF, with tissue located in the center of the explanted conduit as opposed to negative 
control guides which produced nerve tissue only along the surface of the conduit.  The 
distribution of nerve fibers within the guides may reflect the overall improvement in tissue in 
growth with GDNF treatment.  Presumably, axons within GDNF guides were provided with an 
enhanced collagen and tissue scaffold for support of migration and elongation, and thus resulted 
in increased outgrowth throughout the entire length of the experimental conduits.   
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6.2 FUTURE DIRECTIONS 
The delivery of growth factors from nerve guides is one technique used to improve nerve 
regeneration.  At the conclusion of our in vivo studies, it was concluded that axonal elongation 
was supported within GDNF releasing guides in part by inner luminal tissue formation that 
served as a platform for axonal extension across the large nerve defect.  This hypothesis is 
supported by the documented importance of scaffolds for cell migration for nerve repair [36].  
Within the first week of injury, fibrin cables are formed to bridge the proximal and distal nerve 
stumps.  The fibrin bridge is critical for migration of Schwann cells, fibroblasts and 
macrophages, which are ultimately responsible for the regeneration of nerve fibers [261].  We 
now plan to evaluate the potential benefits of incorporating a luminal filler within our GDNF 
releasing nerve guides across long peripheral nerve gaps.  We hypothesize that incorporation of a 
scaffold for cellular and axonal migration at the time of guide implantation would further 
increase the rate of nerve regeneration across breaks in nerve continuity.   
 Fibrin [262], collagen [263-265], laminin [266-268], keratin [269, 270] and hyaluronic 
acid [271, 272] have all been used to provide structural support and topographical cues for 
axonal elongation.  In collaboration with the Wake Forest Institute of Regenerative Medicine, we 
intend to investigate GDNF delivering guides in combination with keratin gels within rat sciatic 
nerve defects.  Sierpinski et al., have reported keratin-based gels as having regulatory molecules 
which are useful for cell attachment and migration [270].  Within this study, Schwann cell 
proliferation and migration were significantly increased above negative controls using keratin 
derived from wool fibers.  Additionally, in a 4 mm tibial nerve defect in Swiss Webster mice, 
keratin gels within silastic tubing resulted in a reduced nerve conduction delay and an increased 
compound motor action potential as compared to both silastic tubes filled with saline as well as 
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autograft controls [269, 270].  While the use of a short nerve gap, 4 mm, allowed for the 
recovery of all animals given enough time, early study results suggest that keratin is a promising 
material for further improving the quality of nerve regeneration within our PCL nerve guides. 
In addition to natural materials for luminal fillers, our lab is also developing novel 
thermo-sensitive hyaluronic acid based hydrogels for use within PCL conduits.  Poly(N-
isopropylacrylamide) (p-NIPAAm) is a thermo-sensitive polymer that undergoes a coil-to-
globule phase transition at temperatures above the lower critical solution temperature of ~32°C 
[273].  When copolymerized with hyaluronic acid, p-NIPAAm-HA is biodegradable and would 
therefore provide space for regenerating tissue within the lumen of nerve guides.   Additionally, 
because p-NIPAAm-HA is liquid at room temperature, this gel could serve as an injectable 
method for initial support for cells migrating within the open conduit lumen from the two nerve 
stumps.   
It is our ultimate goal to transition the novel GDNF delivering nerve conduit to an 
implantable device for use in humans.  As initially conceived, the nerve guide described within 
this dissertation would be considered a combination product; it is a scaffold that also contains a 
drug delivery system and is implanted as a single entity.  Because our nerve guide combines both 
a device and a drug, there are additional challenges to obtaining regulatory clearance.  However, 
the device materials, poly(caprolactone), poly(lactic-co-glycolic acid) and poly(lactide) and the 
delivered drug, GDNF, have been studied in humans, and therefore have previously acquired 
data that may be leveraged to support the safety of the combined materials in this product.  
Therefore, there is great promise for the progression of our described nerve guide toward clinical 
studies.  Additional studies that would be necessary before this goal is met would include an 
analysis of lot-to-lot variation in drug loading and growth factor release.  In addition, it is 
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required that 80% of the encapsulated growth factor be recovered, regardless of the matrix.  
Therefore, additional studies are needed to improve the overall encapsulation efficiency of 
GDNF within the microsphere/nerve guide system as well as to increase the quantity of protein 
that is liberated from the guides.  Further investigation into potential co-encapsulants and protein 
stabilizers would therefore be of great utility before additional preclinical in vivo investigations 
are performed.    
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APPENDIX A 
DEVELOPMENT OF AN IN VITRO MODEL FOR EVALUATING NERVE 
REGENERATION WITH DORSAL ROOT GANGLION EXPLANTS 
As a method for performing preliminary analyses on factors which promote nerve elongation, we 
have preformed intial work towards developing a three dimensional in vitro model of axonal 
elongation.  An in vitro model of nerve regeneration would be useful as a method of comparing 
variable growth factors, growth factor doses or gradients of growth factors with high repetition 
and short time periods.  Within our proposed in vitro design, an explanted dorsal root ganglion is 
suspended within an agarose gel adjacent to a nerve guide such that axons extend through the 
lumen of the nerve guide.  This 3-D culture method is advantageous to existing two dimensional 
culture systems because horizontal neurite sprouting can be used as an internal control.  
Therefore, the unique extent to which each DRG is capable of sprouting neurites can be 
accounted for when determining directed neurite outgrowth.  It was our intentions that this 3-D 
model for axonal outgrowth be used prior to in vivo studies to reduce study variables and 
therefore decrease the number of experimental animals. 
 225 
A.1 METHODS 
For in vitro analysis, dorsal root ganglion (DRG) explants from one month (21 – 29 day old)  
male Lewis rats were used.  Following a complete laminectomy for removal of the spinal 
column, the column was cut in half following along the sagittal axis and DRGs were dissected 
away from the surrounding connected and nerve tissue.  Prior to the DRG isolation process, 
agarose gels were prepared with a 1% (w/v) stock solution in dI water (Invitrogen Ultrapure 
LMP Agarose, 15517-022).  To dissolve the agarose, water was continuously stirred and heated 
to 60°C.  The solution was then sterilized by filtration and added in 2 mL volumes to each well 
of a 24 well plate.  During DRG isolation, well plates with gel were incubated at 37°C so as to 
prevent solidification.  Immediately after isolation, DRGs were suspended in the gel and placed 
at 4°C to allow the gel to solidify.  Neurobasal media with B27 supplements was then added to 
the well.  Following 2 hours of incubation, standard media was replaced with neurobasal media 
containing 50ng/mL Nerve Growth Factor (NGF).  
 To optimize axonal outgrowth, four agarose gel concentrations were prepared: 0.25%, 
0.50%, 0.75% and 1.0%.  Additionally, to minimize the exposure time of DRGs to low 
temperations, 5 time points of 4°C incubation were investigated: 3min to 15 min in 3min 
increments.  Finally, the addition of both collagen and laminin to the agarose gels were 
investigated as a method of further improving the structural support of axonal extension.  To a 
0.5% agarose gel, either 33μl of laminin, 20μl collagen (rat tail) or both were added in soluble 
form per mL of agarose solution. 
 For DRG visualization, immunofluorescence was used with FITC conjugated lectin-IB4 
and antibodies against cGRP receptors.  After DRGs were incubated for at least 48 hours in NGF 
containing culture media to allow axonal sprouting, whole explants were fixed in 4% 
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paraformaldehyde for 4 hours and then rinsed twice with PBS for 5 minutes each wash.  FITC-
conjugated lectin IB-4 (3.125 µg/mL) in solution was then added overnight at 4ºC after which 
the tissue was washed thrice with PBS for 5 minutes each wash.  The tissue was then 
permeabilized with 0.5% triton-X in a 5% Horse Serum solution for 15 minutes and primary 
antibodies against cGRP were added at a 1:200 dilution in 2.5% horse serum in PBS.  Following 
two additional washes in PBS with 0.2% Tween, anti-mouse secondary antibodies were added at 
a 1:1000 dilution in PBS with horse serum and incubated for one hour.  The tissue was then 
washed two more times and incubated with DAPI (0.6 μg/mL) for 30 minutes.  Finally, the tissue 
explants were washed and mounted for fluorescent microscopy.     
A.2 RESULTS 
Following initial preparation of 4 concentrations of agarose gels, it was observed that 0.25% 
agarose gels did not fully solidify and could not physically support DRGs without the gel settling 
on the bottom of the well plate due to gravity.  Furthermore, 1.0% agarose solutions produced a 
very firm gel that inhibited axonal outgrowth.  Excellent axonal outgrowth was seen using DRGs 
in gels prepared from 0.5% agarose solution (Figure A1), and therefore gels of this concentration 
were used for future studies.  In addition, it was observed that both 0.5% and 0.75% solutions of 
agarose began to gel following a 6 min incubation at 4°C and were completely solidified by 9 
min. 
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Figure A 1.  Low (A) and high (B) magnification brightfield micrographs of explanted dorsal root ganglion 
in gel composed of 0.75% agarose in dI water.  
 
 
Addition of extracellular matrix proteins that have been shown to support axonal 
elongation in vitro was also investigated as a method of improving DRG axonal sprouting.  The 
greatest extent of axonal extension was observed using 0.5% agarose solutions containing 20 μl 
per mL rat tail collagen (Figure A2).  
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Figure A 2.  (A) Brightfield Micrographs of a DRG with extended axons in a 0.5% Agarose gel with 20μl 
per mL collagen. (B) DRG is rotated to show extent of axonal sprouting. 
 
 
Because dorsal root ganglion explants contain a heterogeneous population of sensory 
neurons, it was necessary to confirm that explants contained a population of cells which would 
respond to applied neurotrophins that do not specifically target sensory axons.  Therefore, 
immunofluorescense was used to identify neural cells which possess receptors for neutrophins 
such as NGF (cGRP, red) and glial cell-line derived neurotrophic factor (GDNF) (Lectin IB4, 
green).  Following addition of lectin-IB4 and antibodies against cGRP, positive identification of 
cells responsive to both NGF and GDNF were observed (Figure A3).  
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Figure A 3.  Fluorescent micrographs of dorsal root ganglion explants. (A) Positive staining for cGRP, 
indicating cells which are responsive to NGF. (B) Positive staining for lectin IB4, an indication that a population of 
neurons have receptors for GDNF.   
 
 
A.3 DISCUSSION 
 Optimization of the culture methods used for obtaining axonal sprouting from explanted 
dorsal root ganglion from rats was a necessary first step for the development of our in vitro 
model of nerve regeneration.  It is our intentions to create a method of quantifying the capacity 
of exogenously applied neurotrophins to promote axonal elongation, and therefore we can test a 
larger number of factors before in vivo experiments are performed.   
 Figure A4 shows a schematic of our design for such an in vitro model.  Within the 
agarose gel in which the DRG explants is suspended, a PCL nerve guide containing neurotrophin 
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delivering microspheres will be vertically fixed so that one end is on the gel-surface interface 
beneath the DRG while the distal end is located on the gel-well plate interface.  The DRGs will 
be placed in the unsealed end of the guide and cultured for 2 weeks after which the nerve guide 
will be removed from the gel and fixed for histological analysis. It is our hypothesis that growth 
promoting cues delivered from the nerve guides will diffuse throughout the gel and promote 
neurite sprouting into conduits, which can then can be quantified in terms of length and number 
through sectioning in paraffin and immunofluorescence.  This apparatus could be used to 
compare potential growth factors, growth factor dosages, or homogenous versus gradients of 
growth factors.  
 
 
 
 
Figure A 4.  Schematic of in vivo model of axonal outgrowth using a dorsal root ganglion explants 
suspended in an agarose gel with growth factor releasing conduits. 
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APPENDIX B 
COMPARISON OF VIDEO GAIT KINEMATICS AND SCIATIC FUNCTIONAL 
INDEX FOR THE QUANTITATIVE ASSESSMENT OF FUNCTIONAL RECOVERY 
FOLLOWING NERVE TRANSECTION AND REPAIR 
One of the most common animal models reported in literature for peripheral nerve injury is the 
transection of the sciatic nerve in the rat species, which leads to a loss of muscle innervation and 
sensory defects in the lower leg.  The sciatic functional index (SFI) has become a standard tool 
after almost three decades of development and allows a more complete assessment of therapeutic 
interventions following lower limb peripheral nerve injury.  However, as discussed in Section 
5.4, the use of SFI has problems in the implementation of this technique.  
 Also introduced within Chapter 5 is a novel technique for the analysis of the gait 
kinematics during both the stance phase and swing phase in the rat gait cycle using video 
recording of animal movements.  Video capturing with a high-speed digital camera allows the 
fine movements of the rat to be recorded during every portion of the gait cycle.  This digital 
information is tracked and plotted automatically via hind limb markers so as to allow the 
computation of joint angles and velocities.  The parameters measured in video analysis are thus 
not limited by contractures, exo-rotation, or autotomy as are those by other methods of functional 
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analysis such as the sciatic functional index (SFI).  Video gait analysis evaluates function of 
more proximal musculature, which are reinnervated prior to the distal musculature of the limb. 
Consequentially this can be used to detect subtle differences in plantar flexion and dorsiflexion 
following recovery from nerve injury and repair.    
In order to determine if video analysis of gait kinematics could be used in place of SFI 
measurements, a direct comparison of animal recovery following a sharp transection and repair 
of the right sciatic nerve was performed.  The recovery of injured animals were compared to an 
additional group receiving a sham operation to determine if the method of nerve exposure, a 
gluteal muscle splitting incision, also affected gait patterns.  Our goal was to determine which 
method of assessment detected functional recovery at early time points or with less variability so 
as to result in statistically significant differences between animal gait patterns. 
B.1 METHODS 
In the experimental group (n=6), the sciatic nerve was sharply transected and repaired 
with epineurial sutures. SFI and gait kinematics as described in Section 5.2.4.1 and Section 
5.2.4.2 respectively, were used for functional assessment prior to surgery and every week after 
until sacrifice at 9 weeks post-op.  In the control group (n=6), the sciatic nerve was exposed but 
uninjured and functional assessments were conducted at weeks 0, 1, 3, and 5.  
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B.2 RESULTS 
Animals were excluded from SFI measurements due to formation of contractures at week 
6 (1 of 6), week 7 (2 of 6) and week 9 (4 of 6) (Figure B1).  Assessment of reinnervation in male 
Lewis rats revealed a decrease in SFI measurements over the first two weeks following sciatic 
nerve transection.  By week 9, animals had recovered to within ~37% of uninjured measurements 
(Figure B2A).  Analysis of SFI measurements from individual rats shows a consistent trend with 
measured SFI values across all 6 animals (Figure B2B). 
 
 
   
 
Figure B 1.  Schematic of the occurrence of flexion contractures during nerve regeneration following 
sciatic nerve transection.  Animals with contractures were excluded from data pool. 
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Figure B 2.  (A) SFI measurements of animals receiving a sciatic nerve injury ( ) as compared to sham 
animals (  ).  Data is expressed as mean ± std dev  (B) SFI measurements for rats (n = 6) receiving sciatic nerve 
transection to show consistency in animal recovery trends.  Rat 1 ( ), rat 2 ( ), rat 3 ( ), rat 4 ( X ), rat 5 ( * ), 
rat 6 ( ). 
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Initial observations of gait kinematic analysis of the experimental group revealed a sharp 
increase in ankle range of motion (ROM) within the stance phase of the gait cycle following the 
first postoperative week (Figure B3A). As animals lost the ability to maintain the raised paw 
position that is typical for rat gait, the heel dropped and the knee collapsed on the foot in an 
effort to bear weight.  During the swing phase of the gait cycle, a loss of active plantarflexion 
resulted in a decreased ankle ROM from 1 to 4 weeks post-op (Figure B3B).   
Analysis of joint angle range of motion was difficult to assess for the knee and hip 
measurements due to a lack of deviation of range of motion measurements between the 
experimental animal and measurements from the group of animals receiving a sham procedure.  
This challenge occurred because analysis could only be performed on one experimental animal, 
further trends in rat gait following injury cannot be adequately predicted.  Due to technical 
difficulties, this study should be repeated in order to fully describe hind limb loss of function 
following nerve injury. 
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Figure B 3.  Joint range of motion (degrees) at baseline (week 0) and sequential timepoints following 
injury ( ) or sham ( ) procedures.  (A) Ankle range of motion during stance phase (A) and swing phase (B) of the 
gait cycle.  Knee range of motion during stance (C) and swing (D).  Hip range of motion (degrees) in stance (E) and 
swing (F).   
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B.3 DISCUSSION 
Video gait kinematics analysis of hind limb function was developed to more thoroughly describe 
functional recovery in the rat following sciatic nerve injury.  Nerve reinnervation as measured 
through SFI requires a large number of animals to be tested due to the inability to measure lower 
limb function once contractures occur.  However, limitations persist within the presented video 
assessment method.  The validity of joint ROM measurements was highly dependent on the 
velocity of the animals and was difficult to control for using a simple runway.  In addition, it was 
difficult to place static markers on the skin of the animal to represent the knee joint in a dynamic 
measurement.  This is due to the natural fluidity with which the skin moves across the knee joint.  
Therefore, evaluation of animals receiving our experimental nerve guides was performed using 
black ink for marking the five anatomical joint locations. Because we were unable to 
conclusively show that video measurement of gait kinematics could replace SFI measurements, 
video gait kinematics were used in conjunction with SFI measurements for detecting nerve 
regeneration between our final experimental groups. 
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